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A covered stent is one whose length and circumference is enclosed with a membrane 
or fabric like material. When implanted in an artery, the covering of the stent acts as a 
mechanical barrier to prevent contact between the vessel wall and the components of 
blood. Current covered stents have been proposed for the intervention of failed 
saphenous vein grafts (SVG), in the hope of reducing embolism and in-stent 
restenosis. However, clinical trials failed to demonstrate such benefits. The 
deficiencies of existing covered stent include thick stent design, non-degradable PTFE 
membrane with poor endothelialization, high deployment pressure and no drug 
loading capacity. The objective of my PhD study was to develop a new type of 
covered stent, nanofiber covered stent (NCS), which is thinner in wall thickness, more 
flexible and more biocompatible than the commercial design. Electrospinning 
techniques were proposed to deposit a nanofibrous membrane onto bare metal stents. 
The advantages of electrospun nanofiber include ease of fabrication, biomimic 
structure and flexibility.  
 
At a first step, Polyglycolide (PGA), poly(DL-lactide-co-glycolide) (PLGA) and 
poly(L-lactic acid)-co-poly(ε-caprolactone) [P(LLA-CL)] were electrospun into 
nanofibrous mesh with various electrospinning conditions. Optimized concentrations 
of PGA, PLGA and P(LLA-CL) electrospinning using different solvents were 
determined. Hexafluoroisopropanol (HFIP) was found to be a proper solvent which 
could be used to electrospin all three polymers while maintaining good mechanical 
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strength of the resultant nanofibrous mesh. The electrospun nanofibers using HFIP 
can be controlled to have consistent fiber diameter and porosity. 
 
Secondly, porcine coronary artery smooth muscle cells (PCASMC) were cultured on 
three different polymeric nanofibers for up to 15 weeks. Cellular behaviors and 
nanofiber degradation were evaluated. Although PGA supported initial PCASMC 
growth, the rapid degradation of PGA nanofibers may limit its function as a physical 
barrier in NCS application. PLGA nanofibers facilitated cell growth during the first 
30 days after seeding but the cell growth was slow thereafter. P(LLA-CL) facilitated 
long term (1-3 months) cell growth although the initial cell growth was slower than 
that of PLGA nanofiber. We found that cell culture significantly increased the 
degradation of PGA nanofibers while this effect was minor on PLGA and P(LLA-CL) 
nanofibers, although accelerated surface erosion was observed. The molecular weight 
of P(LLA-CL) and PLGA nanofibers decreased linearly during the degradation period 
for up to 100 days. 
 
A separate study was made to evaluate the degradation effect of UV irradiation on 
nanofibers. It was demonstrated that normal dosage UV sterilization induced 
significant damage on PLGA and P(LLA-CL) nanofiber, reducing the molecular 
weights and mechanical strengths, but with no obvious effects on cell proliferation. 
The effect of UV-induced degradation could be utilized to accelerate nanofiber 
degradation and 3D nanofibrous scaffold can be fabricated with controlled 
degradation for tissue engineering applications.  
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Based on the biocompatibility and degradation results of the three polymeric 
nanofibers, P(LLA-CL) was selected for NCS fabrication. Direct electrospinning, 
double-disk and single-disk methods were developed to fabricate P(LLA-CL) 
nanofiber covered stents and single-disk method showed best performance in terms of 
mechanical property. Longitudinally aligned NCS fabricated by single-disk could be 
deployed in vitro without creating any defects on the nanofibrous cover. Paclitaxel 
was loaded onto P(LLA-CL) nanofiber with sustainable release kinetics and 
bioactivity. Paclitaxel was loaded onto NCS without affecting its mechanical property. 
Paclitaxel loaded NCS could potentially minimize the in-stent restenosis by providing 
both anti-proliferative agent and physical barrier.   
  xi
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Chapter 1   
Introduction 
An estimated 80,700,000 American adults (one in three) have one or more types of 
cardiovascular disease (CVD) (W. Rosamond et al., 2008). CVD is the No.1 killer in 
the US and the 2nd worldwide(W. Rosamond et al., 2008). Final mortality data show 
that CVD accounted for 36.3% of all deaths in the U.S. in 2004 (NCHS, 2008). Major 
CVD includes coronary artery disease, stroke from emboli, heart failure etc. And 
amongst them, coronary artery disease (CAD) alone claimed 52% of CVD deaths in 
the U.S. in 2004 (W. Rosamond et al., 2008).  
 
CAD occurs when the coronary arteries become hardened and narrowed. Other than 
the hardening that occurs naturally due to aging, more severe hardening and 
narrowing is, more often than not, due to buildup of plaque material on the vessels’ 
inner walls, a process better known as atherosclerosis. The plaque is made up of fat, 
cholesterol, calcium, and other substances from the blood and results in stenosis, the 
abnormal narrowing of blood vessel. Eventually, blood flow to the heart muscle is 
reduced, which will lead to oxygen starvation of heart muscle (hypoxia). Over time, 
CAD will weaken the heart muscle and reduce its effectiveness in pumping blood 
thereby inducing the many symptoms associated with heart failure. 
  
Current treatments of CAD include medication, bypass surgery and percutaneous 
transluminal intervention (PCI). Bypass surgery is an invasive open-heart surgery. In 
this surgery, a vein, usually taken from one leg of the patient, is grafted to bypass the 
Chapter 1 
 2
blocked artery due to atherosclerosis. About 10% of CAD patients in the U.S. undergo 
bypass surgery (A. D. Michaels and Chatterjee,K., 2002). Although bypass surgery 
has better prognosis, patients with CAD are generally too old, too weak or too 
emergent to receive bypass surgery (A. D. Michaels and Chatterjee,K., 2002). 
Alternatively, roughly one third of CAD patients undergoes percutaneous coronary 
intervention to reopen the narrowed arteries (A. D. Michaels and Chatterjee,K., 2002). 
 
In the following sections, improvement and different types of PCI will be reviewed 
and compared. Briefly, PCI started with balloon angioplasty and later stenting. But 
significant re-narrowing of the target vessel (restenosis) happened in 10-50% of the 
patents. Drug eluting stent (DES) loaded with controlled release drug to reduce 
restenosis was then introduced. A detailed review will then be given for drug eluting 
stent and covered stents, another type of stent with the same purpose of reducing 
restenosis. Thereafter, one special type of artery intervention, namely saphenous vein 
graft (SVG) intervention, will be described and discussed in detail. Finally, the 
limitations of current SVG intervention will be analyzed and treatment using a new 
type of covered stent will be proposed. 
 
1.1 PCI and stents. 
Percutaneous transluminal intervention (PCI), as indicated by the name, is a 
non-invasive procedure in which the coronary artery is accessed percutaneously from 
peripheral vessels. One of the earliest PCI techniques is balloon angioplasty. In 
balloon angioplasty, the diseased artery is widened by an inflating an intraluminal 
balloon at the site of stenosis. However with this technique, the wall of the coronary 
artery can be weakened, and sometimes, the artery may even collapse shortly after. 
Chapter 1 
 3
Furthermore, in about 30-50% of patients who underwent balloon angioplasty 
worldwide, the coronary artery would restenose (J. Al Suwaidi et al., 2000). The 
detailed mechanism of restenosis will be presented in section 1.2. 
 
Figure 1.1 Bare metal Stents: undeployed (left) and deployed (right) 
 
By the mid-80s, stents were invented to overcome the problem of restenosis. The stent 
at that time, now often referred to as bare metal stent (BMS), is a small, lattice-shaped, 
metal tube (usually made of stainless steel 316L) that is inserted permanently into an 
artery (Figure 1.1). Intracoronary bare metal stenting has resulted in a decline of 
restenosis (in-stent restenosis, ISR) rate to 10–40% by the reduction of elastic recoil 
(collapse) and negative remodeling (restenosis) (R. Hoffmann et al., 1996;H. C. Lowe 
et al., 2002). However, clinical results were still not satisfactory due to continuing 
high occurrence of restenosis. Extensive efforts have been made to produce 
restenosis-resistant stents.  
 
1.2 Drug eluting stents. 
The pathological characteristics of ISR differ markedly from primary atherosclerosis. 
Intense vessel wall trauma due to stent implantation causes a perivascular 
inflammatory reaction, characterized by expression of adhesion molecules and 
cytokines, and neutrophil accumulation during the first hours post PCI, followed by 
macrophages during the first week (A. Farb et al., 2002;P. R. Moreno et al., 1996;E. 
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Okamoto et al., 2001). Transiently, the adventitia exhibits high cellular density and 
thickening (K. Wallner et al., 2001). The neoadventitia reveals proliferation and 
expression of heat shock protein, antiapoptotic Bcl-2 protooncogene, myosin heavy 
chains, tenascin and cell migration (H. DeLeon et al., 1997;A. Jabs et al., 2002;S. 
Murakami et al., 2001;N. A. Scott et al., 1996;K. Wallner et al., 2001). These factors 
showed, over a time period of 7–14 days post vessel trauma, a shift from the 
adventitia towards the neointima, underlining the importance of the adventitia for the 
restenosis process. Thus, smooth muscle cells (SMCs) from adventitial may 
contribute to neointima formation. In contrast to primary atheroma, quantitative 
analysis revealed a low prevalence of inflammation and apoptosis, absence of 
infectious pathogens, but markedly increased cellularity (V. Ophascharoensuk et al., 
1998;D. Skowasch et al., 2004). In later stages of the restenotic process, accumulation 
of extracellular matrix rather than cell proliferation contributes to ISR formation (I. M. 
Chung et al., 2002;P. H. Grewe et al., 2000). Figure 1.2 summarizes a contemporary 
view of the pathophysiological mechanisms underlying the pathogenesis of ISR (F. G. 




Figure 1.2 Schematic of mechanisms involved in the pathogenesis of in-stent restenosis. A, 
atherosclerotic plaque before intervention. B, stent placement leading to endothelial denudation and 
platelet/fibrinogen deposition. C and D, leukocyte recruitment, infiltration, and smooth muscle 
proliferation/migration (days after injury). E, continued monocyte and smooth muscle cell 
recruitment, leading to neointimal thickening (weeks after injury). F, reduced cellularity and 
increased extracellular matrix formation, eventually leading to a stable in-stent restenotic lesion 
(weeks to months) (F. G. P. Welt and Rogers,C., 2002). 
Several types of treatment has been proposed to reduce the ISR, including systematic 
drug therapies, cutting balloon, laser cutting and Vascular brachytherapy (T. M. 
Schiele, 2005). However, although some of the treatments have been shown to reduce 
ISR in short-term studies, most of them failed to show clinical benefits due to severe 
late restenosis or thrombosis (T. M. Schiele, 2005).A breakthrough in stenting 
technology was the introduction of drug-eluting stents (DESs), which have reduced 
the ISR rate from 10-40% to <10% (J. J. Popma and Tulli,M., 2006). Generally, the 
drug-eluting stent consists of three major components: (1) the drug, (2) the polymer 
coating, and (3) the stent.  
 
The drug is a biologically active agent that inhibits the formation of neointimal 
hyperplasia by suppression of platelet activation, suppression of inflammatory 
response, inhibition of smooth muscle cell migration or proliferation, or promotion of 
healing. Ideally, this drug also has an outstanding overall safety profile and a broad 
therapeutic window. Figure 1.3 (B.L.van der Hoeven, 2005) shows an overview of the 
main targets of drugs used on current drug-eluting stents. Most of these drugs have 
been originally used as chemotherapeutic agents, agents for anti-transplant rejection, 
or immunosuppressive drugs. Besides the biological effects, the drugs have their own 
chemical properties which influence achieving optimal tissue levels and the 
possibilities for loading on a stent. Tissue levels depend on lipophilic or lipophobic 
characteristics, molecular weight and the degree of protein binding of the drug (C. W. 
Hwang et al., 2001;M. A. Lovich et al., 2001). Some drugs (e.g. Heparin) can be 
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loaded directly onto the metallic surface of the stent, but most drugs (e.g. sirolimus, 
paclitaxel) need a polymer coating, which forms a reservoir for the drug. 
 
 
Figure 1.3 Main targets of drugs in relation to the cell cycle (B.L.van der Hoeven, 2005). 
 
Polymer coatings are needed for most drugs because they do not adhere to the 
metallic stent surface. The polymer coating also dictates drug-elution kinetics, which 
can be varied by using multiple polymer layers to achieve optimal drug release over 
time. Until recently, the polymer was the major limiting factor in the development of 
drug-eluting stents. Initially, all biodegradable or non-biodegradable polymers 
induced an increased inflammatory reaction and enhanced neointimal proliferation (W. 
J. vanderGiessen et al., 1996). Later some polymers such as 
poly(L-lactide-co-caprolactone) [P(LLA-CL)] and poly-n-butyl methacrylate & 
polyethylene–vinyl acetate copolymer were found to be biologically inert and stable 
for at least 6 months (D. E. Drachman et al., 2000;T. Suzuki et al., 2001). 
Biodegradable nanoparticle was also reported to be a potential drug carrier for DES (S. 




The dominant drug eluting stents in the market are Cypher® stent (J&J, USA) and 
Taxus® stent (Boston Scientific, USA). Cypher stents are loaded with sirolimus, an 
immunosuppressive drug, on a polyethylene-co-vinyl acetate and poly n-butyl 
methacrylate coating. In contrast, Taxus stents release paclitaxel, an anti-proliferative 
drug, from a poly(styrene-b-isobutylene-b-styrene) coating. Both of the coatings are 
non-erodible. Numerous randomized clinical trials and meta-analyses unequivocally 
attest that DESs reduce restenosis and repeat target lesion revascularization (TLR) 
rates by 40–70% compared with BMSs (M. N. Babapulle et al., 2004;M. C. Morice, 
1773;J. W. Moses et al., 2003;P. W. Serruys et al., 2006;G. W. Stone et al., 2004). In 
a systematic review examining 11 studies and 5,103 patients followed for 1 year, 
angiographic restenosis was reduced from 36.9% with BMSs to 6.2% with 
sirolimus-eluting stents (SESs) and, in a second analysis, from 16.7% with BMSs to 
8.7% with paclitaxel-eluting stents (PESs) (M. N. Babapulle et al., 2004). The 
reduction of angiographic restenosis was associated with a lower rate of TLR (3.5% 
for SESs vs 18.5% for BMSs; 3.3% for PESs vs 12.2% for BMSs). More recently, the 
benefits of DESs have been confirmed in studies with up to 4 years' follow-up. 
Meta-analysis of data from four double-blind studies incorporating 1,784 patients 
found that TLR was reduced from 23.6% with BMSs to 7.8% with SESs (P <0.001) 
(G. W. Stone et al., 2007). Similarly, TLR dropped from 20.0% with BMSs to 10.1% 
with PESs (P <0.001) in a meta-analysis of five double-blind trials comprising 3,513 
patients (G. W. Stone et al., 2007). 
 
Since their approval in April 2003, drug-eluting stents have revolutionized the 
practice of interventional cardiology. Currently, more than 85% of all coronary 
interventions in the United States are performed with drug-eluting stents (D. E. 
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Kandzari et al., 2005). However, DESs delay healing and impair endothelialization, as 
seen in necropsy studies (A. V. Finn et al., 2007;M. Joner et al., 2006) and clinical 
investigations (S. H. Hofma et al., 2006;M. Togni et al., 2005;M. Togni et al., 2007). 
Intravascular ultrasonography studies show a higher incidence of incomplete stent 
apposition with DESs than with BMSs (S. Cook et al., 2007;F. Feres et al., 2006;G. S. 
Mintz and Weissman,N.J., 2006). It is believed that the drug coating delays healing 
around the stent, creating a risk of thrombosis (M. Joner et al., 2006). The safety of 
DESs as compared with BMSs has been analyzed in several recent systematic reviews 
including some with long-term follow-up. Stone and colleagues observed no 
differences between the use of PES and BMS with regard to the incidences of death 
(6.1% vs 6.6%; P = 0.68) or myocardial infarction (MI, 7.0% vs 6.3%; P = 0.66) at 4 
years in their individual-patient data meta-analysis of five trials comprising 3,513 
patients (G. W. Stone et al., 2007). Kastrati et al.'s meta-analysis of 14 trials 
comprising 4,958 patients reported similar 5-year mortality for SES-treated and 
BMS-treated patients (6.0% vs 5.9%), and similar incidences of the combined end 
point of death or MI (9.7% vs 10.2%) (A. Kastrati et al., 2007). The above results 
question whether there is superiority of DES over BMS in long term clinical 
performance. 
 
Although it is believed that the drug coating delays or prevents the 
re-endothelialization (M. Joner et al., 2006), an ideal coating should not only favor 
endothelial cell attachment, but also smooth muscle cells attachment. In fact, all 
animal and human studies with BMS and DES indicated a stable endothelium is 
shown to lie on a layer of ingrown smooth muscle cells (neointima) (A. V. Finn et al., 
2007;M. Joner et al., 2006;W. Yang et al., 2006). An endothelialized smooth muscle 
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cell-rich neointima could seal the thrombogenic components on the stent underlying 
artery from the lumen and provides protection against the devastating complication of 
stent thrombosis (A. Farb et al., 2003). Stent struts without coverage of endothelium 
tended to be surrounded by fibrin tissues, which could be thrombotic (A. V. Finn et al., 
2007;M. Joner et al., 2006). In artery, a functional endothelium always lies on the 
SMC layers (media), or more accurately, the ECM (Elastica interna) secreted by the 
SMCs (B. Nilius and Droogmans,G., 2001). Therefore, it is important that the drug 
coating be biocompatible for SMC adhesion to facilitate the endothelialization, while 
the proliferation of SMC should be also inhibited for a few months after stenting to 
reduce ISR (T. M. Schiele, 2005).  
 
1.3 SVG intervention and covered stents 
1.3.1 Failed saphenous vein grafts 
More than 500,000 coronary artery bypass surgeries are performed each year in the 
US. Saphenous vein grafts (SVGs) are the most frequently used conduits in coronary 
artery bypass graft surgery (J. H. Alexander et al., 2005). Ten years after bypass 
grafting, at least half of vein grafts are occluded or have significant luminal narrowing 
(G. M. FitzGibbon et al., 1996). Many of these patients are elderly and a significant of 
these have premorbid conditions that will exclude repeat surgery because of the high 
risks involved. Scarring of the original surgical by-pass and the possible lack of 
suitable autologous venous graft further complicate open surgical intervention. 
Therefore usually percutaneous intervention with a bare metal stent (BMS) is the 
alternative choice (N. W. Salomon et al., 1990;W. S. Weintraub et al., 1997). 




1) The first one is embolism of atherosclerotic and thrombotic materials from the 
wall of diseased vessels during stent implantation, with consequent 
peri-interventional MI (S. H. Fenton et al., 1994;M. K. Hong et al., 1999;J. 
Lefkovits et al., 1995;R. N. Piana et al., 1994;M. P. Savage et al., 1997;S. C. 
Wong et al., 1995). SVG atheromas contain fewer fibrocollagenous components 
than native-vessel atheromas. Fibrous caps, common in native-vessel disease, are 
poorly developed or absent in SVG atheromas (N. B. Ratliff and Myles,J.L., 1989), 
explaining the tendency for embolization during stenting. Although distal embolic 
protection device could significantly reduce the rate of embolism (D. S. Baim et 
al., 2002), the utilization rate of distal embolic protection in saphenous vein graft 
interventions is as low as 22% among 19,546 patients, because of clinical 
complications, such as accessibility of device, increase of procedural risks or 
simply higher cost (S. K. Mehta et al., 2007).  
2) The second problem is the high incidence of ISR (20-45%) (A. Frimerman et al., 
1997;M. P. Savage et al., 1997;R. Waksman et al., 1997). To achieve better 
outcomes than BMS, DES should exert anti-proliferative effects in the diseased 
SVGs. Initial publication of the RRISC (Reduction of Restenosis in Saphenous 
Vein Grafts with Cypher Sirolimus-Eluting Stents) trial (P. Vermeersch et al., 
2006) reported that the primary end point of late loss was lower after the use of 
sirolimus-eluting stents than after the use of bare-metal stents, but a follow-up 
study found unfavorable clinical outcomes (P. Agostoni et al., 2007). After a 
median follow-up of 32 months, 11 deaths occurred in the group receiving 
sirolimus-eluting stents (29%) but none occurred in the group receiving 
bare-metal stents (p < 0.001). Three deaths were sudden, and one was caused by 
stent thrombosis (P. Agostoni et al., 2007). Although the findings added to 
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concerns about the long-term safety of DES, the imbalance could also partially 
caused by chance in the 75-patient study. A recent report of a single-arm, 
single-center registry study on SVG intervention using Taxus® PES, however, 
indicated a 12-month angiographic restenosis of only 7% and a 1-year Major 
Adverse Cardiac Events (MACE) of 15% (M. H. Jim et al., 2009). This result 
compared very favorably with that of historical controls using BMS, in the range 
of 19% to 37% and 24% to 38%, respectively (A. Frimerman et al., 1997;L. Ge et 
al., 2005;C. E. E. Hanekamp et al., 2003;M. P. Savage et al., 1997;R. Waksman et 
al., 1997;S. C. Wong et al., 1995). Overall, the benefits of DES versus BMS in 
SVG intervention are still controversial (P. Agostoni et al., 2007;W. W. Chu et al., 
2006;R. Hoffmann et al., 2007;M. H. Jim et al., 2009;P. Vermeersch et al., 2006;J. 
Wohrle et al., 2007).  
 
1.3.2 SVG intervention with covered stent 
A covered stent is one whose length and circumference is enclosed in a material. 
Therefore covered stent, after implantation, can prevent contact between the vessel 
wall and blood by creating a physical barrier. Stents can be “covered” in a variety of 
materials. There are two covered stents commercially available: Jomed Stent graft 
(Figure 1.4 left) and Symbiot (Figure 1.4 right). Both are covered with the low surface 
tension, non-degradable polymer, polytetrafluoroethylene (PTFE). Both stents use the 
sandwich structural design. Jomed Stent employs stent-polymer-stent design while 




Figure 1.4 PTFE covereds stents: Jostent (left) and Symbiot stent (right). 
 
As SVG intervention is haunted by embolism and high rate of ISR, covered stents 
have been proposed as a potential treatment to relieve both of these burdens. The 
physical barrier can prevent the embolic materials on vessel wall from passing 
between stent struts and downstream emoblization. Similarly, in-stent restenosis 
might be reduced by providing a physical barrier to prevent neointimal ingrowth. 
Reduced exposure of blood vessel wall to blood components could also reduce ISR. 
Macrophages that migrate into the vessel wall plays a major role in initiating and 
accelerating SMC proliferation, thus inducing in-stent restenosis by releasing 
cytokines and growth factors. Preventing their passage into vessel wall has been 
proposed as a way to reduce in-stent restenosis. 
 
There were four randomized clinical trials on covered stent in the SVG intervention, 
three of which compared Jomed stent with bare metal stents and the other studied 
Symbiot III covered stent. The first trail was the RECOVERS trial in which patients 
received SVG intervention with either Jomed covered stents or Jsoflex BMS (G. 
Stankovic et al., 2003). 301 patients were studied at 20 European Centers. 6 months 
after intervention, there was no significant difference with in-stent restenosis (24.2 vs. 
24.8%), but the pattern of restenosis in the covered stent was primarily was edge. 
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However, the 30-day MACE rate was higher in the covered stent group (P<0.05), 
although the MACE rate at 6 months was not statistically higher (23.1% vs. 15.9%, 
P=0.15). The authors suggested that possible explanations for the lack of the 
reduction in restenosis and MACE rate could be edge proliferation, which is able to 
extend into the stent, or small disruptions of the PTFE membrane during stent 
deployment. A second randomized trial (STING) had a similar result with 
RECOVERS (V. Schachinger et al., 2003). At the primary endpoint of 6 month , the 
covered stent resulted in higher restenosis rate (29% vs. 20%), although this was not 
statistically significant. There was also a trend toward a higher late occlusion rate in 
the Stentgraft group (7% vs. 16%, p=0.069) at follow-up. Cumulative MACE rates 
(death, myocardial infarction, or target lesion revascularization) were comparable in 
the two groups (31% vs. 31%, p=0.93). The authors also raised the concern about 
bulky design of covered stent and suggested that covered stent with refined design 
and anti-proliferative drug incorporation might give a more favorable clinical 
outcome. The large US BARRICADE trial was similar in design to RECOVERS and 
STING (G. W. Stone et al., 2005). Similar to STING, this trial showed a higher rate of 
total occlusion for Jomed covered stent at 26.7% compared to 9.6% for BMS 
(P=0.028). While delayed endothelialization may induce more thrombotic occlusion 
(G. Stankovic et al., 2003), it is possible that restenosis in the covered stents are 
“more” focal at the edge, increasing the risk of total occlusion. Again, this study 
failed to show any benefit of a covered stent in SVG intervention. 
 
The only prospective randomized trial of the Symbiot covered stent, Symbiot III, was 
published in 2006 (M. A. Turco et al., 2006). 400 patients were randomized to either 
the Symbiot covered stent or bare metal stent. The Symbiot stent was successfully 
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deployed in 86% of lesions when compared with 95% of bare metal stents. At 8 
months follow-up the ISR was not different between groups. Although MACE rates 
were not statistically different (30.6% with the Symbiot stent vs 26.5% with BMS), 
the target vessel revascularization with the Symbiot stent tended to be higher than that 
with BMS (23.5% vs 15.6%, P =0.055). Comparing the Symbiot III trial with 
previous random trials on Jomed covered stents, the authors suggested that PTFE 
might not have been a mechanical barrier to smooth muscle cell migration. 
Alternatively, smooth muscle cells might migrate from the unstented edges to the 
luminal stent surface. The authors also pointed out that higher pressure (18atm for 
covered stents while ~12atm for bare metal stents) required to deploy covered stents 
may induce deeper injury to the vessel wall, leading to a higher rate of restenosis. 
 
In summary, based on the available data from the prospective trials with both the 
Jomed and Symbiot covered stents, no additional benefit is seen either in terms of 
protection from distal embolization or from in-stent restenosis. However, the 
comparable outcomes obtained also indicated that a covered stent with refinement 
may be able to outperform bare metal stents, the current practice in SVG intervention. 
The potential improvement of covered stent includes an alternative covered 
membrane for better hemocompatibility, thinner stent design, lower deployment 
pressure and anti-proliferative drug incorporation.   
 
1.3.3 Prospect of SVG intervention 
Based on the outcomes of previous trials on SVG intervention, SVG lesions remain a 
high-risk subgroup with worse outcomes compared with native vessel disease. 
Although the clinical performance of covered stent fell short of expectations, covered 
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stent may be re-introduced to the operation theatre if the following issues could be 
solved: 
1) Thickness. The only two available covered stents, the Jomed and Symboit stents 
are in three-layer sandwich design. The thickness needs to be reduced since it will 
affect the blood flow and increase the risk of thrombosis and edge restenosis (M. 
C. Petrie et al., 2006;G. Stankovic et al., 2003). 
2) PTFE membrane. There appeared to be a higher incidence of stent thrombosis 
when covered stents are implanted (5-22%) (M. Elsner et al., 1999;E. Sovik et al., 
2003;G. Stankovic et al., 2003). This could be at least partially attributed to 
delayed/incomplete reendothelialization due to the high hydrophobicity of 
non-degradable PTFE membrane (B. L. Dolmatch et al., 1996). In fact, PTFE has 
been used as a vascular graft. Only 15-30% of small-diameter synthetic PTFE 
vascular grafts remain effective after 5 years (B. L. Seal et al., 2001). The rate of 
thrombosis occurred in synthetic vascular grafts is greater than 40% after 6 
months (R. D. Sayers et al., 1998). The permanent existence of PTFE might also 
induce complications in the future. Biodegradable material with better 
biocompatibility should be explored to determine if it could lead to better 
performance. 
3) Deployment pressure. Due to the sandwich design of current covered stent, the 
deployment pressure is much higher than that of bare metal stent (M. A. Turco et 
al., 2006), which could induce deeper injury to the target vascular, leading to 
higher level of inflammation-response and restenosis. 
4) Drug incorporation. As reviewed earlier in this section, studies of DES in SVG 
intervention showed significant reduction in restenosis. It is expected that covered 
stent loaded with antiproliferative drug may give similar reduction on the 
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predominant edge restenosis. Although to date DES failed to show ultimate 
benefit on SVG intervention as compared with BMS, mainly due to incomplete 
endothelialization, improvement of drug-loading polymer on hemo-compatibility 
may produce favorable outcomes. 
 
In summary, a new design of covered stent with reduced thickness, better membrane 
material, lower deployment pressure, and drug incorporation could overcome the 
limitations of traditional covered stent and improve performance in SVG intervention. 
 
1.4 Thesis Objectives 
The objective of the research was to engineer a new type of covered stent, namely a 
nanofiber covered stent, with thinner wall, more flexibility and more biocompatible 
than the current commercial covered stent. Electrospinning techniques are used and 
optimized to deposit a nanofibrous membrane onto bare metal stents. The advantages 
of electrospun nanofiber include ease of fabrication, biomimetic characteristic and 
structural flexibility. Details of these advantages will be reviewed in Chapter 2. The 
study focused on membrane fabrication deposited on commercial bare metal stent, 
which provide sufficient mechanical support and at the same time remain sufficiently 
flexible. The specific aims of the study were: 
 
1. To optimize the electrospinning fabrication of several candidates of biodegradable 
polymer. It is hypothesized that hexafluoroisopropanol (HFIP) would be a good 
solvent for electrospinning polyesters, producing bead-less and mechanically 
consistent nanofibers. 
2. To determine a suitable polymer material that is bioresorbable and biocompatible, 
for stent coverage based on the criteria of SMC/EC-scaffold interaction and 
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biodegradability. It is hypothesized that polymeric nanofibers can support 
long-term cell growth without cytotoxic and mutagenic effects. It is also 
hypothesized that nanofibers degrade gradually without sudden loss of molecular 
weight and mechanical properties. 
3. To characterize UV-induced nanofiber degradation with the aim to engineer 
nanofiber 3D structure on the stent with a desired biodegradation rate. As there are 
only a limited number of polymer types are available suitable for clinical use, it is 
desirable to be able to control the degradation rate of the polymeric implant to 
meet the clinical requirement. It is hypothesized that UV radiation induces 
polymeric nanofiber degradation does not significantly affect cell-nanofiber 
interactions. 
4. To develop an electrospinning set-up to deposit uniformly aligned nanofibers onto 
the bare metal stent. One mechanical challenge of covered stent fabrication is that 
the covered material should not only be highly elastic to withstand the expansion 
during stent deployment without being torn, but also be compliant enough so that 
stent deployment pressure is not excessive. Therefore a longitudinally aligned 
nanofibrous structure was designed to create a highly elastic structure allowing 
minimal resistance to radial expansion. It is hypothesized that longitudinally 
aligned fibers provide the maximal circumferential stretchability and minimize the 
resistance to radial expansion during stent deployment and recoil, while at the 
same time maintaining an acceptable porosity and integrity. 
5. To establish the release kinetics and bioactivity of anti-restenosis drug loaded 
within the nanofiber covers. It is hypothesized that paclitaxel could be loaded 





The results of the present study may provide a better understanding of SMC-scaffold 
interaction with different types of polymeric electropsun nanofibers. The degradation 
behaviors of the polymeric nanofiber could also serve as a reference for tissue 
engineering, since electrospun nanofiber, whose degradation behaviors have not been 
adequately studied, are becoming more and more popular as tissue engineered 
scaffolds. More importantly, the nanofiber covered stent may be a good alternative for 
SVG intervention. 
 
This research mainly focused on the “cover” in the covered stent rather than the whole 
stent design. Because the commercial bare metal stents are readily available with 
optimized flexibility and mechanical properties, nanofiber covered stents were 
designed and developed based on commercial BMS. Due to time and budget 
constraints, in vivo studies on animals, which is currently undergoing, were not 
included in this thesis. 
 
In the next chapter, applications of nanofibers in tissue engineering will be reviewed 
in detail. Specifically, highlights will be given to biodegradable electrospun 
nanofibers. A separate section will be given to the reviews on nanofiber degradation, 
a less studied area compared to blocked polymer degradation. It is important to 
monitor the degradation behavior of polymer nanofiber since serious side-effects of 
polymer materials have been reported to be related to polymer degradation in vivo (B. 
Rihova, 1996). Finally, the rationales of using nanofiber for covered stent will be 
summarized in the end of next chapter. 
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Chapter 2  
 Literature reviews 
 
As mentioned in the previous chapter, nanofiber-covered stent (NCS) was proposed as 
a potential device targeting SVG intervention, whose current practice is not 
satisfactory. In brief, the NCS is a bare metal stent covered by nanofibrous membrane 
(Figure 2.1). Desirable properties of the nanofibrous membrane are biodegradability, 
biocompatibility, high elasticity  and drug carrying and releasing capacity. Before 
justify the rationale of using nanofiber as the stent cover, it is necessary to provide a 
general review on nanofibers, its application in tissue engineering and the 
predominant fabrication method-electrospinning. A brief review will also be given on 
commonly used biodegradable polymers for biomedical applications, as well as the 
applications of their nanofibrous form. Since it would critical to select proper polymer 
candidates for nanofiber-cover stent application,  a detailed review will be given on 
the degradation behaviors of electrospun nanofibers.  
 










2.1 Nanofibers and Electrospinning 
2.1.1 Tissue engineering and nanofibers  
Tissue engineering is emerging as a potential solution to the high demand of tissue 
and organ transplantations (R. Murugan and Ramakrishna,S., 2007). General 
strategies of tissue engineering therapies involves using synthetic/natural functional 
scaffolds cultured with or without appropriate cells harvested from the patient or 
donor, and then implanting the cell-scaffold construct in the patient’s body where 
tissue replacement is required. The basic promise of in vitro tissue engineering is to 
integrate the specific cells with scaffolds under appropriate conditions that lead to 
tissue formation. Essentials of tissue scaffold include biocompatibility, physical 
properties and biodegradability, which should be individually tailored to meet the 
requirements of targeting tissue. Additionally, they could be sub-divided into detailed 
characteristics as shown in Table 2.1. Different engineered tissues have specific 
requirements for tissue scaffolds. For example, bone tissue engineering requires 
scaffolds to be mechanically strong and osteoconductive while liver tissue 





Table 2.1 Details of essentials in designing tissue engineering scaffolds. 
 
Nano-topographic environment is believed to be inductive for the cell and tissue 
growth. This idea is raised from that the in vivo micro-environment where cells and 
tissue resides is a nano-featured environment, comprised of porous and nanofibrous 
extracellular matrix (ECM) (T. A. Desai, 2000;I. Nishimura et al., 2003). It has also 
been suggested that the proper phenotypic cell expression may not be achieved within 
the cellular matrix if the scaffold’s fiber diameter is equivalent to the size of the cell 
or in the order of magnitude greater than the cell size (E. D. Boland et al., 2001;M. M. 
Stevens and George,J.H., 2005). In addition, the nanofibrous structure has a high 
surface area-to-volume ratio which may enhance cell attachment. Therefore, one of 
Essentials Characteristics Remarks 
Non-toxicity Biologically compatible to host tissue (i.e., 
should not provoke any rejection, inflammation, 
and immune responses) 
Cell-scaffold 
interaction 
Could induce certain cellular functions (i.e. 
ECM secretion and certain gene expression), 
cellular proliferation or differentiation where 
required. 
Biocompatibility 
Angiogenicity  Should support vascularization growth where 
blood supply is needed 
Porosity To maximize the space for cellular adhesion, 
growth, extra-cellular matrix secretion, 
revascularization, adequate nutrition and 
oxygen supply 










The degradation rate should match the rate of 
tissue regeneration. The scaffold should provide 








the strategies for the scaffold fabrication is to construct an ECM-like nanofibrous 
structure. 
2.1.2 Electrospun nanofibers as tissue engineering scaffolds 
Although tissue scaffolds can be manufactured by various methods, only limited 
methods have the ability to produce nanofibrous scaffolds. Currently, nanofibrous 
structures can be generated by mainly three methods: 1) self-assembly (J. D. 
Hartgerink et al., 2001), 2) phase separation (F. Yang et al., 2004) and 3) 
electrospinning (S. Ramakrishna et al., 2005), which are briefly described in Table 2.2. 
Among them, electrospinning has become most popular technique in recent years (Z. 
M. Huang et al., 2003;W. E. Teo and Ramakrishna,S., 2006). This technology uses 
static electricity to draw fibers from a polymer solution, and deposits the fibers on the 
surface, where the fibers deposit to form a thin, uniform mesh. Electrospinning 
generates continuous, uniformed and long fibers, which have diameters down to 
nano-scale dimension. The advantages of the electrospinning technology make it 
suitable for both small quantity production for laboratory research use and mass 
production for industrial production. By using different setups as shown in Figure 2.2, 
electrospinning can produce different nanofibrous structures with various 2D or 3D 
shapes, including aligned nanofibers (C. Y. Xu et al., 2004a;F. Yang et al., 2005), 
nanofibrous yarn (W. E. Teo et al., 2007;X. Wang, 2008), tubular structure (W. He et 
al., 2009) and core-shell nanofibers (Y. Z. Zhang et al., 2006b). The flexibility and 





 Phase Separation Self-Assembly Electrospinning 
Process
Solvent extraction from 
gelated polymer solution to 
form nanofibrous foam-like 
structures 
Molecules organize and 
arrange themselves into 
an ordered structure 
through weak and 
non-covalent bonds 
Use static electricity to draw 
fibers from polymer 
solution, and deposits the 
fibers on the surface 
Scalable X X √ 
Convenient to 










Good for obtaining 
small nanofibers. 
Cost effective.  
Continuous fibers  
Disadvantages Limited to specific polymers Complex process 
Jet instability, difficult to 
obtain uniform fibers 
with diameter below 
100nm. 
 
Table 2.2 Comparison of three different methods of nanofiber fabrication: electrospinning, 
















Figure 2.2 Schematic diagrams of different electrospinning setups with resultant structures on the 
upper right corner. (a) Standard electrospinning setup (b) Aligned electrospinning, where the fiber is 
collected on the edge of a fast rotating disk (C. Y. Xu et al., 2004a), (c) Nanofibrous yarn collected 
from fluidic system (W. E. Teo et al., 2007). (d) Tubular structure collected from a rotating wire 
(W. He et al., 2009). (e) Core-shell nanofiber fabricated by a co-axial electrospinning setup (Y. Z. 






2.2 Biodegradable polyester nanofibers and its application in tissue engineering 
Commonly used biodegradable polymers include synthetic and natural polymers. 
Degradable polyesters are one of the most widely used synthetic materials to be 
electrospun as tissue engineering scaffolds because 1) they are biodegradable with 
metabolizable degradation products (e.g. lactic acid), 2) the degradation rate of 
polyesters can be controlled by changing the constitute of the polymer, 3) they are 
synthetic polymers and highly scalable in terms of production, 4) some of the 
common members such as polylactic acid (PLA), polyglycolic acid (PGA), 
polycaprolactone (PCL) and their copolymers have been approved by the U.S. Food 
and Drug Administration (FDA) and used in medical application such as sutures and 
drug delivery systems, 5) their nanofibers can be produced by electrospinning 
conveniently and economically (Z. M. Huang et al., 2003). Commonly used 
biodegradable polyesters are PGA, PLA, PCL, Poly(3- 
hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and their copolymers. Table 2.3 lists 








PGA  Heart (E. D. Boland et al., 2004) 
Fast degradation 




Nerve (T. B. Bini et al., 2004a;T. B. 
Bini et al., 2004b), Skin (B. M. Min et 
al., 2004), Heart (X. H. Zong et al., 
2005), Vascular graft (S. I. Jeong et al., 







Skin (J. Venugopal and Ramakrishna,S., 
2005;Y. Z. Zhang et al., 2005b), Bone 
tissue engineering (K. Fujihara et al., 
2005;W. J. Li et al., 2003;W. J. Li et al., 
2005;M. Shin et al., 2004b;H. 
Yoshimoto et al., 2003), Heart (M. Shin 
et al., 2004a), Vascular graft (Z. W. Ma 
et al., 2005a;C. M. Vaz et al., 2005;J. 
Venugopal et al., 2005), Stem cells (H. 







Nerve (M. S. Widmer et al., 1998;F. 
Yang et al., 2005), Bone tissue 
engineering (A. S. Badami et al., 
2006;A. Fertala et al., 2001;K. M. Woo 
et al., 2003;K. M. Woo et al., 2007), 
Heart (X. H. Zong et al., 2005), 







Bone tissue engineering (A. S. Badami 
et al., 2006;K. Kim et al., 2003), Heart 
(X. H. Zong et al., 2005), Vascular 








Vascular graft (W. He et al., 2005a;H. 
Inoguchi et al., 2006;I. K. Kwon et al., 
2005;X. M. Mo et al., 2004;C. Y. Xu et 
al., 2004a;C. Y. Xu et al., 2004b) 
Faster 
degradation than 
PLLA and PCL. 
PHBV 
Bone tissue engineering (I. S. Lee et 
al., 2004) 
Highly stable 
with very long 
degradation time.
 





Polyglycolic acid (PGA) 
PGA is the simplest linear aliphatic polyester. It is a rigid thermoplastic material with 
high strength (up to 250MPa (S. Vainionpaa et al., 1987)) and has metabolizable 
degradation products. Therefore PGA has been used in various biomaterial 
applications. PGA was used to develop the first synthetic absorbable suture, marketed 
as Dexon in the 1960s by Davis and Geck, Inc. (Danbury, CT). Thanks to its high 
strength and degradability, PGA implants has widely tested in bone fracture fixation, 
in the form of pins, screws, plates and rods (N. Ashammakhi and Rokkanen,P., 1997). 
However, complications of PGA implants includes displacement of fracture, fixation 
failure and more importantly, inflammatory foreign body reaction (N. Ashammakhi 
and Rokkanen,P., 1997). It has been found that young patients with PGA bone 
implant had less risk of foreign body reaction. In particular, PGA pins have shown 
promising results in treating fractures in children (O. Bostman et al., 1993). Recently, 
PGA has been fabricated into biodegradable conduit for nerve repair (M. F. Meek and 
Coert,J.H., 2008). The clinical trail demonstrated the better outcome of PGA conduit 
as compared to nerve graft. The product is now marketed as Neurotubetm (Synovis 
Micro Companies Alliance Inc., UK). 
 
Although the degradation product glycolic acid can be metabolized, at high 
concentrations, they can cause an increase of localized acid concentration and result 
in tissue damage (K. A. Athanasiou et al., 1996;O. Bostman et al., 1990;O. Bostman 
and Pihlajamaki,H., 2000;O. M. Bostman, 1992;Y. L. Cao et al., 1998;K. Ceonzo et 
al., 2006). The ultimate fate of glycolic acid in vivo is considered to be the conversion 
to carbon dioxide and water, with removal from the body via the respiratory system. 
However, Hollinger (J. O. Hollinger, 1983) suggested that only the lactic acid follows 
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this pathway, and that glycolic acid is converted into glyoxylate (by glycolate 
oxidase), which is then transferred into glycine after reacting with glycine 
transaminase. 
 
Due to its high crystallinity, with reported values ranging from 35% to 50% ((C. C. 
Chu, 1981b;R. M. Ginde and Gupta,R.K., 1987a;A. M. Reed and Gilding,D.K., 
1981)), it is insoluble in general organic solvents except highly fluorinated solvents. 
Most PGA nanofibers were electrospun using hexafluoro-isopropanol (HFIP) as 
solvent. However, due to its fast degradation (<20 days  (Y. You et al., 2005a)), 
electrospun pure PGA was rarely used as a tissue scaffold. Boland et al. (E. D. Boland 
et al., 2004) claimed that electrospun PGA nanofibers, after pretreated with 
hydrochloride acid, showed an improved biocompatibility with rat cardiac fibroblasts 
in vitro and rat muscle tissue in vivo. It was also claimed that thinner PGA nanofiber 
(fiber diameter=220nm) exhibited better biocompatibility both in vitro and in vivo as 
compared to thick one (fiber diameter=880nm). However, the degradation effect of 
HCL on PGA nanofiber was not adequately addressed by the authors. Our group has 
[unpublished data] cultured porcine smooth muscle cells on electrospun PGA 
nanofibers (d=380nm). Results suggested the PGA nanofiber can only support cell 
growth in the first 7 days followed by rapid disintegration of the nanofiber. One 
concern raised in the study is that the fast degradation of PGA nanofiber would 
provide not enough support for tissue regeneration. 
 
Polylactic acid (PLA) 
PLA, with the addition of a methyl group in each unit, degrades more slowly than 
PGA with increased hydrophobicity (J. C. Middleton and Tipton,A.J., 2000). The 
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lactide monomer exists in three different forms: two stereoisomers L- and D- lactide 
(L-LA and D-LA) and racemic D, L-lactide (DL-LA). The chirality of the LA units 
provides a method to adjust degradation rates, physical and mechanical properties. 
The three stereoisomers of PLA exhibit distinct properties. Poly(L-lactide) (PLLA) is 
a semicrystalline polymer, with a melting temperature between 173-178°C and 
crystallinity varying from 37% to 72% (S. M. Li, 1999;A. M. Reed and Gilding,D.K., 
1981;H. Tsuji et al., 1998). In contrast PDLLA is an amorphous polymer, with no 
fixed melting point. PLA polymers are used in a broad variety of medical applications 
including bioresorbable sutures (C. W. Lou et al., 2008), dental implants (J. R. Hooley 
and Golden,D.P., 1995), bone screws and plates (M. Walton and Cotton,N.J., 2007) 
and controlled drug delivery (K. S. Soppimath et al., 2001). 
 
Nanofibrous PLA has been used as scaffold for nerve regeneration (F. Yang et al., 
2005), bone tissue engineering (K. M. Woo et al., 2003;K. M. Woo et al., 2007), 
vascular engineering (C. Y. Xu et al., 2004c) and stem cell tissue engineering (U. 
Boudriot et al., 2005). Yang et al. (F. Yang et al., 2005) designed an electrospun 
aligned PLLA nanofibrous scaffold to evaluate the efficacy in promoting neuron 
differentiation and guiding neurite outgrowth of C17.2 cells in vitro. C17.2 cell is a 
primordial, multipotents self-renewing cell that can be used as neuron precursors and 
is involved in the normal development of cerebellum embryonic neocortex and other 
structures upon implantation (E. Y. Snyder et al., 1992;E. Y. Snyder et al., 1997;F. 
Yang et al., 2005). The study revealed that C17.2 cells seeded on the scaffolds 
adhered to the scaffolds and started to differentiate on the fibrous scaffold 10 hours 
after the seeding, and by 24 hours around 70% of cells exhibited a spindle-like shape 
with extended processes. The fiber alignment had a strong effect on the cell 
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phenotype: neural cells on aligned fibers grew parallel to the fiber orientation and the 
aligned nanofibers improved neurite outgrowth when compared with random 
nanofibers or microfibrous scaffolds. 
 
Poly(lactic-co-glycolic) acid (PLGA) 
PLGA, the copolymer of PLA and PGA is probably the most popular synthetic 
polymer in tissue engineering application thanking to it excellent biocompatibility and 
variable degradability (S. J. Holland et al., 1986;M. Vert et al., 1992). Several 
end-products are already on the biomedical market. VicrylTM (Ethicon Inc. USA) and 
PolysorbTM (US surgical, USA) sutures use PLGA with GA:LA=90:10 and are 
reported to be absorbed within 8-10 weeks. But VicrylTM can maintain 50% of the 
original strength after 3 weeks while PolysorbTM have 30% remained (information 
obtained from manufacturer website). PLGA with LA/GA ratio of 7:3 has been 
chosen for biodegradable bone clips and staples (LactomerTM, US Surgical, USA). 
PLGA microspheres have been widely used for drug delivery. The commercial 
products include Lupron DepotTM (TAP Pharmaceutical Products, Inc. USA) and 
Prostap SRTM (Wyeth Pharmaceuticals, USA) for cancer chemotherapy, Risperdal 
ConstaTM (Janssen-Cilag Pty Ltd. Australia) for the treatment of schizophrenia and 
Sandostatin LARTM depot (Novartis, Switzerland) for severe watery diarrhea. 
Additionally, ZoladexTM (AstraZeneca, UK) is a subcutaneous PLGA rod implant for 
sustainable release of goserelin acetate, a luteinizing hormone-releasing hormone 
analogue to treat prostate cancer. The wide use of PLGA could be contributed to its 
flexibility of copolymerizing different ratios of PLA and PGA. Depending on the ratio 





PLGA was one of the first electrospun biodegradable polymers for tissue engineering 
applications. The PLGA copolymer has an amorphous structure, because the 
constituent PGA and PLA molecules are unable to pack tightly to one another. Li et al. 
(W. J. Li et al., 2002) have shown that nanofibrous PLGA scaffolds have an 
interconnected-porous structure with more than 90% porosity and sound mechanical 
properties close to that of skins. The authors claimed electrospun PLGA possesses 
good properties for tissue engineered scaffolds. Electrospun PLGA has successful 
served as a scaffold for skin tissue engineering (B. M. Min et al., 2004), nerve 
regeneration (T. B. Bini et al., 2004a), vessel engineering (S. I. Jeong et al., 2007;J. 
Stitzel et al., 2006) and bone regeneration (W. J. Li et al., 2002;H. Terai et al., 2002). 
With high surface to volume ratio, electrospun PLGA nanofibers have been proposed 
for cell capture. Ma et al. (K. Ma et al., 2008) compared the ability of PLGA and 
blended PLGA-collagen to capture hematopoietic stem cells (HSC) in vitro, using 
tissue culture polystyrene (TCP) as control. All three samples of nanofibers exhibited 
more than 5-fold increase of HSC capture. Blending collagen with PLGA nanofiber 
additionally increased the cell capture percentage from 7.5% to 23% in 30mins, 
whereas the number could reach 67% if the PLGA-collagen blended nanofiber 
pre-coated with endothelial leukocyte adhesion molecule-1 (E-selectin).  
 
Poly(ε-caprolactone) (PCL) 
Another member of the polyester family is PCL, a semi-crystalline biodegradable 
polymer. Its crystallinity was reported to be 45%-67% (C. G. Pitt et al., 1981;H. Tsuji 
et al., 1998;W. P. Ye et al., 1997). Compared to other polyester family members such 
as PLA, PGA, and PLGA, PCL has been used less frequently as a material for 
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fabricating biomaterial scaffolds, mainly because of concern over its slower 
degradation kinetics (PITT C.G., 1990). But the slow degradation makes PCL an ideal 
polymer for long-term drug delivery (PITT C.G., 1990). Capronor, a 1-year 
contraceptive represents such a system (S. J. Ory et al., 1983). The drug release is thus 
diffusion control rather than erosion controlled. 
 
However, the ease of fabrication and low cost make PCL an attractive polymer for the 
fabrication of electrospun nanofibers (M. S. Khil et al., 2005;W. J. Li et al., 2005;M. 
Shin et al., 2004a;M. Shin et al., 2004b;C. M. Vaz et al., 2005;J. Venugopal and 
Ramakrishna,S., 2005;Y. Z. Zhang et al., 2005b). It is also known that the 
electrospinning process re-organizes PCL polymer chains and, compared with 
unprocessed PCL, electrospun nanofibers have a reduced crystallinity (K. H. Lee et al., 
2003). Electrospun PCL has been used in skin tissue engineering (J. Venugopal and 
Ramakrishna,S., 2005), bone regeneration (W. J. Li et al., 2003;W. J. Li et al., 
2005;M. Shin et al., 2004b;H. Yoshimoto et al., 2003) and heart tissue engineering (M. 
Shin et al., 2004a). Our group has successfully fabricated co-axial (Y. Z. Zhang et al., 
2006b), porous (Y. Z. Zhang et al., 2006a), gelatin blended (Y. Z. Zhang et al., 2005a) 
and Hydroxyapatite (HA) blended (J. Venugopal et al., 2008) PCL electrospun 
nanofibers. Zhang et al. (Y. Z. Zhang et al., 2006b) used co-axial electrospinning 
(core: PEG; shell: PCL) to successfully encapsulate bovine serum albumin (BSA) into 
the PEG matrix (Figure 2.2e). The release kinetics of fluoro-isothiocyanate (FITC) 
conjugated BSA showed a burst release of 60% BSA within 24 hours. However, 






P(LLA-CL) is the copolymer of PLLA and PCL. Although less popular than PLGA, 
electrospun P(LLA-CL) has shown distinctive properties in tissue engineering. Our 
groups first demonstrated that electrospun P(LLA-CL) could be a good candidate for 
vascular engineering with biocompatibility of human coronary artery smooth muscle 
cells (HCASMC) and human coronary artery endothelial cells (HCAEC) (C. Y. Xu et 
al., 2004a;C. Y. Xu et al., 2004b;C. Y. Xu et al., 2004c). Dong et al. (Y. X. Dong et 
al., 2008) cultured porcine coronary artery smooth muscle cells (PCASMC) on 
electrospun P(LLA-CL) for up to 100 days and multilayers of cells were tightly 
grown on the scaffold, while PCASMC on electrospun PLGA failed to reach full 
confluency. He et al. (W. He et al., 2009) implanted electrospun P(LLA-CL) vascular 
grafts into the epigastric vein of a rabbit model. The grafts remained patent 7 weeks 
after the implantation. The above studies indicated that electrospun P(LLA-CL) has 
good potential in the vascular engineering application 
 
Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)  
PHBV belongs to the family of polyhydroxyalkanoate (PHA), a polyesters class that 
was first isolated from Bacillus megaterium in 1925 by French microbiologist 
Maurice Lemoigne. The most common form, Poly(3-hydroxybutyrate) (PHB) is 
produced by a number of micro-organisms (like Alcaligenes eutrophus or Bacillus 
megaterium) apparently in response to conditions of physiological stress. Native PHB 
is amorphous but easily crystallized after purification. To reduce the brittleness of 
PHB, it is often copolymerized with 3-hydroxyvalerate in various ratios, forming 
PHBV. PHBV is now widely used in packing materials, like thin film or paper coating 
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(J. K. Hobbs and Barham,P.J., 1997) . In the last decade, PHBV has also attracted 
attention for tissue engineering applications (G. Q. Chen and Wu,Q., 2005). 
 
A number of studies investigated the tissue engineering application of electrospun 
PHBV. Lee et al. (I. S. Lee et al., 2004) reported that chondrocytes better attached 
and appeared to have greater spreaded morphology on the surface of the electrospun 
PHBV fabric than they did on flat PHBV cast films in the early culture stage. 2 hours 
after the cell seeding, 30.1% of chondrocytes were attached on the surfaces of the 
PHBV nanofibrous mat while only 19.0% on flat PHBV film. Chondrocytes tended to 
spread on the nanofibers and remain rounded on the cast film. Ito et al. (Y. Ito et al., 
2005) fabricated a composite of hydroxyapatite and PHBV nanofibers, by soaking the 
electrospun nanofibrous membrane in simulated body fluid, a solution has similar 
concentration of Na+, K+, Mg2+, Ca2+, Cl–, HCO3–, HPO4 2– and SO42– as those in 
human plasma. HA deposition greatly increased the hydrophilicity of the scaffold. 
COS-7, a cell line originated from the kidney of an Africa green monkey was seeded 
on the scaffold. 1.5hrs after the cell seeding, the attached cell number on the 
electrospun membrane were significantly higher than that on cast film (P<0.01), 
although cell adhesion was not significantly affected by the combination with HA. 
Electrospun PHBV mat were investigated for wound dressing by Han et al. (I. Han, 
2007), compared with PHBV/collagen (70:30, wt/wt) and PHBV/gelatin (70:30, wt/wt) 
nanofiber matrices. Dermal sheath cell, one of the two major dermal (dermal sheath 
and dermal papilla) cells in the hair follicle, were used to study the cell attachment. 
Although PHBV mixed with collagen and gelatin improved the attachment of dermal 
sheath cells, pure PHBV mat promoted faster wound closure in a wounded mouse 
model than PHBV/collagen and PHBV/gelatin. The authors suggested that the 
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mechanical stability of matrices seemed to be more important for early-stage wound 
dressings since PHBV/collagen and PHBV/gelatin matrices have poor mechanical 
strength. The stress at yield of PHBV, PHBV/collagen and PHBV/gelatin matrices 
were 2.96, 5.23 and 2.20 MPa, respectively. But the strength of PHBV/collagen and 
PHBV/gelatin were greatly reduced only 10 mins after water contact, while the 
strength of PHBV matrices was not affected.  
 
2.3 Degradation behaviors of polyester nanofibers 
One advantage of degradable polyesters in medical applications is that their 
degradation products are metabolizable in the human body, with no future 
complication after their complete absorption (M. Hakkarainen, 2002). Although 
degradation of traditional macroscale (in the dimension of millimeters) degradable 
polyesters have been comprehensively studied (M. Hakkarainen, 2002), degradation 
studies on electrospun degradable polymeric nanofiber are still in its infancy stage. It 
is reasonable that the degradation behavior (in vivo and in vitro) of nano-scale 
materials will be different from that of macroscale ones for (1) the surface to volume 
ratio of nanofibers is much higher than that of macroscale polymer; (2) The 
crystallinity, polymer chain configuration and orientation and hydrophobicity could 
be different; And (3) the bio-mimic structure of nanofibers may affect the activity of 
surround cells or tissue, which may in turn affect their degradation. In the following 
sections, degradation behaviors of electrospun degradable polyesters will be 
systematically reviewed and compared with the degradation behaviors of polyesters in 
macroscale. 
 
Many in vitro factors could influence the biodegradation of polyesters. These factors 
include pH, ionic strength of the medium, enzymatic activity etc. Commonly used in 
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vitro methods for the assessment of polymer degradation study is by immersing the 
sample in phosphate buffered saline (PBS) or equivalent buffer solution at pH ~7.4 at 
37℃. The following discussion about in vitro degradation will be carried out in this 
type of solution unless stated otherwise. For in vivo degradation, normally a piece of 
sample will be placed subdermally in a small animal, such as in a mouse and rat 
model. 
 
2.3.1 High surface to volume ratio greatly increases the degradation rate of PGA 
nanofiber 
PGA was among the fastest degraded polyesters due to its hydrophilicity and 
non-side-chained molecular structure. The degradation rate of PGA was greatly 
affected by dimensions, crystallinity and degradation environment (N. Ashammakhi 
and Rokkanen,P., 1997). Chu et al. (C. C. Chu, 1981a;C. C. Chu, 1981b;C. C. Chu, 
1981c;C. C. Chu, 1981d) systematically studied the in vitro degradation of Dexon 
PGA sutures and established a simple degradation mechanism via homogeneous 
erosion. The degradation process occurs in two stages: the first stage involves the 
diffusion of water molecules into the amorphous regions of the matrix and simple 
hydrolytic chain scission of the ester groups. In this stage degradation predominates 
during the first 21 days while crystallinity increased from 40% to a peak of 52%. The 
second stage of degradation involves largely the crystalline areas of the polymer, 
which becomes predominant when the majority of the amorphous regions have been 
eroded. After 49 days, the weight loss of PGA suture was around 42 % with complete 
loss of mechanical properties (C. C. Chu, 1981b). A number of studies (N. 
Ashammakhi and Rokkanen,P., 1997) have investigated the in vivo degradation of 
PGA bone implant. The results revealed the complete degradation time in vivo can be 
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range from 4 to 9 months. Ginde and Gupta (R. M. Ginde and Gupta,R.K., 1987a) 
examined increase the degradation of PGA fibers and pellets of comparable 
crystallinities. Degradation of pellets was faster than that of fibers. But the authors 
attributed this to the long-range order of PGA fibers produced by melt spinning, not to 
the dimensional difference. Later studies believed that the degradation rate of PGA 
increases when its dimension decreases (S. Hurrell et al., 2003;P. Tormala et al., 
1991). 
 
A few studies have investigated the degradation behavior of electrospun PGA 
nanofibers. You et al. (Y. You et al., 2005b) reported that PGA nanofibers showed a 
rapid degradation rate without an induction period, the first stage of polymer 
degradation in which the mass and morphology remains unchanged. After 20 days of 
degradation in vitro, the weight remaining of PGA nanofiber mesh was only 40%. 
PGA nanofibers started to break down after 1 day. The surface defect was believed to 
lead to fiber rupture after several days of degradation. The authors also compared the 
degradation study of PGA microfiber by Shum and Mak (A. W. T. Shum and 
Mak,A.F.T., 2003) and found that PGA nanofibers showed a much faster degradation 
rate than microfibers while the crystallinity of PGA nanofiber did not increase during 
degradation as that of microfibers did. Park et al. (K. E. Park et al., 2006) observed 
similar degradation profile of electrospun PGA nanofibers. The weight loss of PGA 
nanofibers was above 90% after 45 days. After only 12 days, PGA nanofibers were 
broken down into short fiber fragments. In contrast to You’s study, the crystallinity of 




Table 2.4 lists the differences of in vitro degradation rates among different 
dimensionss of PGA polymers. To sum up, the degradation rates of PGA are in the 
order of nanofibers>pellets>microfibers. Only a few days of exposure to aqueous 
medium could lead to complete disintegration of PGA nanofiber (Y. X. Dong et al., 
2009) while macroscale PGA such as PGA rod remains intact after 56 days of 





 Pellet Suture Microfiber Nanofiber 
Diameter NA 0.35mm 13μm 380nm 380nm 310 nm 
Surface area (m2) 
per cm3 materialsa 0.002e 0.011 0.308 10.53 10.53 12.9 
Mw 60kD NA 69kD 100kD 14-20kD 14-20kD
20% degradation 
time in massb ~56days  35 days 14 days 8 days 4 days 10 days 
Half degradation in 
massc NA 55 days 28 days NA 12 days 16 days 
Half degradation in 























Table 2.4 Effects of different shapes and dimensions on PGA degradation  
Notes:  
aCalculation based on the assumption that pellet is cubic, films are infinitely large and fibers are 
infinitely long 
b20% degradation time in mass: the degradation time leading to 20% of mass loss. 
cHalf degradation in mass: the degradation time leading to 50% of mass loss 
dHalf degradation in ultimate strength: the degradation time when the ultimate strength of material 
drop to 50% of its original strength 
eEstimation made presumed that the pellet is 3mm cube. 
Same definitions are applied to Table 2.5&2.6. 
NA: Not Available.  
2.3.2 Composition of D-LA and L-LA greatly affect the degradation rate of PLA 
nanofibers 
The degradation of macroscale PLA in aqueous media generally occurs in two stages 
similar to PGA (S. M. Li, 1999). The first stage starts with water diffusion into the 
amorphous regions, which is less organized, allowing water to penetrate in more 
easily. The second stage starts when most of the amorphous regions are degraded. The 
hydrolytic attack then proceeds from the edge towards the center of the crystalline 
domains. This explains the much faster hydrolysis rate of the amorphous PDLLA 




The composition of the polymer chains, i.e. the content of L-LA, D-LA units greatly 
influences the degradation rate of PLA nanofibers (S. M. Li, 1999). PDLLA is 
amorphous while PLLA is semi-crystalline. The half life of PLA with different 
L-LA:D-LA ratios can be varied from 10 weeks for PDLLA (50:50) to 110 weeks for 
PLLA. The higher the crystallinity is, the lower the degradation rate. During early 
degradation, the amorphous PDLLA showed increased crystallinity. This could be 
explained by the the shortened polymer chains restructuring and recrystallizing. And 
the transition and melting temperature of PLA decreases with the degradation time. 
Bulk amorphous PDLLA tends to degrade into a ‘‘hollow” structure, because of the 
autocatalytic effect together with ease of water penetration (S. M. Li et al., 1990a;S. 
M. Li, 1999;M. Therin et al., 1992).  
 
The dimension and shape of the polymers is another important factor affecting the 
degradation properties. Grizzi et al. (I. Grizzi et al., 1995) compared the degradation 
rate among different shapes of PDLLA: compression-molded plate, millimetric beads, 
microspheres and cast films. Results showed that the degradation of plates and beads, 
finally leading to bulk disintegration, were faster than that of microspheres and films, 
during which only surface hydrolysis was observed. This can be explained by the 
autocatalytic degradation occurs in the large-scale materials (S. M. Li et al., 1996). 
 
Degradation studies on PLA nanofibers mainly used amorphous PDLLA, because of 
the much lower degradation rate of PLLA. Cui et al. (W. G. Cui et al., 2006) studied 
the in vitro degradation of 5% paracetamol-loaded electrospun PDLLA fiber with 
average diameters of 212nm, 551nm and 1310nm, as compared with PDLLA cast film 
with thickness of 100um. After incubation in the degradation medium, the fiber size 
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of the electrospun PDLLA increased and fiber space decreased. After incubation in 
the degradation medium, the fiber size of electrospun PDLLA increased, and fiber 
space decreased. This was explained by the shrinkage of fibers. Thicker fibers showed 
faster mass loss: nanofibrous mat with average fiber diameter of 212nm lost 18% of 
mass in 9 weeks while casting film and microfibrous mat with average fiber diameter 
of 1.31μm lost only 8%. However, reduction in molecular weight (50% in 9 weeks) 
was only observed in casting film while no obvious change in molecular weight (Mw) 
was found on electrospun mats after 9 weeks of study time. The authors explained 
that casting film underwent bulk degradation with autocatalysis, resulting in Mw 
reduction but a minor mass loss and electrospun mats were degraded by surface 
erosion, which led to mass loss but minor Mw reduction. Recent study from the same 
group (W. G. Cui et al., 2008) confirmed a similar degradation behavior of pure 
PDLLA electrospun fibers. In addition, the authors pointed out that high 
hydrophobicity of PDLLA electrospun mats could result in slower water penetration 
thus a degradation profile of surface erosion.  
 
Two studies (S. R. Bhattarai et al., 2006;Y. You et al., 2005b) investigated the 
degradation of electrospun PLLA nanofibers with fiber diameters of 290nm and 
650nm, Mw of 450kD and 650kD, respectively. No significant degradations were 
observed during the study periods (7 weeks and 14 weeks respectively). A more 
recent study, however, recorded a 10% of mass loss of electrospun PLLA nanofiber 
(fiber diameter at 368nm) with Mw reduced from 238kD to 200kD in 8 weeks (G. Sui 




Table 2.5 lists the size dependent degradation rate of PDLLA. As seen, the 
degradation rate of PDLLA increased when the dimension of PDLLA is reduced from 
millimeters to micrometers. But the degradation rate decreased when the dimension 
further reduced from micrometers to nanometers. As for PLLA, the degradation rate is 
so slow that there are only limited studies on its degradation. At present, no 
conclusive comparisons can be made on PLLA degradation with different dimensions. 
 
Shape 
 Rod Plate Film  Nanofiber 
Diameter NA 2mm 300μm 100μm 212nm 
Surface area 
(m2) per cm3 
materials 0.001a 0.001 0.007 0.02 18.87 
Mw 65kD 43kD 67kD 78kD 78kD 
20% 
degradation 
time in mass NA 11 weeks 29 weeks NA 10weeks 
half degradation 
in mass 10 weeks 12 weeks NA NA NA 
Half 
degradation 
time in Mw NA 6 weeks 12 weeks 9 week NA 
Reference 
(S. M. Li 
et al., 
1990a) 
(I. Grizzi et 
al., 1995) 
(I. Grizzi et 
al., 1995) 
(W. G. Cui 
et al., 2006) 
(W. G. Cui 
et al., 2006) 
 
Table 2.5 Effects of PDLLA degradation due to different shapes and dimensions 
aEstimation made presumed that the Rod is 3mm in diameter and 3mm in length 
 
Studies have been made on enzymatic degradation of PLLA. It has been reported that 
80% weight loss was accomplished within 65 hr for a PLLA film when exposed to 
proteinase K with concentration of 200ug/mL (S. M. Li and McCarthy,S., 1999). The 
same weight loss was achieved within 7-9 hrs for electrospun PLLA nanofiber mats 
when the concentration was only 2ug/mL. The concentration of proteinase K was 
99% lower while the degradation rate was nearly 10 times higher (J. Zeng et al., 2004). 
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The study revealed that increased surface-to-volume ratio of PDLLA nanofiber 
greatly increased the enzymatic degradation rate. 
 
2.3.3 Controllable Degradation of PLGA nanofiber 
The composition of the polymer chain of PLGA, i.e., the content of L-LA, D-LA, and 
glycolic acid (GA) units greatly influence the degradation behavior (M. Hakkarainen 
et al., 1996;S. M. Li et al., 1990b;S. M. Li, 1999). Glycolic acid-rich PLGA 
copolymers are more hydrophilic and degrade faster in aqueous media than PLA and 
lactic acid-rich PLGA copolymers (H. J. Shin et al., 2006;X. H. Zong et al., 2005). 
For blended PGA and PLA nanofibers, increased PGA content also induces faster 
degradation (Y. You et al., 2005a). Mixing of D-LA and L-LA copolymer reduces its 
crystallinity thus increasing the degradation rate (S. R. Bhattarai et al., 2006;W. G. 
Cui et al., 2006;S. M. Li, 1999). As a result, the half life of PLGA with different 
compositions can vary from 3 weeks for P(DLLA-GA) (37.5:37.5:25) to 20 weeks for 
P(LLA-GA) (85:15) (S. M. Li, 1999). However, commonly used is 
Poly(DL-lactide-co-glycolide) [P(DL-LGA)], in which the lactic acid component is 
amorphous. The PLGA mentioned in this paper will be P(DL-LGA) unless otherwise 
specified. 
 
Shin et al. (H. J. Shin et al., 2006) compared the in vitro degradation between 
electrospun PLGA (50:50) and PLGA (75:25) (d=550nm) for the period of 8 weeks. 
There was little change in mass and pH for the 75:25 PLGA scaffolds until week 7, 
after which there was a decrease in mass (5%) and pH value (from 7.4 to 7.35) in 
week 8. Similarly, for the 50:50 PLGA scaffolds, the mass and pH changed slightly 
during the first 4 weeks and decreased markedly thereafter (35% mass loss till 8 
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weeks and pH drop from 7.4 to 7.27). The molecular weight of all scaffolds decreased 
gradually, but the decrease in the molecular weight of the 50:50 PLGA scaffolds was 
more rapid than that of the 75:25 PLGA scaffolds. The molecular weights of the 
75:25 and 50:50 PLGA scaffolds decreased by 36.8 and 88.0% over 8 weeks, 
respectively. 
 
Size dependent degradation of PLGA (75:25) and PLGA (50:50) is listed in Table 2.6. 
For both polymers, their degradation rates decreased with the reduction of dimension. 
Autocatalysis greatly increases its degradation rate when the dimension of material is 
larger than the scale of a millimeter. 
Shape 
 Rod Thin film Nanofiber 
Diameter NA 85-100μm 5-10μm 550nm 484nm 
Surface area (m2) 
per cm3 materials 0.001a 0.022 0.276 7.27 8.26 
Mw 51kD 68kD 68kD 123kD 80kD 
20% degradation 
time in mass NA 45 days 60 days >> 8 weeks 60 days 
half degradation 




time in Mw NA 20 days 45 days > 8 weeks 80 days 
Reference 
(S. M. Li et 
al., 1990b) 
(L. Lu et al., 
1999) 
(L. Lu et 
al., 1999) 









 Thick film Thin film Nanofiber 
Dimension 0.5mm 85-100μm  5-10μm 760nm 550nm 
Surface area (m2) 
per cm3 materials 0.004 0.022 0.276 5.26 7.27 
Mw NA 44kD 44kD 108kD 98kD 
20% degradation 
time in mass 14 days 25 days 35 days 25 days 49 days 
half degradation in 












(L. Lu et al., 
1999) 
(L. Lu et 
al., 1999) 
(Y. You et 
al., 2005b) 





Table 2.6 (a) Comparison of the PLGA (75:25) degradation rate in different shapes and dimensions. 
(b) Comparison of the PLGA (50:50) degradation rate in different shapes and dimensions 
aEstimation made presumed that the Rod is 3mm in diameter and 3mm in length 
 
A degradation study on PLGA (80:20) electrospun fibers (d＝300nm) in the period of 
10 weeks was reported by Duan et al. (B. Duan et al., 2007). The pH value of the 
degradation medium remained relatively constant (around 7.40) throughout the 
degradation period of 10 weeks. The molecular weight (Mw) of PLGA, as determined 
by gel permeation chromatography (GPC), decreased from 250kD to 200kD in 10 
weeks. During the in vitro degradation period, the fibers shrunk a little and seemed to 
lose their initial surface smoothness. However, no obvious morphological change in 
the PLGA scaffolds was observed for up to 10 weeks. The tensile strength and 
Young’s modulus of electrospun PLGA membranes did not change significantly after 
10 weeks of degradation. The electrospun PLGA showed a significant decrease in 
their elongation-at-break by 83% after a 10-week degradation period with respect to 
their initial value. Electrospun PLGA membranes maintained their 
elongation-at-break during the first two weeks and thereafter the elongation-at-break 
decreased sharply. This could be explained by the thermal induced re-crystallization, 
leading to more brittle structure. 
 
Compared to the PLGA with higher content of lactide, PLGA (10:90) is more 
crystalline due to the high ratio of glycolic acid. Zong et al. (X. H. Zong et al., 2003) 
divided the degradation of this semi-crystalline polyester nanofiber into four stages 
(Figure 2.3). In stage I (within the first day), because the glass transition temperature 
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(Tg) is close to the incubation temperature (37˚C), a rapid thermally induced 
crystallization process resulted in two-phase lamellar structure. In stage II (day 2 to 
day 5) the polymer chains in the amorphous regions between the lamellar stacks begin 
to degrade due to ease of water penetration. This chain scission process increases the 
polymer chain mobility, which leads to further crystallization. The process is often 
termed as cleavage-induced crystallization. Several studies have shown similar 
phenomenon of increased crystallinity during degradation (Y. You et al., 2005a;Y. 
You et al., 2005b;X. H. Zong et al., 2003). In the first two stages, mass loss is trivial 
(10%) but molecular weight could decrease sharply. In stage III (day 6 to day 11), the 
degradation rate of the electrospun membrane increases due to autocatalysis. The 
sample fragments because the amorphous regions degrade faster than the crystalline 
regions. In this stage, breach of the nanofibers can be observed with a large mass loss 
(40%). The degraded sample is more hydrophilic than the initial sample due to the 
exposed carboxylic groups from hydrolysis of ester bonds. Stage IV (day 12 onwards) 
can be described as mass loss from the crystalline region. This model has been 






Figure 2.3 A four-stage model of structure and morphology changes of electrospun PLGA (10:90) 
membranes during in vitro degradation. Stage I: thermally induced crystallization from amorphous 
PLGA (10:90) nanofibers and lamellar stacks are formed. Stage II: the mobility of polymer chains 
within large amorphous gaps increases after chain scission, cleavage-induced crystallization occurs 
and thinner lamellae/lamellar stacks form. Stage III: mass loss rate is accelerated and large 
amorphous gaps disappear, nanofibers start to break down. Stage IV: lamellar stacks start to 
collapse and accelerated mass loss is observed. (X. H. Zong et al., 2003) 
 
A recent study by Pan et al. (H. Pan et al., 2008) investigated the degradation of 
electrospun PLGA (75:25) in a fibroblast/macrophage co-culture system. Results 
showed that both fibroblasts and macrophages were able to accelerate the degradation 
of the scaffold. Lysozyme, non-specific esterase (NSE), gelatinase, hyaluronidase-1 
and a-glucosidase were up-regulated in the presence of the scaffold. Author believed 
they played important roles in the cell-mediated scaffold degradation. Comparable to 
in vivo degradation in a mouse subdermal model, authors claimed that the co-cultured 
system would be an in vitro tool for initial biomaterial evaluation. While macrophages 
were responsible to the accelerated degradation, fibroblasts had less effect on 
degradation. In my PhD study where SMC were cultured, it is hypothesized that SMC 




2.3.4 Slow degradation of PCL nanofibers 
Polycaprolactone is relatively stable against in vitro hydrolysis, but it was shown that 
it can be degraded by microorganisms. PCL degrades in pure fungal cultures (C. 
Eldsater et al., 2000;F. R. Fields, 1974;C. A. Murphy et al., 1996;Y. Oda et al., 1995), 
in compost (C. Bastioli et al., 1995;C. Eldsater et al., 2000;F. Lefebvre et al., 1994;A. 
Ohtaki et al., 1998), in active sludge (C. Bastioli et al., 1995;C. Eldsater et al., 2000), 
by enzymes (Z. H. Gan et al., 1997), and in soil (V. Toncheva et al., 1996). In the 
biodegradation of PCL, rapid mass loss was observed by surface erosion, with less 
reduction of molecular weight. In contrast, the in vitro hydrolysis of polyester is 
normally preceded with a decrease in molecular weight with minor mass loss. 
Therefore the microorganism plays a key role in PCL surface erosion. 
 
Degradation of PCL nanofibers in vitro over 6 months and in vivo over 90 days were 
reported by Bolgen et al. (N. Bolgen et al., 2005). During the in vitro degradation 
period, samples with different diameters were characterized by mechanical properties 
and molecular weights. Overall, thinner fibers degraded faster than thicker ones in 
mechanical strength, where PCL fiber with an average diameter of 196 nm lost 70% 
of the strength over 6 months while that with a diameter of 689nm lost only 35%. The 
reduction of molecular weight ranged from 7% to 15%, but there were no significant 
differences among fibers with different diameters. In the in vivo degradation study, 
electrospun PCL (d=250nm) meshes were subdermally implanted in the back skin of 
rats. At different time intervals, the samples were collected and the Mw were 
analyzed. After 90 days of implantation, the Mw fell by 27%, as compared to a 13% 
drop after 6 months in vitro degradation. The mass change was not reported in this 
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article. It is likely that no mass change was observed in the study throughout the study 
period given the small reduction of Mw. 
 
Enzymatic and environmental degradation of PCL nanofibers also has been studied. 
PCL exhibited a fast degradation with 47% weight loss in 8.5 hrs in the presence of 
lipase (J. Zeng et al., 2004). The crystallinity of PCL fibers was increased during the 
degradation. It was explained by thermally induced recrystallization. Ohkawa et al. (B. 
Duan et al., 2007;S. M. Li, 1999;K. Ohkawa et al., 2004) has done two biodegradation 
studies of electrospun PCL cultured with seven strains of Fungi. As expected, PCL 
nanofibers with thinner diameters experienced faster degradation. 
 
2.3.5 Summary of nanofiber degradation studies. 
While tissue engineering has become a popular topic and more and more efforts have 
been made to explore new scaffolds, “nano” and “biodegradable” are always the 
popular words to claim superiority of a new scaffold. However, although the 
emerging new type of scaffold or polymers were claimed to be degradable by 
incorporating hydrolytical bond (ester bond, amide bond, etc.), less studied are the 
actual degradation behaviors, either in vitro or in vivo. This review aimed to 
summarize the degradation behaviors of popular nanofibrous scaffolds made by 
mostly used degradable polymer---polyesters, only to find out that the literature is 
very limited, both in quantity and depth. Other than giving a “yes” or “no” to answer 





Most of the degradation studies of polymeric nanofibers only revealed weight loss and 
morphological change. Mechanical strength is one of critical factors for tissue 
engineering application----the nanofiber scaffold must not degrade too rapid before 
tissue growth takes place. However, only a few studies were conducted to investigate 
the mechanical loss during nanofiber degradation. Detailed characterization of 
nanofiber mechanical strength during degradation is desired. 
 
Although the advantages of using biodegradable nanofibers are immense, much work 
needs to be done in order for these materials to be widely accepted in a wide array of 
tissue engineering applications. Considerations include: 1) How does the nanofiber 
finally disappear? 2) Does the degradation of the nanofibers affect the cellular growth 
if it is used for tissue engineering in vitro? 3) Lastly, how does the degradation of 
nanofibers induce a foreign body reaction? These questions need to be dealt with. 
 
Therefore, in my PhD project, a long term systematic degradation study (chapter 5) of 
polymeric nanofibers was designed under smooth muscle cell-culture condition, in 
order to mimic the nanofiber degradation behavior in the case of vascular implant. 
 
2.4 Rationale of Nanofiber covered stent (NCS) 
NCS can be made from any current BMS by coating a thin layer (~10μm) of 
nanofibers using electrospinning technique. The nanofiber-covered stent will address 
many of the limitations of current covered stent. NCS aim to treat SVG stenosis, also 
potentially brain aneurysm and coronary artery perforations that are either currently 
not treatable or adequately addressed with the existing stent designs. Very recently, 
the first paper about nanofiber covered stent was published by Kuraishi et al., 
targeting its application in brain aneurysm (K. Kuraishi et al., 2009). The authors 
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developed a nanofiber-covered stent by electrospinning fine polyurethane (PU) fibers 
onto stents. The efficacy of the covered stents was evaluated with a rabbit model, in 
which aneurysms had been formed at the right common carotid artery by the elastase 
method. Angiographic evaluation on day 1 post-treatment (acute phase) revealed 
complete occlusion of the aneurysms and the patency of the parent arteries in animals 
treated with covered stents. At 10 days post-stenting, the aneurysm neck was 
completely covered with neointimal layer. 
 
In this project, we propose NCS for SVG intervention. Potentially, NCS can reduce 
restenosis by the nanofibrous barrier which prevents transgraft tissue migration while 
maintaining the nutrient exchange. The nanotopography of NCS will potentially 
promote early re-endothelialization (W. He et al., 2005a;W. He et al., 2009). 
Complete endothelialization would be expected before or upon resorption of the 
biodegradable nanofibers, reducing the risks of thrombosis. The major advantages of 
NCS are:  
a) It creates a physical barrier to prevent ISR; 
b) Nanofiber cover is both biocompatible and biodegradable; 
c) Nanofibrous structure of NCS promotes early endothelialization; 
d) Nanofiber can be loaded with anti-proliferative drugs; 
e) More flexible than traditional PTFE covered stent; 
f) Wall thickness can be precisely controlled; 
g) The aligned nanofiber cover could be highly expandable, readily 
accommodate any BMS with diameters of 2.5-8mm. 
 
In the next three chapters, nanofibers electrospun from three different polymer, 
namely PGA, PLGA and P(LLA-CL) will be compared in terms of fabrication 
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process, physical properties, biocompatibilities and degradation behaviors. The best 
one with combinatory advantages will be selected for NCS application, which will be 





Chapter 3  
Fabrication of PGA, PLGA and P(LLA-CL) Nanofibers by 
Electrospinning 
 
Biodegradable polyesters are widely electrospun as tissue engineering scaffolds 
because 1) They are biodegradable with metabolizable degradation products (e.g. 
lactic acid); 2) The degradation rate of the scaffold can be controlled by choosing 
different types of polyesters/copolymers and their combinations; 3) Some polyesters, 
such as polylactide (PLA), polyglycolide (PGA), polycaprolactone (PCL) and their 
copolymers, are FDA approved biomaterials for medical device with a long history of 
medical applications; 4) Polyester nanofibrous scaffolds are easy to produce by 
electrospinning. Commonly used biodegradable polyesters are PGA, PLA, PCL and 
their copolymers. 
 
In this study, three types of polymers---- PGA, poly(DL-lactide-co-glycolide) (PLGA), 
Poly(L-Lactide-co-ε-Caprolactone) [P(LLA-CL)], which have been used for vascular 
applications (S. I. Jeong et al., 2007;L. E. Niklason et al., 1999;C. Y. Xu et al., 
2004a;C. Y. Xu et al., 2004b;C. Y. Xu et al., 2004c), were selected as candidates for 
nanofiber-covered stent fabrication. This chapter will present the results on 
optimization of electrospinning processes of the three polymers. 
 
3.1 Materials and methods 
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3.1.1 Materials  
Poly(L-lactic acid)-co-poly(epsilon-caprolactone) block copolymer [P(LLA-CL), 
70:30, Mw=250kD] was bought from Boehringer (Ingelheim, Germany). 
Polyglycolic acid (PGA, Mw=100kD) was bought from Polysciences (Eppelheim, 
Germany). 
Poly(DL-lactide-co-glycolide) random copolymer (PLGA, LA:GA=75:25, 
Mw=150kD) was bought from Sigma (MO, USA). 
1,1,1,3,3,3-hexafluro-isopropanol (HFIP) was purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  
Dichloromethane (DCM), dimethyl formamide (DMF), chloroform and methanol 
were purchased from Merck Ltd. (Singapore). 
 
3.1.2 Fabrication of PGA, PLGA and P(LLA-CL) nanofibers 
To fabricate polymeric nanofibers by electrospinning, the polymer was dissolved in 
an appropriate solvent. The resultant solution was then filled in a syringe. With the aid 
of a syringe pump, the solution was ejected out through a needle tip with an inner 
diameter of 0.21 mm at a constant feed-rate. A high DC voltage ranging from 10-15 
kV (Gamma High Voltage Research, Ormond Beach, FL, USA) was applied between 
the needle and a grounded aluminum plate which was 15cm below the needle.  
 
The electric field generated by the surface charge causes the solution drop at the tip of 
the needle to distort into the Taylor cone. Once the electric potential at the surface 
charge exceeded a critical value, the electrostatic forces overcome the solution surface 
tension and a thin jet of solution erupts from the surface of the cone. The parameters 
for fabrication of PGA, PLGA and P(LLA-CL) nanofibers mesh (NFM) are shown in 




Polymer Solvent Concentration 
(w/v) 
voltage Feed rate 
PGA HFIP 8%,10%, 15% 12kV 2ml/hr 











HFIP 15%, 20% 12.5kV 1ml/hr 
DCM/DMF 
(70:30) 
8%, 10% 10kV 1.5ml/hr P(LLA-CL) 
 




Table 3.1 Electrospinning parameters of PGA, PLGA and P(LLA-CL) 
 
3.1.3 Material characterization 
Scanning electron microscopy (SEM) micrographs of the electrospun nanofibers were 
obtained with a JSM-5800LV SEM (JEOL, Tokyo, Japan). The average diameter of 
the fabricated nanofibers was measured using image analysis software (Image J, 
National Institutes of Health, Bethesda, MD, USA) by measuring ALL nanofibers on 
three SEM images (10000×-25000× in magnification) from different samples (>100 
fibers measured for each samples). The thickness of the collagen-blended P(LLA-CL) 
NFM was measured with a micrometer (Mitutoyo, Kawasaki, Japan) and its apparent 
density and porosity were calculated according to the following equations (Z. W. Ma 
et al., 2005b): 
areasamplethickness






densityapparentNFMporosityNFM   
 
Tensile tests were carried out with a 5848 microtester (Instron, Norwood, MA, USA) 
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at a stretching speed of 5 mm/min and with a 20 mm gauge length. NFM samples 
were cut into a rectangular (10 × 40 mm) shape according to the guideline for fabric 
materials (ASTM D4595). The NFM thickness measured by the micrometer and the 
sample width (10 mm) were used to calculate the ultimate strength and strain. 
 
Briefly, a stress-strain curve was plotted as shown in Figure 3.1 as a typical example, 
where Stress (σ)=
A
F  and strain (ε)=
0L
L , where F is tensile force, A is the 
cross-section area (equaling to 
width×thickness in this case), L is travel 
distance and L0 is gauge length. The values at 
point (a) and (b) indicate the ultimate strength 
and failure strain, respectively. 
Figure 3.1 A typical stress-stain curve 
 
3.1.4 Statistical analysis 
Data were obtained at least in triplicate and expressed as mean ± standard deviation 
(SD). Each experiment was repeated two to three times. Statistical differences were 
determined by student’s two-tailed t test. Differences are considered statistically 
significant at p < 0.05. 
 
3.2 Results and discussions 
3.2.1 Morphology of electrospun PGA, PLGA and P(LLA-CL) nanofibers 
SEM images of PGA, PLGA and P(LLA-CL) nanofibers with different 
electrospinning conditions are shown in Figure 3.2 to Figure 3.4 respectively, 












   
10% PGA in HFIP       15% PGA in HFIP 
 
Figure 3.2 Electrospun PGA nanofibers from A) 10% (w/v) and B) 20% (w/v) HFIP solutions 
 
    
35% PLGA in DMF       40% PLGA in DMF 
 
  







   
15% PLGA in Chloroform/Methanol    20% PLGA in Chloroform/Methanol 
 
 
25% PLGA in Chloroform/Methanol 
 
   
15% PLGA in HFIP      20% PLGA in HFIP 
 
Figure 3.3 Electrospun PLGA nanofibers from A) 35% DMF, B) 40% DMF, C) 45% DMF, D) 50% 
DMF, E) 15% Chloroform/Methanol (70:30), F) 20% Chloroform/Methanol (70:30), G) 25% 






   
8% P(LLA-CL) in DCM/DMF     10% P(LLA-CL) in DCM/DMF 
 
   
10% P(LLA-CL) in HFIP      12% P(LLA-CL) in HFIP 
 
 
13% P(LLA-CL) in HFIP 
 
Figure 3.4 Electrospun P(LLA-CL) nanofibers from A) 8% DCM/DMF (70:30), B) 10% 
DCM/DMF, C) 10% HFIP, D) 12% HFIP and E) 13% HFIP solutions 
 
Polymer Solvent Concentration 
(w/v) 
Diameters/nm Beads 
8% 260±94 A few PGA HFIP 






15% 949±169 No 
35% 306±157 Many 
40% 371±141 A few 
45%* 652±227 No 
DMF 
50% 1048±233 No 
15% 283±150 Many 
20% 445±270 A few 
Chloroform/ 
Methanol 
( 70:30) 25%* 1016±293 No 




20%* 523±155 No 
8% 323±142 A few DCM/DMF 
(70:30) 10%* 486±161 No 
10% 247±76 A few 




13% 576±152 No 
 
Table 3.2 Fiber diameters of electrospun PGA, PLGA and P(LLA-CL) from different solutions. 
The optimized concentrations in corresponding solvents were mark with “*”. 
 
The diameters of the resultant electrospun fibers were measured and listed in Table 
3.2. PGA can only be dissolved in HFIP. PLGA has been reported to be electrospun 
from DMF (X. H. Zong et al., 2003) and chloroform (Y. You et al., 2005b), and HFIP 
was also tested in the study. P(LLA-CL) has been optimized to electrospin in 
DCM/DMF in our lab (W. He et al., 2005a). To minimize the effects of different 
solvents in future studies, HFIP was also tested. It was clearly shown that the fiber 
diameter increased with concentration of prepared solutions and if the concentration is 
too low, the beads were formed along the fibers as shown in Figure 3.3-3.4. The 
beads-on-string structure has been widely reported in the area of electrospinning (Z. 
M. Huang et al., 2003). It is believed that the formation of the beaded nanofibers can 
be considered as the capillary breakup of the electrospinning jets by surface tension 
(H. Fong et al., 1999). The formation of beads and beaded fibers is driven by the 
surface tension (H. Fong et al., 1999). Surface tension tries to make the surface area 
per unit mass smaller, by changing the jets into spheres. It is reported that surface 
tension reduces with increase of polymer concentration (A. Bhattacharya and Ray,P., 
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2004;H. Fong et al., 1999). In addition, viscoelastic force, which increases with 
polymer concentration, resists rapid changes in shape (H. Fong et al., 1999). 
Therefore, higher polymer concentration results in smoother fiber morphology. 
Nevertheless, it is not clear that whether beads will affect its biocompatibility. 
Nanofiber was proposed for tissue engineering applications for its biomimetic 
structure to ECM. However, the beaded structure never appears on the natural ECM 
(e.g. collagen fiber), thus current studies on the nanofiber in tissue engineering are 
mainly limited to nanofibrous scaffolds with smooth fibrous morphology without 
beads. However, there is no study to date to compare the biocompatibility between 
beaded nanofibrous scaffolds and bead-free ones. In addition, the beads on 
nanofibrous would be an ideal site of drug reservoir (D. Li and Xia,Y.N., 2004). 
Therefore, studies are desired to study effects of beaded nanofibers for biomedical 
applications. Nevertheless, it is known that excessive beads reduce the mechanical 
strength (Z. M. Huang et al., 2003). In this study, the optimized concentration for 
electrospinning is defined as the lowest concentration at which the resultant fibers 
were thinnest and beadless (marked by “*’ in Table 3.2). 
 
3.2.2 Mechanical properties of electrospun PGA, PLGA and P(LLA-CL) nanofibers 
The electrospun PGA, PLGA and P(LLA-CL) fibrous meshes with optimized 
concentration were tested for their mechanical properties. Typical stress-strain curves 
of the three nanofibers are shown in Figure 3.5 and summarized in Table 3.3. PGA 
shows highest tensile strength as compared to PLGA and P(LLA-CL). 
 
It was observed that in order to get beadless PLGA nanofiber, the polymer 
concentration in DMF was significantly higher than that in HFIP or 
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chloroform/methanol. This finding is consistent with electrospinning studies using 
DMF as the solvent, where high polymer concentration is desired (T. Uyar and 
Besenbacher,F., 2008;X. H. Zong et al., 2003). This could be explained by the low 
evaporation rate of DMF. During the elongation of the charged jet in electrospinning, 
the capillary instability developed if the solvent evaporation rate is too slow, inducing 
beads on the fibers (S. Tripatanasuwan et al., 2007). Therefore, in order to get 
beadless fibers, high polymer concentration is desired to obtain high viscosity and 
also to lower the DMF proportion. In addition, the PLGA fiber from DMF and 
chloroform/methanol solutions showed significantly lower strength than those from 
HFIP solutions. The difference in mechanical strength could be attributed to the 
alignment of polymer chain within nanofibers. High chain alignment along the 
nanofiber axis renders high strength (F. Chen et al., 2008). As mentioned above, 
although DMF has good electric conductivity, the low evaporation rate of DMF could 
lead to high mobility of the polymer chain in the electrospinning jet, which could 
compromise the chain alignment in the resultant nanofibers. In contrast, although 
chloroform/methanol mixture is highly volatile, the conductivity is relatively low. The 
low conductivity reduces the effective electrostatic force over the polymer molecules, 
which could also reduce the chain alignment in the nanofibers (T. Uyar and 
Besenbacher,F., 2008). HFIP, however, is a highly volatile solvent with high 
conductivity, which helps to produce both uniformed and mechanically strong 
electrospun fibers.  
 
While HFIP is the only solvent to electrospin PGA, and HFIP is shown to help 
improve the spinnability and mechanical strength of PLGA and P(LLA-CL), it is a 
good option to use HFIP as solvent to produce PGA, PLGA and P(LLA-CL) 
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nanofibers, which could also minimize the solvent effects (S. Tripatanasuwan et al., 
2007;T. Uyar and Besenbacher,F., 2008) when PGA, PLGA and P(LLA-CL) are 
compared for the following biocompatibility and biodegradation studies in the 






























PGA HFIP 10% 5.07±0.79 165±32 




25% 1.14 ± 0.21 90±8 
PLGA 
HFIP 20% 3.24±0.14 201±19 
DCM/DMF 
(70:30) 
10% 2.27±0.23 176 ± 15 P(LLA-CL) 
HFIP 12% 2.59±0.13 228±5 
 
Table 3.3 Mechanical properties of electrospun PGA, PLGA and P(LLA-CL) fibrous mesh with 
optimized concentration. 
*Data are representative of five independent measurements and represented as means ± SD. 
 
3.2.3 Apparent density, and porosity of PGA, PLGA and P(LLA-CL) nanofibers 
Electrospun PGA, PLGA and P(LLA-CL) using HFIP as solvent were further 
characterized by apparent density and porosity. Table 3.4 shows that all three 
nanofibers have comparable porosities. PGA nanofibers have the highest porosity, 
followed by P(LLA-CL) and PLGA nanofibers. No studies have investigated the 
factors (e.g. electrospinning conditions, polymer crystallinity) affecting the 
nanofibrous porosity. One has to take note this calculation of the porosity assumes 
that the individual nanofibers have the same density as the original materials. It is also 
known that the electrospinning process re-organizes polymer chains and, compared 
with unprocessed raw materials, electrospun nanofibers may have a reduced 
crystallinity (K. H. Lee et al., 2003). The re-organized polymer with reduced 
crystallinity may result in lower density of individual nanofibers as compared to raw 
materials. PGA is a highly crystalline polymer (C. C. Chu, 1981b;R. M. Ginde and 
Gupta,R.K., 1987a;A. M. Reed and Gilding,D.K., 1981) with high density 
(1.53g/cm3), therefore the density of nanofibers could be significantly reduced by 
electrospinning, resulting in an overestimation of its porosity. The same situation 
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could be applied to P(LLA-CL), which was shown to be semi-crystalline (chapter 5). 
However, PLGA (75:25) is an amorphous polymer; therefore the porosity value could 













PGA 10% 1.53 0.215±0.012 85.9±0.8 
PLGA 20% 1.22 0.249± 0.013 79.6±1.1 
P(LLA-CL) 12% 1.25 0.219± 0.012 82.5±0.9 
 
Table 3.4 Apparent density and porosity of PGA, PLGA and P(LLA-CL) nanofibers. 
*Data are represented as means ± SD (n=5) 
 
3.3 Summary  
PGA, PLGA and P(LLA-CL) were successfully electrospun into nanofibrous mesh 
with various electrospinning conditions. Optimized concentrations of PGA, PLGA 
and P(LLA-CL) electrospinning using different solvents were determined. HFIP is a 
unique solvent which could be used to electrospin all three polymers with good 
mechanical strength of resultant nanofibrous mesh. The electrospun nanofibers using 
HFIP have comparable fiber diameter and porosity. 
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Chapter 4  
Biocompatibility of PGA, PLGA and P(LLA-CL) nanofibers 
with Smooth Muscle Cells and Endothelial Cells  
 
 
As introduced in chapter 1, the key player of in-stent restenosis is vascular smooth 
muscle cells (SMC) over-proliferation shortly after the stent implantation. On the 
other hand, long term biocompatibility of SMC on implanted materials is necessary 
for functional endothelialization (A. V. Finn et al., 2007;M. Joner et al., 2006;M. F. 
Vanbuulwortelboer et al., 1986;W. Yang et al., 2006) . In addition, the process of 
restenosis in humans typically has its peak at 3–5 months after vascular injury (T. M. 
Schiele, 2005). Therefore there is a need to understand the long-term SMC behaviors 
on the implanted materials. 
 
SMC-Scaffold interaction has been studied in the area of tissue-engineered vascular 
grafts. Niklason et al. reported the first functional artificial artery graft in vitro by 
dynamic culture of SMCs on PGA microfibrous scaffold for eight weeks. The 
resultant artery graft can sustain a pressure up to 2000mmHg (L. E. Niklason et al., 
1999). Recently, nanofiber has been introduced as a scaffold for blood vessel 
engineering. Jeong et al. reported a vascular graft by culturing SMCs on collagen and 
PLGA nanofibrous scaffolds for 23 days (S. I. Jeong et al., 2007). Xu et al. has 
reported several short-term (<2 weeks) SMC-P(LLA-CL) nanofibrous scaffold 
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interaction studies for potential applications in blood vessel engineering (C. Y. Xu et 
al., 2004a;C. Y. Xu et al., 2004b;C. Y. Xu et al., 2004c). It has been reported that 
implanted biodegradable block polymer could induce inflammation and vigorous 
immunoresponse due to the acidic degradation products (B. Rihova, 1996). The 
degradation of PGA scaffold has also been reported to affect cellular response in 
vascular tissue engineering (S. P. Higgins et al., 2003). However, the side effects of 
nanofiber degradation for long-term tissue engineering applications are not well 
studied both in vitro and in vivo. 
 
In this study, the biodegradable PGA, PLGA, P(LLA-CL) nanofibrous scaffolds were 
seeded with porcine coronary artery smooth muscle cells (PCASMC) and cultured in 
vitro for up to 105 days, with the aim to evaluate the long term behaviors of SMC 
cultured on the scaffolds and to investigate the effects of polymer degradation on 
cellular behaviors. Meanwhile, the short-term study of endothelial cells (ECs) 
behaviors on the nanofibrous scaffolds was made to evaluate the ability of nanofibers 
to promote early endothelialization.  
 
4.1 Materials and methods 
4.1.1 Materials 
Poly(L-lactic acid)-co-poly(epsilon-caprolactone) block copolymer [P(LLA-CL), 
70:30, Mw=250kD] was bought from Boehringer (Ingelheim, Germany) 
Polyglycolic acid (PGA, Mw=100kD) was bought from Polysciences (Eppelheim, 
Germany) 
Poly(DL-lactide-co-glycolide) random copolymer (PLGA, LA:GA=75:25, 
Mw=150kD) was bought from Sigma (MO, USA) 
Chapter 5 
 68
1,1,1,3,3,3-hexafluro-isopropanol (HFIP) was purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  
CellTiter 96® AQueous One Solution assay was purchased from Promega (Madison, 
WI, USA). 
Porcine coronary artery smooth muscle cells (PCASMC) were obtained at passage 2 
from Cell Applications Inc. (USA). All cells used in the studies were under passage 6. 
All culture mediums and reagents were purchased from Cell Applications Inc. (USA). 
 
4.1.2 Fabrication of PGA, PLGA and P(LLA-CL) Nanofibers by Electrospinning 
PGA (Polysciences, German, Mw=100kD), PLGA (Sigma, LA:GA=75:25, 
Mw=150kD) and P(LLA-CL) (Boehringer Ingelheim, 70:30, Mw=250kD) solutions 
were prepared by dissolving in Hexafluoroisopropanol HFIP (Sigma, USA). The 
solution was placed in a plastic syringe fitted with a 27G½ needle (Becton Dickinson, 
USA). An electrospinning voltage was applied between the needle and the collecting 
plate with a high voltage power supply (Gamma High Voltage Research, USA). The 
solution was delivered at a constant feed rate. Detailed conditions are listed in Table 
4.1. The resultant nanofibers were collected on an aluminum collector located at a 
distance of 15 cm from the needle tip. All electrospun samples were placed in vacuum 








Table 4.1 Electrospinning parameters for three different polymers.  
 
Polymer Concentration(w/v) Voltage(kV) Feed rate 
(ml/hr) 
PGA 10% 12 2 
PLGA 20% 12.5kV 1 
P(LLA-CL) 12% 10kV 1.5 
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4.1.3 Cell culture 
Porcine smooth muscle cells (PCASMC, Cell Applications Inc. USA) were cultured 
in the supplied basal medium (Cell Applications Inc. USA) supplemented with SMC 
growth supplements (Cell Applications Inc. USA) and 10 % (v/v) fetal bovine serum 
(Cell Applications Inc. USA). The medium was replaced every 2-4 days and the 
cultures were maintained in a humidified incubator at 37°C with 5 % CO2. When the 
cells reached 80-90% confluence (5×104 cells/cm2), the cultures were trypsinized and 
subcultured at 1:3 ratios. 
 
Human coronary artery endothelial cells (HCAECs) were obtained at passage 3 from 
Biowhittaker (New Jersey, USA). Cells were cultured in endothelial cell basal 
medium (CloneticsTM EBM®-2) supplemented with EC growth supplements (vascular 
endothelial growth factor (VEGF), human epidermal growth factor (hEGF), human 
fibroblast growth factor-B (hFGF-B) insulin-like growth factor type I (IGF-I), 
hydrocortisone, and ascorbic acid) purchased from Cambrex (North Brunswick, NJ, 
USA), 5% fetal bovine serum (FBS), penicillin (100 units/mL), and streptomycin (100 
µg/mL). Medium was replaced every 4 days and cultures were maintained in a 
humidified incubator at 37°C with 5% CO2. When the cells reached 80-90% 
confluence (confluence density, 5 × 104 cells/cm2), they were trypsinized and 
sub-cultured at a 1:3 ratio. 
 
Electrospun fibers used for small scale cell culture (e.g. MTS assay) were collected on 
15mm round cover slips. The cover slips were placed in a 24-well plate. A stainless 
steel O-ring was placed to hold each fibrous sample in place. Additionally, for PLGA 
nanofibers which would shrink under cell culture, medical grade adhesive (RTV 
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Silicone, Bluestar Silicones, NJ) was used to hold the PLGA nanofibers from 
shrinking. For large scale cell culture (e.g. mRNA extraction), electrospun nanofibers 
were mounted on a 75mm by 25mm glass slide by the same medical adhesive. The 
glass slides were placed in 4 chamber plate for cell culture (Nunc, NY).  
 
The nanofibrous scaffolds were sterilized in 70% ethanol solution for 30 minutes 
followed by three washes with 1X phosphate buffered saline (PBS). The cells were 
seeded onto the nanofibers at a seeding density of 1.8×104 cells/cm2 and cultured for 
desired periods to evaluate cell viability and cell-related degradation. 
 
4.1.4 Cell morphology confluency observed by Scanning electron microscopy (SEM). 
SEM was used to examine the morphologies of nanofibers and cells cultured for up to 
105 days on the nanofibrous scaffolds. The cell-nanofiber samples were washed with 
1× PBS to remove non-adherent cells. The adherent cells were fixed with 2.5 % (v/v) 
glutaraldehyde for 45 minutes at 4°C. Thereafter, the samples were sequentially 
dehydrated in 50, 70, 80, 90, 95, 100% ethanol solutions for 10 minutes each and 
vacuum dried. The samples were sputter coated with gold (JEOL JFC-1200 Fine 
Coater, Japan) and observed under a field-emission scanning electron microscopy 
(FESEM; FEI Quanta 200, USA) at an accelerating voltage of 10 kV. 
 
SEM images were taken at magnification from ×50 to ×400 and analyzed by 
Photoshop 9.0 (Adobe, USA) to measure the cell coverage. The “magic wand” tool, 
refined by manual adjustment, was used to define the cell coverage area on the 
nanofibrous scaffolds. To minimize errors and artifacts, only high contrast images 
with well-defined cell boundaries were used. The cell confluency was then calculated 
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as cell coverage area (in pixels) divided by the whole area of interest (in pixels). At 
least three images from three randomly selected areas for such sample were measured 
and averaged at each time point. 
 
4.1.5 MTS assay for PCASMC viability 
To assess cell viability, cells were seeded onto the nanofibers at a density of 1.8×104 
cells/cm2. After culturing the cells for 1, 3, 5, 7, 10, 17, 30 and 40 days, unattached 
cells were removed by washing and the viability of the cells attached on the 
nanofibrous scaffolds were quantified by the colorimetric MTS assay (CellTiter 96® 
AQueous One Solution Cell Proliferation Assay, Promega, USA). Briefly, the 
cell-nanofiber samples were incubated with 20% (v/v) MTS reagent in complete 
medium for 4 hrs. Thereafter, aliquots (in triplicates) were transferred to a 96-well 
plate and the reduction of the tetrazolium salt as indicated by colorimetric change was 
determined by measuring the absorbance at 490nm with a spectrophotometric plate 
reader (FLUOstar OPTIMA, BMG Lab Technologies, Germany). 
 
4.1.6 Quantification of mRNA to determine gene expression 
Quantitative reverse-transcribed PCR (RT-PCR) was used to determine the expression 
of some key genes in PCASMC cultured on the three different substrates with tissue 
culture polystyrene (TCPS) as a control. Three ECM-related genes namely collagen 
type I α-1, fibronectin 1 and integrin α-V, two cytoskeleton-related gene namely  
α-1 actinin and myosin light chain 1 and two regulatory genes including proliferating 
cell nuclear antigen (PCNA) and calponin were selected. ECM-related genes were 
selected to evaluate the effect of cell-scaffold interaction on matrix production. 
α−actinin, myosin and calponin are SMC markers. PCNA can indicate the rate of cell 
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proliferation (Z. G. Wang et al., 2003). The primer sets were designed according to 
the gene sequences submitted in Genbank (Table 4.2). 
 
Briefly, after culturing PCASMC on the different substrates for various time intervals, 
total RNA from each sample was isolated using an RNeasy Mini Kit (QIAGEN, 
Valencia, CA). Equal amounts of the extracted RNA were reverse-transcribed into 
cDNA using SuperScript™ First-Strand Synthesis system (Invitrogen, USA). 
Real-time qPCR (Express SYBR Green, Invitrogen, UK) was and analyzed using the 
rotor-gene 6000 Real Time PCR system from Corbett Life Science (CA, US). Melt 
curve analysis was performed after 40 cycles of amplification. The genes of interest 
were normalized to GAPDH expression. The comparative cycle-threshold method 
was used for quantification of gene expression. The relative transcript levels were 
expressed as mean ±s.d. (n=3 for each group).  
 
Standard 30-cycle PCR was also carried out using Taq PCR Master Mix Kit (Qiagen) 
to validate the length of amplicons. The PCR products were resolved by gel 
electrophoresis in a 1% (w/v) agarose (Cambrex Bioscience, ME, USA) and 
visualized with a UV transilluminator (BioRad Laboratories, CA, USA).  
. 
 Functions GI number size Primers 5’->3’ 
115553423 282 CAAGAACAGCGTGGCCTA Collagen type I 
α1 
ECM proteins 
  AGGAAGCAGACAGGGCTAAG 
115551872 245 TGTGGGAGAACAGTGGCA Fibronectin 1 ECM proteins 
  GGGAATCTTCTCTGTCAGCCT 
145208000 284 TGTGGACCGAGACCTTTATG Integrin αV ECM proteins 
  AGGTGGTCGGACACGTTT 
115553451 240 CATCGATTTCATGTCCCGT α-1 actinin cytoskeletons 
  AGGTCACTCTCGCCGTACA 
Myosin light cytoskeletons 157427686 250 GAGTTTGAACAATTCCTGCCT 
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chain   TGATGTGCTTGACAAAGGC 
52351679 259 GGAGAACTCGGAAATGGAAA PCNA Proliferating 
Cell Nuclear 
Antigen 
  CTTCATCTTCGATCTTGGGAG 
47523105 230 ACCAAGCGGCAGATCTTC Calponin Differentiation 
marker   GCACCCTAGGCAGAGTTGTAG
2407183 222 GGAGAAACCTGCCAAATATGAGAPDH internal control
  CTGTTGCTGTAGCCAAATTCA 
 
Table 4.2 PCR primers for RT-PCR analysis 
 
4.1.7 BCA protein assay 
The amount of ECM proteins secreted by PCASMC on nanofibrous scaffolds during 
long-term culture was measured using the BCA Protein Assay Kit (Pierce, USA) 
(Stich, 1990). Briefly, PCASMC were seeded onto the nanofibrous scaffolds at the 
density of 1.8×104 cells/cm2 (30 % confluence). The culture medium was changed 
every 2-3 days. PCASMC cultured on P(LLA-CL) nanofibrous scaffolds for 15, 25, 
40, 50, 70, 90 and 110 days were collected and trypsinized for 5 minutes and this was 
repeated 3 times to ensure complete removal of all the cells from the nanofibrous 
scaffolds as confirmed by SEM (data not shown). The nanofibrous scaffolds were 
then immersed in 0.1 ml PBS together with 2 ml BCA working reagent at room 
temperature for 1 hour, and the absorbance at 590 nm was measured with a 
spectrophotometric plate reader (FLUOstar OPTIMA, BMG Lab Technologies, 
Germany). The ECM protein concentration was determined from the bovine serum 
albumin (BSA) standard curve. 
 
4.1.8 Statistical Analysis  
Data were obtained at least in triplicate and expressed as mean + standard deviation 
(SD). Each experiment was repeated two to three times. For comparison of a single 
variable, statistical differences were determined by student’s two-tailed t test. For 
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comparisons with two variables, two-way ANOVA using Scheffé’s method was 
performed to determine the statistical significance (Scott E.Maxwell and Harold 
D.Delaney, 2005). Differences were considered statistically significant at p < 0.05. 
 
4.2 Results  
4.2.1 Morphology of the nanofibers 
SEM images of electrospun PGA, PLGA and P(LLA-CL) nanofibers showed that the 
fibers in these scaffolds were uniform and randomly oriented (Figure 4.1). The 
average fiber diameter was 380 ± 134 nm (average ± standard deviation) for PGA, 
523 ± 155 nm for PLGA and 484 ± 172 nm for P(LLA-CL). There was no significant 
difference in diameter between the three types of nanofibers. Even though these fibers 
are sub-micron in diameter (nanofibers by definition are less than 100 nm in diameter), 
they resemble the micron/sub-micron diameter of collagen fibers in the native ECM 
and possess good potential as substrates for tissue engineering.  
  







Figure 4.1 SEM micrographs of (a) PGA, (b) PLGA and (c) P(LLA-CL) electrospun nanofibers. 
Magnification 12000x. 
 
4.2.2 PCASMC Cell density and viability on nanofibers 
A plot of cell density (confluency) for up to 105 days for PCASMC cultured on PGA, 
PLGA and P(LLA-CL) nanofiber scaffold is shown in Figure 4.2a. PGA and PLGA 
scaffolds supported better cell growth and at a higher initial cell density when 
compared to P(LLA-CL) nanofiber scaffold. However, the PGA nanofiber scaffold 
was only able to support PCASMC growth until day 5 (Figure 4.2b) due to significant 
degradation of the scaffold, and with complete degradation by day 20. Growth of 
PCASMC on P(LLA-CL) nanofibrous scaffolds was initially slow (Figure 4.2f) but 
after 30 days of culture, showed higher cell density than on PLGA fibers (Figure 4.2a). 
After 45 days of culture, PCASMC fully covered the P(LLA-CL) nanofiber scaffold 
(Figure 4.2h) while this was not observed on PLGA nanofibers even at the end of the 
study on day 75 (Figure 4.2d&2e). Moreover, by the end of the study at day 105, the 
cells remained confluent and multi-cell layers were observed on P(LLA-CL) 
nanofibers (Figure 4.3).  
 
Figure 4.4 shows the short term (Figure 4.4a) and long term (Figure 4.4b) cell 
viability of PCASMC cultured on PGA, PLGA and P(LLA-CL) nanofibrous scaffolds. 
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Since PGA nanofiber scaffolds were degraded within 20 days, a long term study was 
not performed. The short term results showed that p(LLA-CL) was less conducive for 
initial cell growth or attachment than PGA and PLGA fibers. PGA nanofibers support 
cell growth in the first five days, with comparable cell viabilities to that on the PLGA 
nanofibers. The cell viabilities of PCASMC on P(LLA-CL) in the first 10 days were 
significantly lower than those on PLGA (Two-way ANOVA, p<0.01). However, after 
18 days in cell culture, the cell viabilities on P(LLA-CL) were significantly higher 
than those on PLGA (p<0.05).  After ~30 days of culture, the number of viable cells 
cultured on P(LLA-CL) nanofibers was comparable to that cultured on TCPS. PGA 
showed higher cell viability at the first 5 days of culture, followed by a sharp decrease. 
PLGA showed highest cell viability among the three nanofibers materials at the first 
20 days of culture and increased slowly thereafter. These results were consistent with 






(b) PGA 5 days 
 
(c) PGA 10 days 
 
(d) PLGA 25 days 
 



























(f) P(LLA-CL) 15 days (g) P(LLA-CL) 25 days 
(h) P(LLA-CL) 45 days (i) P(LLA-CL) 75 days 
Figure 4.2 PCASMC were seeded and cultured on P(LLA-CL), PLGA and PGA nanofiber 
meshes at a density of ~1.8×104 cells/cm2. After various time intervals, the samples were 
harvested and observed under SEM. The images were then analyzed by Adobe© Photoshop 
9.0 for confluency. (a) The confluency of PCASMC on three types of nanofibers at various 
culture periods (3-6 measurement were made at each time point with error bar for standard 
deviation). Δ indicates the PCASMC confluency on PLGA is significantly higher than that 
on P(LLA-CL) (P<0.01).* indicates the confluency on P(LLA-CL) is significantly higher than 
that on PLGA (P<0.01).Representative  SEM images at selected time points areshown: (b) 
PGA 5 days, (c) PGA 10 days, (d) PLGA 25 days, (e) PLGA 75days, (f) P(LLA-CL) 15 days, 





Figure 4.3 SEM images of P(LLA-CL) nanofibers cultured with PCASMC for 105 days. Multilayer 
of PSCM is shown by the arrows. (b) is the enlarged view of (a). The cross-section views of the 
PCASMC/nanofiber constructed are shown by SEM (c) and histological staining (d). The solid 
two-way arrow indicates the cell layers and the broken arrow indicates the nanofibrous 
scaffolds. The SEM micrograph (c) shows the multiple cell-layer which was approximately 





















































Figure 4.4 Viability of PCASMC cultured on PGA, PLGA, P(LLA-CL) nanofiber scaffold, and 
tissue culture polystyrene (TCP). PCASMC were seeded at a density of 1.8×104 cells/cm2 and 
cultured for up to 40 days. (a) Short term results (1-7 days); (b) long term results (2-40 days). Data 
was representative of three independent experiments and all data points were plotted. Mean for 
n=3±SD. * indicates the time points at which cell viabilities on TCP were significantly higher than 
that on nanofiber scaffolds (P<0.01). Δ indicates the viability of PCASMC on P(LLA-CL) 










4.2.3 Gene expression of PCASMC on three types of nanofibers. 
RT-PCR was performed to evaluate the expression of genes of PCASMC involved in 
adhesion (integrin α-V), cytoskeletal integrity (α-actinin, myosin light chain) and 
regulatory function (PCNA, calponin), and genes of ECM proteins (Collagen & 
fibronectin). Figure 4.5 shows the gene expression profile of PCASMC cultured on 
PGA, PLGA and P(LLA-CL) nanofiber scaffolds, with cells cultured on TCPS and 
GAPDH gene expression as controls.  
 
At 20 days of culture, gene expressions was determined in PCASMC cultured on 
PLGA and P(LLA-CL) nanofiber scaffolds, as well as on TCPS (Figure 4.5a). This 
data was not available for PGA nanofibers since it degraded before 20 days of culture. 
Instead, for PGA nanofiber scaffolds, expression of these genes in PCASMC was 
determined at 7 days. The genes of interest were amplified to amplicons with desired 
length. The relative intensities of the genes as shown in the gel imaging system 
remained stable over all the samples (data not fully shown). 
 
Real-time RT-PCR was performed to quantify the mRNA levels at 5, 20 and 60 days 
samples of PLGA, P(PLLA-CL) and TCPS except for myosin light chain, whose 
expression was too low to be detected. The relative mRNA levels were normalized to 
the TCPS 5 days sample (Figure 4.5b). For SMC cell markers like α-actinin and 
calponin, the mRNA levels decreased with time of culture. Collagen and Integrin αV 














Figure 4.5 (a) Electrophoresis of RT-PCR product of collagen type I α-1 (lane 1), 
fibronectin 1 (lane 2), integrin αV (lane 3), α-1 actinin (lane 4), myosin light Chain 1 
(lane 5), PCNA (lane 6) and calponin (lane 7) in porcine vascular smooth muscle cells 
cultured on PGA, PLGA and P(LLA-CL) nanofiber scaffold, and tissue culture 
polystyrene (TCPS). GAPDH served as control (lane 8). (b) Relative expression of the 
above genes normalized to expressions of PCASMC on TCPS for 5 days, significant 
differences (p<0.05) are marked by “*”. 
 
 
4.2.4 HCAEC cellular behaviors on P(LLA-CL) nanofibers. 
The studies of PCASMC on PGA, PLGA and P(LLA-CL) nanofibers indicated that 
P(LLA-CL) nanofibers could be a better candidate for nanofiber-covered stent 
application. Apart from the biocompatibility of nanofiber with smooth muscle cells, 
equally important is the potential of endothelialization on the nanofibers. HCAEC was 
therefore cultured on P(LLA-CL) nanofibers for 30 days to investigate its 
proliferation on nanofibers. 
 
SEM images (Figure 4.6) indicated that the density of endothelial cells on P(LLA-CL) 
nanofibers increased over the culture time. Cell viability results (Figure 4.7), however, 
revealed that the metabolic activity peaks between day 10 and day 15 for both 
HCAECs cultured on P(LLA-CL) and TCP. This could be explained by the contact 




 (a) 4 days  (b) 8 days 
 (c) 15 days  (d) 22 days 
(e) 30 days 
 
 
Figure 4.6 Equal density (~ 1.8×104 cells/cm2) of HCAECs were seeded and cultured on p(LLA-CL) 
nanofiber meshes. After various time intervals, the samples were harvested and observed under 






















Figure 4.7 Viability of HCAECs cultured on P(LLA-CL) nanofibers and tissue culture polystyrene 
(TCP). HCAECs were seeded at a density of 1.8×104 cells/cm2 and cultured for up to 30 days. 
 
4.2.5 ECM protein secretion of PCASMC on P(LLA-CL) nanofibers. 
In the physiological environment, vascular endothelial cells are attached on the 
extracellular matrix (ECM) secreted by vascular SMCs (intima). Since the results of 
direct endothelialization on nanofibers were not satisfactory, as shown in Section 
4.2.4, it is necessary to monitor the ECM section by SMCs cultured on nanofibers to 
evaluate the potential of late endothelialization. BCA assays were performed to 
quantify the amount of ECM proteins secreted by PCASMC cultured on P(LLA-CL) 
nanofibrous scaffolds (Figure 4.8). Nanofibrous scaffolds immersed in pure culture 
medium served as controls to determine the absorption of proteins from the culture 
medium. Minimum amount of soluble proteins from culture medium were adsorbed 
on to nanofibrous scaffolds as shown by the pink graph in Figure 4.8. For cells 
cultured on the P(LLA-CL) nanofibrous scaffolds, the amount of ECM proteins 
secreted by PCASMC was not significant for cultures of less than 50 days. However, 
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a significant increase in the amount of ECM protein secretion was observed starting 
from around day 50 of culture which increased sharply thereafter (p<0.01). The 
amount of ECM was increased 10 times from day 50 to day 105. Even after prolonged 
treatment with trypsin for complete cell removal from the scaffolds after 3 months of 
culture, the remaining amount of ECM proteins bound to the scaffolds was as high as 




















NFS seeded with PCASMC
NFS in pure medium
 
Figure 4.8 BCA assay to quantify the ECM proteins secreted by PCASMC seeded at 1.8×104 
cells/cm2 on P(LLA-CL) nanofibrous scaffolds (NFS) and cultured for up to 105 days. After various 
time intervals as depicted on the graph, the cell-scaffold constructs were collected, the cells were 
removed from the scaffolds by repeated trypsinization. Then the scaffolds were assayed for the 
amount of ECM proteins secreted by the cells. The blue points show the ECM proteins secreted by 
the cells on the scaffolds. The scaffolds immersed in pure medium were served as controls (pink 
points). Data was representative of three independent experiments and all data points were plotted. 
 
4.3 Discussion 
In this study, long-term PCASMC-nanofiber interactions were evaluated on three 
different polymeric nanofibers. PCASMC were found to attach better on PGA and 
PLGA than P(LLA-CL) nanofiber scaffolds, and exhibited higher cell viability within 
the first few days following cell seeding (Figure 4.2). This could be explained by the 
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higher hydrophilicity of PGA and PLGA when compared with P(LLA-CL) (W. He et 
al., 2005a;S. J. Lee et al., 2002;K. E. Park et al., 2007). However, the cell viability on 
PGA nanofibers dramatically decreased after day 5 and this was due to the rapid 
degradation of the scaffold. Hence, pure PGA nanofibers may not be a good choice as 
scaffolds for tissue engineering where structural support is required for more than 1 
week. However, it could be a good candidate for rapid drug release and delivery 
applications. PLGA is one of the biodegradable polymers widely used in biomedical 
application (S. J. Holland et al., 1986;M. Vert et al., 1992) and PLGA nanofibers have 
been widely studied as tissue engineering scaffolds (V. Thomas et al., 2006a). 
Although PCASMC exhibited high cell density and viability when cultured on PLGA 
nanofiber scaffolds during the first 20 days, the cell growth thereafter was not 
satisfactory (Figure 4.4b). At the end of the study at day 75, the cells still did not fully 
cover the scaffold when compared to cells cultured on P(LLA-CL) nanofibrous 
scaffolds (Figure 4.2e). Another potential limitation for PLGA nanofiber as scaffolds 
for tissue engineering application is that the amorphous PLGA nanofibers tend to 
shrink in the aqueous media due to polymer chain relaxation (X. H. Zong et al., 2003). 
This shrinkage could be more than 50% and non-reversible (data not shown). In this 
study, medical glue was used to avoid the shrinkage. P(LLA-CL) is another polymer 
which has been successfully electrospun into nanofiber. The initial growth of 
PCASMC was slow on P(LLA-CL) nanofibers and this was probably resulted from 
the high hydrophobicity of the polymer, but the cell growth began to accelerate after 
10 days of culture as determined by MTS assay and SEM (Figure 4.4). After 30 days 
of culture, PCASMC was found to fully cover the P(LLA-CL) nanofibers. The cell 
viability on P(LLA-CL) was higher than that on PLGA nanofibers and comparable 
with that on TCP after 40 days. After 3 months of culture, multilayer of cells was 
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formed on the nanofibers (Figure 4.3). The slow adaptation could be explained by cell 
growth after ECM deposition on the scaffold (Y. X. Dong et al., 2008). The 
P(LLA-CL) nanofibers would be a good choice as scaffolds for tissue engineering 
applications if extended in vitro culturing of more than 30 days is required. In terms 
of application in nanofiber-covered stent, the property of P(LLA-CL) would be 
advantageous. Initial slow growth of SMCs on the P(LLA-CL) nanofibers may helps 
to reduce the risk of restenosis right after stent implantation. The later smooth growth 
of SMCs on the nanofibers will accelerate the healing resulting from the initial trauma 
during implantation. 
 
To further investigate gene expression of PCASMC cultured on the nanofibers, three 
ECM related genes (collagen, fibronectin and integrin), two cytoskeletal gene (actinin 
and myosin) and two regulatory genes (PCNA and calponin) were evaluated for cells 
on the different scaffolds for various time periods (Figure 4.5). The genes of interest 
maintained expression even after prolonged culture of PCASMC on the PLGA and 
P(LLA-CL) nanofiber scaffolds. The mRNA levels of the studied genes seemed to 
decrease with increased cell density. For instance, the expression of calponin was 
reduced with time of culture. At day 5, the cell density on TCPS is higher than that on 
PLGA and P(LLA-CL) nanofibers, which could lead to lower expression of calponin. 
This could be explained by limited cellular activity with high cell density. Similarly, 
integrin, which plays an important role in cell adhesion, is down-regulated with 
increased cell density, which could result in limited space for cell adhesion. The 





An important factor in the success of tissue-substrate constructs is the ability of the 
attached cells to secrete extracellular matrix to replace and reinforce the structural 
integrity and strength of the constructs as the polymer is being degraded (E. W. 
Raines, 2000;A. Ratcliffe, 2000;F. Rosso et al., 2004). In blood vessel tissue 
engineering, mechanical properties such as tensile stiffness, elasticity, compressibility, 
and viscoelasticity of the construct are important considerations for the success of the 
vascular graft, and the ECM contents such as collagens, elastin and proteoglycans 
secreted by the cells in graft maturation contribute to these physical and mechanical 
properties of the vascular grafts (E. W. Raines, 2000;A. Ratcliffe, 2000). Coronary 
artery smooth muscle cells have been shown to possess the ability to secrete their own 
ECM components (E. Allaire and Clowes,A.W., 1997;Colin M.Fitzsimmons, 2002;M. 
G. Davies and Hagen,P.O., 1994;B. D. MacNeill et al., 2002;A. C. Newby and 
Zaltsman,A.B., 2000). It is essential that these cells are able to produce and secrete 
ECM components to replace the polymer scaffold as it degrades. In this study, total 
ECM proteins secreted by PCASMC on the nanofibrous scaffolds were evaluated. 
The amount of ECM deposited on the scaffolds increased dramatically from day 50 of 
culture. After three months of culturing PCASMC on the nanofibrous scaffolds, the 
amount of ECM deposition on the scaffold was more than 10 folds higher compared 
to day 50 of culture. Even after prolonged treatment with trypsin for complete cell 
removal from the scaffolds after 3 months of culture, the remaining amount of ECM 
proteins bound to the scaffolds was as high as 0.1 mg/cm2. This could be explained by 
the high secretion of ECM after 50 days of culture. It is also possible that the ECM 
tends to resist trypsinization by crosslinking after 50 days of culture. The actual 
amount of ECM secreted by PCASMC (before trypsinization) could be much higher 
than that. These results indicated that after certain period of SMC growth on 
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P(LLA-CL) nanofibers, the secreted ECM could help endothelialization, although 
P(LLA-CL) nanofiber itself was shown to be suboptimal for direct endothelial cell 
attachment (Figure 4.6-4.7).  
 
Endothelial cell (EC) studies proved that P(LLA-CL) nanofiber could well support 
EC proliferation. Concurrent to the research, my collaborator Dr. Wei He implanted a 
1mm vascular graft made by P(LLA-CL) nanofibers in the epigastric vein of a rabbit 
model. After 7 weeks’ implantation, the vascular graft remain patent without any 
thrombosis or stenosis even though it was in a low-flow-rate vein system (He Wei, 
2008). This study demonstrated that P(LLA-CL) nanofibers may achieve primary 
patency in the short to medium term.  
 
4.4 Summary 
PCASMC cultured on three different polymeric nanofibers were evaluated in this 
study. The fast degradation of PGA nanofibers may limit its usage for tissue 
engineering applications. PLGA nanofibers facilitated cell growth during the first 30 
days after seeding but the cell growth are slow thereafter. P(LLA-CL) facilitated long 
term (1-3 months) cell growth although the initial cell growth was slower than that of 
PLGA nanofiber. There is no significant difference in gene expression of PCASMC 
cultured on the three different nanofibers as compared to PCASMC cultured on TCP. 
ECM secretion was greatly accelerated after 50 days’ culture of PCASMC on 
P(LLA-CL). 
 
P(LLA-CL) also supported endothelial cells proliferation for the first 10 days. Above 
results suggest that P(LLA-CL) nanofibers could be a potential candidate for vascular 




Chapter 5  
In vitro degradation behavior of electrospun PGA, PLGA 
and P(LLA-CL) nanofibers. 
 
Extensive studies have been made to investigate the cellular response on 
biodegradable polyester nanofibrous scaffolds. However, the degradation studies of 
nanofibers are very few (K. Kim et al., 2003;H. J. Shin et al., 2006;Y. You et al., 
2005a;Y. You et al., 2005b;X. H. Zong et al., 2003) while the degradation of 
traditional block polyester has been extensively studied (M. Hakkarainen, 2002). For 
certain tissue engineering such as vascular grafts (L. E. Niklason et al., 1999), 
prolonged in vitro culture time is needed to allow the cellular reorganization and 
tissue remodeling (W. W. Minuth et al., 2000). Therefore, there is a crucial need to 
understand how the cell culture may affect the scaffold degradation in tissue 
engineering in vitro. On the other hand, it has been reported that implanted 
biodegradable block polymer could induce inflammation and vigorous 
immunoresponse due to the acidic degradation product (B. Rihova, 1996). It is not 
known whether nanofibrous implants will induce similar body reactions during its 
degradation. 
 
In this chapter, the in vitro degradation behaviors of PGA, PLGA, P(LLA-CL) 
nanofibers are presented. The degradation was studied with and without smooth 
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muscle cell culture. Nanofibers cultured with smooth muscle cell would mimic the in 
vivo environment of implanted nanofiber-covered stent. Meanwhile, it was found that 
ultraviolet (UV) irradiation could accelerate degradation of electrospun nanofibers. A 
separate study is also presented here to investigate the degradation effect of UV 
irradiation, which could be utilized to control nanofiber degradation. 
 
5.1 Materials and Methods 
5.1.1 Materials 
Poly(L-lactic acid)-co-poly(epsilon-caprolactone) block copolymer [P(LLA-CL), 
70:30, Mw=250kD] was bought from Boehringer (Ingelheim, Germany). 
Polyglycolic acid (PGA, Mw=100kD) was bought from Polysciences (Eppelheim, 
Germany). 
Poly(DL-lactide-co-glycolide) random copolymer (PLGA, LA:GA=75:25, 
Mw=150kD) was bought from Sigma (MO, USA). 
1,1,1,3,3,3-hexafluro-isopropanol (HFIP) was purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  
Porcine coronary artery smooth muscle cells (PCASMC) were obtained at passage 2 
from Cell Applications Inc. (USA). All cells used in the studies were under passage 6. 
All culture medium and reagents were purchased from Cell Applications Inc. (USA). 
 
5.1.2 Nanofiber fabrication by electrospinning 
PGA, PLGA and P(LLA-CL) were electrospun as described in section 4.1.2 
 
5.1.3 In vitro degradation of nanofibers with or without cell culture 
PGA, PLGA and P(LLA-CL) nanofibrous meshes with thickness of around 50 
microns were cut into 75mm×35mm rectangular pieces. The rectangular pieces were 
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then wrapped over a 75mm by 25mm glass slide using non-cytotoxic silicone glue 
(Bluestar Silicones, Factor2 Inc., AZ, USA ) and placed in four-chamber cell culture 
plate (Nunc, USA) for the degradation studies. The nanofiber scaffolds were either 
immersed in pure culture medium or cultured with PCASMC at a seeding density of 
1.8×104 cells/cm2 for various durations. The medium of the samples without cells was 
refreshed every week while the samples with cells were refreshed every 2-4 days. 
Meanwhile, PLGA and P(LLA-CL) pellets were immersed in pure culture medium 
and refreshed every week for comparison.  
 
At various time intervals, the samples were collected. To prepare dried samples for 
mass loss determination, mechanical tensile testing and molecular weight 
determination by Gel Permeation Chromatography (GPC), samples with cells were 
trypsinized 3 times for 5 mins each at 37°C to remove all the cells on the scaffold as 
confirmed by microscopy. The cells harvested from these nanofiber scaffolds were 
washed three times with 1×PBS, followed by total RNA extraction and stored in 
-80°C for gene expression study. Samples without cell culture were also trypsinized 3 
times for 5 mins each at 37°C. All the nanofibrous scaffolds were then vacuum-dried 
for 24 hours. The polymer pellet samples were collected at different time intervals, 
washed three times with 1×PBS and the molecular weight determined by GPC. 
 
5.1.4 Scanning electron microscopy (SEM) 
SEM was used to examine the morphology of nanofibers during degradation. The 
samples were sputter coated with gold (JEOL JFC-1200 Fine Coater, Japan) and 
observed under a field-emission scanning electron microscopy (FESEM; FEI Quanta 




To measure fiber diameters, SEM images at a magnification of 12000-25000 were 
taken. For each sample, three identical specimens were randomly selected and each 
specimen was randomly imaged at three different areas. To avoid any artifact, all the 
visible fibers in each image were measured using ImageJ (NIH, USA). In total, more 
than 200 fibers were measured for each sample. 
 
5.1.5 Gel Permeation Chromatography (GPC) 
The average polymer molecular weight of the nanofibrous scaffolds were determined 
using GPC equipped with a refractive index detector (Waters, Model 1515, Mildford, 
Massachusetts, USA). PLGA and P(LLA-CL) nanofibers cultured with PCASMC for 
different durations were collected after trypsinization to remove the cells. The 
nanofibrous scaffolds and the pellets (1 to 2 mm in diameter) were dissolved in 
tetrahydrofuran (THF) (Sigma, USA) and GPC was performed at an elution flow rate 
of 1 ml/min. Polystyrene standards (Polysciences, Warrington, Pennsylvania, USA) 
were used to obtain a primary calibration curve. 
 
5.1.6 Mechanical strength 
Tensile tests were performed using a 5848 Microtester (Instron, Canton, MA, USA) at 
a stroke rate of 5 mm/min with a 20 mm gauge length for nanofibrous scaffolds cut 
into a rectangular (10 × 40 mm) shape. This tensile test was performed following the 




5.1.7 Differential Scanning Calorimetry (DSC) and wide-angle X-ray diffraction 
(WXRD) 
DSC measurements were conducted with a PerkinElmer (MA) DSC7 instrument 
under a nitrogen atmosphere. About 2.5 mg of sample were sealed in an aluminum 
pan for the measurements. The samples were heated from 20 to 200°C at a rate of 
10°C/min. The crystalline structure of the samples was analyzed on a wide-angle 
X-ray diffractometer (model, XRD-6000, Shimadzu Oceania Pty Ltd, Japan). The 
scan speed was 2 Deg/min. 
 
5.1.8 UV irradiation of scaffolds 
PLGA and P(LLA-CL) nanofiber meshes were irradiated by commercial 254 nm 
ultraviolet germicidal lamp (Sankyo Denki, 30w) for different duration in a biological 
cabinet (Thermo Forma Inc., USA). Nanofiber meshes were evenly irradiated on both 
sides with effective UV intensity of 285μw/cm2 and mesh-to-lamp distance fixed at 
40cm.  
 
5.1.9 Statistical Analysis  
Data was obtained at least in triplicate and expressed as mean ± standard deviation 
(SD). Each experiment was repeated two or three times. Statistical differences were 
determined by student’s two-tailed t test. Differences are considered statistically 
significant at p < 0.05. 
 
5.2 Degradation behavior of electrospun PGA, PLGA and P(LLA-CL) 
nanofibers with and without cell culture 
5.2.1 Nanofiber morphology during degradation 
High magnification SEM images depicting changes in electrospun nanofiber 
morphology during degradation in cell culture medium and cultured with PCASMC 
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are shown in Figures 5.1 to 5.3. Electrospun PGA nanofibers underwent fast 
degradation. The PGA nanofibers without cells started to break after 15 days (Figure 
5.1g) and were completely degraded after that time. The PGA nanofibers cultured 
with PCASMC exhibited faster degradation. The nanofibers started to disintegrate 
from day 10 and were completely degraded after 20 days (Figure 5.1d).  
 
Electrospun PLGA nanofibers degraded much slower than PGA nanofibers. Broken 
nanofibers were observed after 25 days of degradation with or without cells (Figure 
5.2a&e). Compared to degradation in the absence of cells (Figure 5.2f-h), the 
breakage of PLGA nanofibers in cell culture was accelerated at the surface (Figure 
5.2b-d), with broken nanofibers observed to curl and shrink. However, the nanofibers 
below the surface seemed to remain unaffected. After 70 days of cell culture, the 
PLGA nanofibrous scaffolds were disrupted and shrunken. PLGA degradation 
without cell culture was continued until 120 days when the scaffolds broke into pieces 
and SEM revealed a rough structure along the nanofibers (Figure 5.3). 
 
There was no obvious change in P(LLA-CL) nanofiber morphology up to 100 days 
during degradation with or without cell culture (images not shown). However, post 
100 days of culture, the structural integrity of P(LLA-CL) nanofiber scaffolds were 
compromised by the cell culture and were observed to tear and shrink. P(LLA-CL) 
degradation without cell culture was continued until 209 days when it broke into 
pieces (Figure 5.4). 
 
The diameters of nanofibers from the three different polymers were monitored during 
degradation. There was no significant change in fiber diameter during degradation 
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without cell culture (Figure 5.5). Furthermore, the thickness of the nanofiber scaffolds 





Degradation with cell culture Degradation without cell culture 
(a) 7 days 
 
(e) 7 days 
(b) 10 days 
 
(f) 10 days 
(c) 15 days 
 
(g) 15 days 
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(d) 20 days (h) 20 days 
 
Figure 5.1 Morphological change of PGA nanofibers during the degradation with PCASMC culture 
[(a) 7 days, (b) 10 days (c) 15 days and (d) 20 days] and without cell culture [(e) 7 days, (f) 10 days 
(g) 15 days and (h) 20 days]. 
 
Degradation with cell culture Degradation without cell culture 
 
(a) 25 days 
 
(e) 25 days 
 
(b) 45 days 
 




(c) 60 days 
 
(g) 60 days 
 
(d) 70 days 
 
(h) 70 days 
 
Figure 5.2 Morphological change of PLGA nanofibers during the degradation with PCASMC 
culture [(a) 25 days, (b) 45 days (c) 60 days and (d) 70 days] and without cell culture [(e) 25 days, (f) 
45 days (g) 60 days and (h) 70 days]. 
(a) 100 days without cell culture (b) 120 days without cell culture 
 
Figure 5.3 Morphology of PLGA nanofibers after (a) 100 days and (b) 120 days of degradation 







Figure 5.4 SEM micrographs of P(LLA-CL) nanofibers immersed in culture medium for 150 days 
























Figure 5.5 Fiber diameter change of PGA, PLGA and P(LLA-CL) nanofibers during degradation 




5.2.2 Mass loss of nanofibers and Molecular weight change of polymers 
Cell growth on the nanofibers did not significantly increase the mass loss of the 
polymer (Figure 5.6) except PGA. PGA nanofibers cultured with cells lost 50% of the 
original mass while without cells lost ~30% of the original mass within 10 days of 
degradation. PLGA scaffolds lost only 20% of their mass after 70 days and 
P(LLA-CL) did not show significant mass loss during the study period. In fact, the 
P(LLA-CL) nanofibers even showed a slight increase in mass after 50 days. 
 
Figure 5.7 shows the molecular weight reduction of P(LLA-CL) and PLGA as 
determined by measuring the molecular weight of the polymer using GPC. The 
number-average molecular weight (Mn) of PLGA without cell culture was reduced 
from 85 kDa to 33 kDa in 100 days, while that of PLGA with cell culture was reduced 
from 85 kDa to 37 kDa in 75 days. Mn of P(LLA-CL) with or without cell culture 
reduced at similar rate from ~140 kDa to 65 kDa in 110 days. Both polydispersities of 
P(LLA-CL) and PLGA nanofibers were maintained at 1.5 throughout the study period. 
In contrast to pellets of the polymer (blue curve and orange curve in Figure 5.7), the 
molecular weight of the nanofiber polymer decreased more slowly than the respective 
polymer pellet. The molecular weight of PLGA and P(LLA-CL) nanofibers reduced 
in a linear profile during degradation. Although cell culture was shown to slightly 
increase Mn reduction of PLGA, there was no significant difference between 
degradation with and without cell culture, indicating that cell culture did not 



























Figure 5.6 Mass loss of PGA, PLGA and P(LLA-CL) nanofibrous scaffolds during degradation 
with cell culture and without PCASMC culture. Mean for n=3±SD. * indicates that Mass loss of 






































Figure 5.7 The molecular weight loss as determined by GPC for nanofibers degradation with and 
without cell culture. 
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5.2.3 Mechanical Strength loss of the nanofibrous scaffolds 
As shown in Figure 5.8, PGA scaffolds with cell culture lost most of their mechanical 
strength in 2 days and without cell, in 4 days. PLGA nanofibers lost their mechanical 
strength in 70 days. There was little difference in the loss of mechanical strength 
between PLGA degradation with and without cell culture. The mechanical strength 
reduction of P(LLA-CL) nanofibers with cell culture is greater than those without 
cells in the first 80 days. 
 
5.2.4 Thermo-property and crystallinity during degradation 
DSC (Figure 5.9a) and WXRD (Figure 5.10a) results showed that PLGA nanofibers 
were fully amorphous before and after degradation without cell culture. The glass 
transition temperature (Tg) decreased from 48.2°C to 40.4°C before and after 100 
days of degradation without cell culture (Figure 5.9a). The DSC thermogram (Figure 
5.9b) of degraded P(LLA-CL) nanofiber was analyzed and summarized in Table 5.1. 
There are two separate melting peaks which indicate the melting temperature (Tm) of 
PCL and PLLA, respectively. The crystallinity of the PCL component increased with 
the degradation time, as did the melting temperature, indicating the induced 
re-crystallization of the PCL component during degradation. In contrast, the Tm of the 
PLLA component decreased during degradation with peak broadening, which could 
result from the degradation of the crystalline region. Cleavage-induced crystallization 
of the PLLA component was observed during the degradation, as indicated by the 
melting enthalpy which increased from 26.31 J/g to 30.86 J/g. This finding is 
consistent with the WXRD results, where the distinctive peak (~16º) of the crystalline 






















































Figure 5.8 Tensile tests results: (a) ultimate strength and (b) elong-at-break of PGA, PLGA and 


































































Figure 5.9 DSC thermograms of electrospun (a) PLGA and (b) P(LLA-CL) nanofibers during in 





















































Figure 5.10 WAXD patterns of electrospun (a) PLGA and (b) P(LLA-CL) nanofibers during in 







 Peaks of PCL 
Samples Tm/°C ΔH J/g Crystallinity*
pellet NA NA NA
0 day NA NA NA
30 days 43.10 ±0.60 1.36±0.25 3.34±0.62%
60 days 43.36±0.32 2.80±0.19 6.90±0.48%
80 days 43.74±0.26 3.22±0.20 7.94±0.48%
111 days 44.35±0.51 3.75±0.08 9.24±0.19%
 
 Peaks of PLLA 
Samples Tm/°C ΔH J/g Crystallinity**
pellet 164.73±1.09 34.26±0.28 52.07±0.43%
0 day 159.74±0.64 26.31±0.58 39.98±0.87%
30 days 159.60±0.55 28.24±1.05 42.92±1.59%
60 days 158.67±0.15 28.99±1.14 44.05±1.73%
80 days 158.90±0.45 30.18±0.73 45.87±1.11%
111 days 155.07±0.13 30.86±2.19 46.89±3.33%
 
Table 5.1 Tm, melting enthalpy and Crystallinity of PCL and PLLA components of P(LLA-CL) 
nanofibers during degradation without cell culture. 
 






Δ= ωχ , where XC is the crystallinity of one component in the P(LLA-CL) 
copolymer, where ΔHm,100% is the melting enthalpy of a 100% crystalline homopolymer for the 
corresponding component and ΔHm is that of the component within the copolymer. ω is the weight 
fraction of the investigated component in the copolymer. ω of PCL component is 30% and that of 
PLLA is 70%.ΔHm,100% of PCL and PLLA are 135.31J/g (V. Crescenzi et al., 1972) and 94J/g (H. 




Degradation behaviors of polymeric nanofibers have recently received more attention 
in tissue engineering applications (K. Kim et al., 2003;H. J. Shin et al., 2006;Y. You 
et al., 2005a;Y. You et al., 2005b;X. H. Zong et al., 2003). Although biodegradable 
nanofibers have been extensively studied as tissue engineering scaffolds, the 
degradation behavior of polymer nanofibers with cultured cells was not well 
understood. Degradation study of scaffolds with cultured cells is a more reliable 
reference to evaluate the development of cell/scaffold constructs. In this study, the 
effects of PCASMC on three types of nanofiber degradation were evaluated. The 
results revealed that the cells increased the degradation rate of PGA nanofibers 
(Figure 5.1) as well as accelerated the mass loss, mechanical strength reduction and 
fiber disintegration. Cell culture also increased the breakage of PLGA nanofibers at 
the cell-nanofiber interface (Figure 5.2) and this could be explained by the aggressive 
cellular activity together with the shrinkage of nanofibers. However, cell culture did 
not significantly increase the degradation of bulk PLGA nanofibers — PLGA with 
and without cell culture showed similar mass loss, and mechanical change during 
degradation. Slight acceleration of molecular weight reduction and mass loss after 50 
days was observed on PLGA nanofibers with cell culture and this could be attributed 
to the erosion of nanofibers with immediate contacts by the cells. P(LLA-CL) 
degradation was slightly accelerated by cell culture as indicated by a slight 
acceleration of reduction in mechanical strength in the first 80 days of culture (Figure 
5.8). This observation is supported by the slightly faster mass loss of P(LLA-CL) with 
cell culture for the first 30 days. It is interesting that from 30 days onward there was 
slight increase in the mass of P(LLA-CL) with cell culture. This could be explained 
by massive ECM secretion from the highly confluenced cells, being deposited onto 
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the scaffold (Y. X. Dong et al., 2008). However, degradation with and without cell 
culture showed similar rate of molecular weight loss (Figure 5.7). It is possible that 
active cell activity, such as release of acidic metabolites, may accelerate the erosion of 
the nanofibrous scaffolds with immediate contacts by the cell culture while the bulk 
scaffold remained unaffected. 
 
PGA, PLGA and P(LLA-CL) nanofibers showed distinct degradation behaviors. PGA 
is among the fastest hydrolytically degradable polyesters due to its hydrophilicity and 
molecular structure with no side groups. Ginde and Gupta reported that PGA pellets 
retained 80% of their mass after 8 weeks of in vitro degradation (R. M. Ginde and 
Gupta,R.K., 1987b). Although PGA is relatively hydrophilic and its molecular chain 
is not protected by side groups, the bulk PGA polymer degraded relatively slowly 
because of high crystallinity, which prevents water penetration. In our study, however, 
PGA nanofibers exhibited a much faster degradation rate (30% mass loss in 10 days) 
and this could be explained by the large exposure of the polymer to hydrolytic attack 
(Y. You et al., 2005b). The PGA nanofibers completely lost their mechanical strength 
in 2 days (with PCASMC culture) and 4 days (without cell culture) with 
disintegration of the fibrous structure. This property may limit the use of PGA 
nanofibers as tissue engineering scaffolds. However, they could be a good candidate 
for rapid drug delivery. On the other hand, blocks of PLGA (75:25) were reported to 
experience fast degradation of bulk disintegration with a half life of 3 weeks due to 
autocatalysis (S. M. Li, 1999). But this was not observed with PLGA nanofibers. 
Instead, PLGA nanofibers exhibited gradual degradation with a linear decrease in the 
molecular weight while the block PLGA (i.e. pellet) showed a sharp decrease in 
molecular weight caused by autocatalysis (Figure 5.7). PLGA nanofibers without cell 
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culture were able to maintain fibrous structures for up to 120 days, followed by 
massive disintegration (images not shown). A rough surface was observed on the 
PLGA nanofibers after 120 days of degradation (Figure 5.3b), which might be 
explained by uneven hydrolysis of the polymer region, preferably glycolic acid-rich 
area. The lower degradation rate of PLGA nanofibers as compared to PLGA pellets 
indicated that the autocatalysis is probably greatly reduced in PLGA nanofibers. 
P(LLA-CL) nanofibers were shown to degrade more slowly than PLGA. In the first 
70 days, P(LLA-CL) pellets degraded at a slightly faster rate than P(LLA-CL) 
nanofibers followed by a sharper decrease, indicating that there could be a mild 
autocatalysis in block P(LLA-CL) polymer (Figure 5.7). Another explanation of 
slower degradation of PLGA and P(LLA-CL) nanofibers is the molecular chain 
orientation within individual nanofibers. It is believed that the polymer chains orient 
along the direction of the electrospun fibers (X. H. Zong et al., 2003). Chain 
orientation along the fiber axis renders the fiber material  less susceptible to water 
penetration and more resistant hydrolytic attack (A. Browning and Chu,C.C., 1986;R. 
M. Ginde and Gupta,R.K., 1987a). This is because the lateral surface of the crystalline 
regions on the outer surface of the fiber has been shown to exhibit remarkable 
resistance to hydrolytic degradation (C. C. Chu and Campbell,N.D., 1982). This could 
lead to a lower degradation rate of electrospun nanofibers.  Small pieces of broken 
nanofibrous membrane were observed at late stage of PGA (15 days) and PLGA (120 
days) nanofibers without cell culture.   
 
Both PLGA and P(LLA-CL) nanofibers showed a similar linear reduction of the 
molecular weight during degradation, regardless of whether they were cultured with 
cells or not. This degradation profile was dramatically different from that of the 
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respective block polymer, which showed a sharp decrease in the molecular weight 
during degradation. Similar gradual molecular weight reduction of nanofibers has 
been reported and explained by non-autocatalytic degradation (H. J. Shin et al., 2006). 
But linear molecular weight reduction in the nanofibers is observed for the first time. 
The underlying mechanism of this linear reduction is not clear. It is possible that the 
polymer chain in the nanofibers was degraded from the end(s) of the polymer chain in 
a constant rate rather than random scission of the polymer chain which happens in 
autocatalysis. This hypothesis could be supported by the stable morphology during 
degradation where there was no mass disintegration. Table 5.2 summarizes the 
degradation behaviors of the three types of nanofibers with proposed explanation. In 
brief, we hypothesize that PGA nanofibers undergo degradation by random scission of 
the molecular chain and cell culture accelerates their degradation. PLGA and 
P(LLA-CL) nanofibers degrade with unzipping of the molecular chain from one or 
both end(s). It is further postulated that the resultant oligomers of PLGA can be 
partially dissolved in the surrounding medium while those of P(LLA-CL) cannot 
dissolve but could be neutralized by the surrounding medium, given that fact that 
mass loss of PLGA nanofibers was relatively slower than molecular weight loss and 
mass of P(LLA-CL) nanofibers which remained unchanged over the study period. In 
addition, the degradation of PLGA and P(LLA-CL) nanofibers could be accelerated 
by cell culture through surface erosion. Based on the linear profile of molecular 
weight reduction, the degradation half time for PLGA nanofibers without cell culture 
is around 80 days and that of PLGA with cell culture is around 70 days, while both 




  Stage I Stage II Stage III Stage IV  
PGA Phenomenon Complete loss of 
mechanical strength with 
little mass reduction 
Sharp mass reduction.  Further mass reduction.  
Fibers start to break. 
Fibers dissolved. 
 
 Mechanisms High level of water 
penetration due to high 
surface area. Hydrolytic 
attack on ester bond 
results in random 
scission. 
Shortened molecular 
chain results in  
increased 
hydrophilicity which 
in return accelerates 
the hydrolysis  
Further shortened 
molecular chain results in 
weak points along the 
nanofibers, resulting in 
breaches of nanofibers. 
Molecular chains are 
further trimmed to 
soluble oligomers. 
 Time (day) Without cell: 0-5 days;  
With cell 0-5 days 
Without cell: 5-10 
days  
With cell culture: 5-7 
days 
Without cell: 10-20 days 
With cell culture: 7-15 days
Without cell: >20 days 
With cell culture:>15 
days  
Effects of cell culture Cellular activity increases the degradation process 
Rough surface along 
nanofibers. 
Fibers dissolved* PLGA Phenomenon Mass and Mw decrease gradually/linearly. Fibers 
break slowly and shrink thereafter. Mechanical 
strength gradually reduces to zero. Broken nanofibers are embedded into the surrounding cells and dissolved. (70 day onward)* 
Preferential hydrolysis of 
glycolic rich region results 
in altering the surface 
morphology of nanofiber. 
Further hydrolysis.*  Mechanisms Water slowly penetrates the polymer matrix. The 
hydrolysis happens only on one /both end(s) of 
molecular chain. The resultant soluble 
monomers/oligomers are quickly neutralized by the 
surrounding medium. Part of them are dissolved in 
the medium.  
Cells penetrate into the weaken nanofiber network, 
increasing the fiber dissolution. 
 Time (day) 0-70 days 100 days onwards 
Effects of cell culture Cell culture induces surface erosion on PLGA nanofibers. Fibers on the cell-scaffold interface tend to break 
and shrink more easily. Bulk part of nanofibers are less affected 
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  Stage I Stage II Stage III Stage IV  
Fibers breach. Small pieces 
of fiber mesh fall off. Mass 
starts to decrease.* 
Fibers dissolved.* P(LLA-CL) Phenomenon Molecular weight decreases linearly.  
Mass remains unchanged.  
Mechanical strength gradually reduces to zero. (0-100 
days) Nanofibers are embedded into the surrounding cells and dissolved.* 
Weak points along the 
nanofibers result in fiber 
breaches.* 
Further hydrolysis.*  Mechanisms Water slowly penetrated the polymer matrix. The 
hydrolysis happens only on one /both end(s) of 
molecular chain. The resultant monomers/oligomers 
are insoluble and neutralized by the surrounding 
medium. 
Cell penetrate into the weaken nanofiber network, 
increasing the fiber dissolution.* 
 Time (day) 0-100 days 100 days onwards 
Effects of cell culture PCASMC induces slight surface erosion on P(LLA-CL) nanofibers. PCASMC induces significant shrinkage 
on the P(LLA-CL) nanofibers. 
 
Table 5.2 Hypothesized degradation model of PGA, PLGA and P(LLA-CL) nanofiber. 
* based on conjecture without direction observation. 
Note: Degradation without cell culture and with cell culture are distinguished by light and dark filled color. 
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5.3 PLGA and P(LLA-CL) degradation induced by Ultraviolet irradiation 
After different duration of UV irradiation (λ=254 nm, 285 µW/cm2) on both sides of 
the nanofiber meshes, the morphology changes are showed in Figure 5.11. There is no 
obvious morphological change of PLGA and P(LLA-CL) nanofibers after 
UV-irradiation for up to 2 hours and 8 hours, respectively (Figure 5.11b & 5.11e). 
Although there is no obvious morphological change for short duration of UV radiation, 
the mechanical strengths were highly compromised (Figure 5.12). Tensile test results 
showed than the ultimate strength of materials was decreased with the duration of UV 
treatment. Only after 30mins of UV irradiation, the ultimate strength of PLGA and 
P(LLA-CL) were reduced by 47% and 43%, respectively. PLGA and P(LLA-CL) 
completely lost their strength after 2 hours and 8 hours of UV irradiation. It is 
surprising that the polymer has completely lost their mechanical strength without 
showing any morphological defects. It is reasonable that the molecular chains within 
the nanofibers had been broken. 
 
To determine how much damage on the molecular chains of nanofibers, GPC with 
THF as the mobile phase was performed to evaluate the molecular weights. As shown 
in Figure 5.13, the molecular weights of both polymers were reduced 
anti-proportionally to the duration of treatment. After 30 mins of irradiation, the 
average molecular weights of PLGA and P(LLA-CL) were reduced by 30% and 17%, 
respectively. Melt-like morphology was observed after longer UV radiation time 
which is shown in Figure 5.11c for 8 hours treated PLGA and Figure 5.11f for 48 
hours treated P(LLA-CL). The delayed morphological change indicates that after the 
prolonged irradiation, the polymer chains has been “trimmed” to so short that the 
glass transition temperatures (Tg) could have dropped far below the room temperature. 




To evaluate the effects of UV on in vitro degradation, electrospun PLGA was 
pretreated by UV irradiation for 30mins and incubated in PBS (PH 7.4), 37˚C, with 
PBS changed weekly. Untreated PLGA was served as control. The samples were then 
collected at different intervals and observed under scanning electrical microscopy 
(SEM). Figure 5.14 showed that UV-irradiated PLGA nanofiber degraded much faster 
than non-treated ones. After one week of degradation, the UV-irradiated PLGA 
nanofiber (Figure 5.14f) showed similar morphology of non-treated PLGA that 
degraded for 1 month (Figure 5.14d). These results indicated that the polymers were 
seriously damaged and degraded with just a small dosage of UV irradiation which is 
equivalent to normal UV sterilization procedure in lab experiment. However, SEM 
imaging showed little difference in appearance of treated polymers compared with the 
non-treated ones (Figure 5.11). The degradation effect of UV sterilization might be 
easily overlooked due to the unchanged morphology.  
 
    
(a)           (d) 
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(b)            (e) 
    
(c)     (f) 
Figure 5.11 SEM images of nanofiber after different time of UV irradiation. PLGA were irradiated 
















































Figure 5.12 Mechanical loss of electrospun nanofiber due to UV irradiation. (a) Tensile strength 





















Figure 5.13 Number-Average molecular weight (Mn) of PLGA (pink) and P(LLA-CL) (blue) after 




           
Non-treated UV irradiated 
(a) (e)  
(b) (f)  
(c) (g)  
(d )  (h)  
 
Figure 5.14 UV-irradiated (285 μw/cm2, 30 mins) (a,b,c,d) and non-treated (e,f,g,h) electrospun 
PLGA nanofiber membranes were incubated in PBS (PH 7.4), 37˚C for up to 30 days. At day 1 




Polymers degraded by UV is not a new phenomenon and has been extensively studied 
in 1980s in term of UV ablation (S. R. Cain et al., 1992;T. F. Deutsch and Geis,M.W., 
1983;P. E. Dyer, 2003;Y. Kawamura et al., 1982a;Y. Kawamura et al., 1982b;R. 
Srinivasan, 1982;R. Srinivasan et al., 1990;R. Srinivasan and Leigh,W.J., 1982;R. 
Srinivasan and Maynebanton,V., 1982). At that time, PMMA was served as a 
standard polymer of UV ablation. UV with wavelength of ~250 nm has been shown to 
cleave its ester bond, which indicates that the polyester commonly used as tissue 
engineering scaffold is probably vulnerable (R. Srinivasan et al., 1990). For normal 
UV sterilization in biological cabinet, the energy exposing on the material is around 
0.6J per hour. This amount of energy would only etch through in the depth of a few 
hundred nanometers (S. R. Cain et al., 1992;Y. Kawamura et al., 1982b), which 
would be trivial for block polymeric materials. However, the damage would be 
significant for nanofibers. If the etch depth of the UV dosage is only 300 nm, for 
example, nanofibers with diameter smaller than 600 nm would be considerably 
damaged due to the all-directional scattering. Furthermore, the average unit molecular 
weights of PLGA (75:25) and P(LLA-CL) (70:30) are 103 and 68.5 Dalton 
respectively. This means at the same weight, PLGA has 50% more ester bond than of 
P(LLA-CL). This could explain in this study PLGA degraded faster than P(LLA-CL) 
under UV irradiation. 
 
Nanofibrous scaffolds must be either fabricated aseptically or sterilized before cell 
culture or implant. Ethylene oxide, γ-irradiation, 70% ethanol and ultraviolet (UV) 
irradiation are well-established techniques for sterilization in biomedical application 
and lab research (C. E. Holy et al., 2001;H. Shearer et al., 2006;J. Stitzel et al., 2006). 
The wavelength of UV for sterilization is 254 nm. UV sterilization is widely adopted 
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in nanofiber tissue engineering research due to its convenience. Up to now, there is no 
study to evaluate the effect of UV sterilization on polymer nanofibers. In this study, 
we demonstrated that normal dosage UV sterilization induced significant damage on 
PLGA and P(LLA-CL) nanofibers, reducing the molecular weights and mechanical 
strengths. Precautions may have to be taken into consideration when sterilizing 
polymeric nanofibers by UV. 
 
However, this degradation property of UV irradiation may be utilized. One potential 
usage is to pre-treat some slow degraded polymeric nanofibers to shorten its 
degradation time in vitro or in vivo. Metabolism study of smooth muscle cells on the 
UV treated or non-treated PLGA and P(LLA-CL) polymer nanofibers indicated the 
UV irradiation did not affect the cell viability (Figure 5.15). MTS assay revealed that 
the viabilities of PCASMC cultured on PLGA and P(LLA-CL) were not affected by 
UV pre-treatment. 
 
Another potential application of UV irradiation is to fabricate micro-porous 
nanofibers scaffold by photolithography techniques. By placing a porous masked 
(pore diameter ~ 100um) on top of a nanofiber mesh, we were able to produce porous 
nanofiber scaffold using UV laser irradiated through the mask (Figure 5.16a). 
Different irradiation durations were tried to achieve good “microporous” nanofiber 
scaffold. Figure 5.16b and 5.16c shows the porous PLGA and P(LLA-CL) nanofiber 
after UV radiation of 1 hour and 15 hours, respectively. SMCs were seeded on the 
P(LLA-CL) microporous nanofibers. At day 1, there were few SMCs at the pores of 
the scaffold (Figure 5.17a). The SMCs were found to migrate through the pores 
(Figure 5.17b) and attached on the coverslip underneath after 20 days of seeding as 
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shown by the arrow in Figure 5.17c. But the approach of seeding SMCs on PLGA 
scaffold was failed due to shrinkage of the scaffold, which is a commonly reported 
property of electrospun PLGA nanofiber (J. Nam et al., 2007;X. H. Zong et al., 2003). 
One big drawback of nanofiber scaffolds for biomedical application is that the pore 
size of nanofiber is too small to let cells migrate through (J. Lannutti et al., 2007) and 
some approaches were made to address the problem, such as combination of 
microfibers and nanofibers(Q. P. Pham et al., 2006), salt leaching (J. Nam et al., 2007) 
and low-temperature electrospinning (M. Simonet et al., 2007). In our study, UV 
irradiation may be an alternative approach. Above example provided basic concept to 
construct 3D electrospun nanofiber scaffold by UV radiation and layer-by-layer 
assembly. We can superpose the “photolithographied” nanofiber on each other to 
achieve desired thickness and volume. We can also roll a “photolithographied” 
nanofiber mesh into a tubular scaffold, followed by cell (i.e. SMC) seeding. The cells 
would be able to migrate through the wall of the tubular scaffold, forming an 
















































Figure 5.15 Effects of UV-irradiation on SMC viability. Electrospun P(LLA-CL) (a) and PLGA (b) 
were irradiated by UV (285 μw/cm2, 30 mins) and seeded with SMC cells. The cells were cultured 
for up to 40 days. The cell viabilities were tested by MTS assay at different interval. No significant 
difference of cell viability was observed between UV-irradiated and non-UV treated samples. Mean 









Figure 5.16 (a) Schematic diagram of UV photolithography to make porous nanofibers. (b) PLGA 
nanofiber and (c) P(LLA-CL) after 1 hour and 15 hours of UV photolithography. 












Figure 5.17 UV-photolithography treated P(LLA-CL) nanofiber scaffolds cultured with SMCs for 








Degradation of PGA, PLGA and P(LLA-CL) nanofibers cultured with or without 
PCASMC were evaluated in this study. We found that cell culture significantly 
increased the degradation of PGA nanofibers while this effect on PLGA and 
P(LLA-CL) was limited though accelerated surface erosion was observed. The 
molecular weight of P(LLA-CL) and PLGA nanofibers decrease linearly during 
degradation period of up to 100 days. Half lives of PLGA and P(LLA-CL) nanofibers 
were shown to be 80 days and 110 days, respectively. 
 
We also demonstrated that normal dosage UV sterilization induced significant 
damage on PLGA and P(LLA-CL) nanofiber, reducing the molecular weights and 
mechanical strengths. Precautions may have to be taken into consideration when 
sterilizing polymeric nanofibers by UV. On the other hand, the nature of UV-induced 
degradation could be utilized for tissue engineering application. We can pretreat 
nanofiber scaffolds with UV to reduce its degradation time. Another usage is 





Chapter 6  
Nanofiber covered stent 
 
As described in Chapter 1, patients using commercial covered stents suffered from 
acute thrombosis, restenosis and delayed/incomplete re-endothelialization (M. C. 
Petrie et al., 2006). This could be contributed to the large thickness and high 
deployment pressure of the current covered stent design, and the non-degradable and 
poor-endothelializable PTFE membrane. Nanofiber-covered stent (NCS) could 
potentially help to reduce the wall thickness by introducing a two-layer low-profile 
design (bare metal stent + nanofibrous membrane), as compared to the previous 
three-layer sandwich designs (M. C. Petrie et al., 2006). Highly porous but small 
pore-sized nanofibrous membrane could potential reduce restenosis but maintain 
nutrient exchange. Previous biocompatibility and degradation studies revealed 
P(LLA-CL) could be a good candidate for nanofiber covered stent (NCS). In vitro 
study showed that P(LLA-CL) nanofibers suppressed the short-term but supported 
long-term proliferation of porcine coronary artery smooth muscle cells, inducing 
significant amount of ECM formation in long term. P(LLA-CL) nanofibers were also 
shown to facilitate endothelial cells adhesion and proliferation. In vitro degradation 
study indicated that P(LLA-CL) nanofibers underwent a smooth degradation, with 
linear decrease of molecular weight. The in vitro degradation time was expected to be 
7 months. It is believed that the in vivo degradation rate would be higher (C. Briguori 
et al., 2000). Therefore, the combinatorial benefits of P(LLA-CL) NCS include 




However, the mechanical requirement of the nanofibrous membrane on NCS is 
rigorous. The stent is deployed with an inflated balloon within seconds, from 1mm in 
diameter to 2.5-5mm in diameter (T. Olbrich et al., 2006). It would be challenging to 
produce nanofibrous membrane, which could be rapidly stretched up to 400% of 
original length without being torn (W. He et al., 2006;R. Inai et al., 2005;S. F. Li et al., 
2007;V. Thomas et al., 2006b). In this chapter, three different methods for NCS 
fabrication were developed and compared to deposit mechanically sound nanofibrous 
membrane onto a bare metal stent.  
 
Additionally, the drug loading ability of P(LLA-CL) nanofiber was investigated. As 
described in chapter 1, commercial covered stent failed to reduce the in-stent 
restenosis as compared to bare metal stent, due to severe edge restenosis (M. C. Petrie 
et al., 2006). Therefore, a period of anti-proliferative drug release from NCS could be 
necessary to reduce restenosis. However, although the inhibition of smooth muscle 
cells (SMCs) growth is necessary to reduce restenosis at the first stage. At later stage, 
biocompatibility of implant materials with SMCs is important for complete 
re-endothelialization (A. V. Finn et al., 2007;M. Joner et al., 2006;W. Yang et al., 
2006). After the drug is completely released, P(LLA-CL) nanofiber could be a good 
scaffold for healing. In the study, we have explored the feasibility of loading 
paclitaxel, an anti-proliferation drug used in Taxus® stent, onto the NCS. We believe 
the physical barriers created by nanofibrous membrane, together with release of 
paclitaxel could efficiently reduce the in-stent restenosis. 
 




Poly(L-lactic acid)-co-poly(epsilon-caprolactone) block copolymer [P(LLA-CL), 
70:30, Mw=250kD] was bought from Boehringer (Ingelheim, Germany). 
Phoenix bare metal stents (2.5mm in diameter after deployment and 13mm in length) 
were purchased from Curatives Ltd. (Germany). The undeployed BMS was used, 
whose diameter is 1mm. 
Medical grade Paclitaxel (power) was obtained Dabur Pharma Ltd. (New Delhi, 
India) 
 
6.1.2 NCS fabrication 
12% (w/v) P(LLA-CL) was dissolved in Hexafluoroisopropanol (HFIP, Sigma) for 
electrospinning. A schematic diagram of three different fabrication setups is 
illustrated in Figure 6.1. In brief, P(LLA-CL) solution was fed through a 27G needle 
with flow rate at 1ml/hr. High voltage (10kV) was applied on the needle tip.  
 
The first design (Figure 6.1a) was to get random nanofiber-covered stents by direct 
electrospinning. In brief, a bare metal stent (BMS) was mounted on a grounded 
rotating rod at the speed of 20rpm. The electrospun nanofiber was deposited evenly 
on the BMS. The coating time is 10 mins. 
 
The second (Figure 6.1b) and third design (Figure 6.1c) aimed to fabricate 
longitudinally aligned fibers along the stent. In the double-disk method (Figure 6.1b), 
the aligned electrospun fibers were collected between two rotating disks as previously 
reported (W. E. Teo and Ramakrishna,S., 2005). The disks were rotated at 120rpm 
and transferred the aligned fiber onto a BMS. The BMS also was rotated at 18rpm to 
get an even coating. The coating time is 30 mins. In the single-disk method (Figure 
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6.1c), the electrospun fibers were collected on the edge of high-speed rotating disk 
(2000rpm). A BMS was mounted on the edge of the disk. Every 3 minutes, the disk 
was stopped and the aligned fibers on the stent were cut off at the stent edge to 
disconnect the fibers on the stent with the fibers on the disk. The stent was then 
manually rotated for 60 degrees and the disk was restarted to rotate at 2000rpm for 
another 3 minutes. The total coating time is 30 mins. Figure 6.1d is a typical NCS 
made from above methods (NCS made from the three methods had similar 
appearance). 
 
The reason of having three different fabrication methods is to compare and maximize 
the stretchability and integrity of produced nanofibrous membrane. The nanofibrous 
cover need to be extensively stretched in the circumferential direction during NCS 
deployment without being torn. Therefore, in addition to random nanofibers, 
longitudinally aligned fibers (double-disk and single-disk method) were proposed to 
increase the stretchability of the nanofibrous cover on the BMS. Additionally, the 
resistance from the nanofibrous cover would be minimized if it is longitudinally 













Figure 6.1 Three different electrospinning setups for NCS fabrication. (a) Direct electrospinning, 
Setup for random nanofiber covered stent. (b) Double-disk method and (c) Single-disk method, 






The NCS samples were sputter coated with gold (JEOL JFC-1200 Fine Coater, Japan) 
and observed under the SEM (FESEM; FEI Quanta 200, USA) at an accelerating 
voltage of 15 kV or 20 kV. 
 
6.1.4  Mechanical characterization 
Tensile tests were conducted using a 5848 microtester (Instron, Canton, MA) at a 
stroke rate of 25%/min (i.e. 25% of the gauge length per minute). Nanofibers on NCS 
were cut off and unfolded into a rectangular shape and for each NCS we could get a 
rectangular piece of nanofibrous mesh sized 13mm by 3.2mm. For tensile test in the 
longitudinal direction, the sample is further cut into 3mm in width and the gauge 
length is 7mm, with stroke rate of 1.75mm/min. For test in the circumferential 
direction, the sample was cut into 5mm in width and the gauge length is 2mm, with 
stroke rate of 0.75mm/min. In both tests the nanofibrous meshes were attached to a 
sample holder by epoxy glue (3M, USA). 
 
Standard pressure-volume of stent deployment was plotted by compression test using 
the microtester as shown in Figure 6.2. In brief, the compressed “object” is a 
water-filled syringe (BD 5ml syringe), which was connected to the inflation system of 
the stent. The pressure calculated as compression force divided by cross section area 
(CSA) of the syringe while the inject volume is travel distance times CSA. The 
injecting rate was 40μl/s as previously described (T. Olbrich et al., 2006). The 
obtained curve (“pressure” versus “injected volume”) was corrected by the 
non-loading control, in which the inflation system was not connected. The Phoenix 
CC (Germany) 25-13 BMS-balloon (2.5mm in diameter and 13 mm in length) system 





Figure 6.2 Diagram of setup to obtain pressure-volume curve during NCS deployment. The photo 
of expanded NCS is shown in the top right corner. 
 
6.1.5 Degradation study of nanofibers on the stent. 
Three longitudinally aligned nanofiber covered stents by double-disk method were 
deployed in the 2.5mm silicone tubing (Coleparmer, UK). The three deployed NCS 
and three other non-deployed NCS were immersed in PBS and placed in a shaker 
(100rpm) in 37ºC for up to 7 months. After different intervals, the samples were 
collected for SEM imaging.  
 
6.1.6 Drug loading and release 
Paclitaxel, an anti-proliferation drug was loaded onto the nanofiber by blended 
electrospinning. The electrospinning solution was prepared by dissolving 1.33% (w/v) 
of paclitaxel and 12% (w/v) P(LLA-CL) in HFIP. The paclitaxel-P(LLA-CL) solution 
was electrospun and collected on 1) A flat sheet of aluminum foil or 2) on 15mm 
glass cover slips under the same condition as electrospinning pure P(LLA-CL) 






Moving arm of Instron 
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To determine encapsulation efficiency, 2mg of paclitaxel-loaded P(LLA-CL) 
nanofibers were dissolved in 1 ml DCM. Subsequently, 5 ml of mobile phase 
(Acetonitrile: Water = 1:1) was added to the solution. A nitrogen stream was 
introduced to evaporate DCM at room temperature until a clear solution was obtained. 
The resulting solution was then filtered and analyzed by high performance liquid 
chromatography (HPLC) mentioned below. 
 
Around 10 mg of nanofiber meshes were cut and the samples were immersed in 20 ml 
of PBS (pH 7.4) containing 0.05% of Tween 20 (PBST20) to enhance the solubility of 
paclitaxel. The buffer solution was kept at constant temperature of 37ºC and shaken at 
100rpm. At different time intervals, three tubes of samples were withdrawn and 
centrifuged at 11,500 rpm for 10 min. The precipitated samples were resuspended in 
20 ml fresh release medium, kept in a complete sink condition and placed back to the 
shaker. The supernatant solution was retained for HPLC analysis. At the end of the 
drug release study (60 days), the amount of paclitaxel remaining in the nanofibers was 
determined by the same method of measuring encapsulation efficiency. 
  
Paclitaxel in the release medium was first extracted with 2 ml of DCM. A mixture of 
acetonitrile and water (50:50 v/v) was added to the extracted paclitaxel after the DCM 
had evaporated. The resulting solutions were analyzed using HPLC, in which a C-18 
Column (Agilent, US) was used and the mobile phase was delivered at a rate of 1 
ml/min. 50 microliters of sample was injected by an auto-sampler and the eluent was 
detected at 227 nm using an ultra violet (UV) detector. Standard curve were generated 
by injection with known amounts of paclitaxel, which are proportional to the 
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integration of eluent peaks. The amounts of paclitaxel in the samples were determined 
by linear fitting to the standard curve.  
 
6.1.7 Cell culture and cytotoxicity test 
Porcine smooth muscle cell (PCASMC, Cell Applications Inc. USA) was cultured in 
the provided culture medium. The medium was refreshed every 2-4 days and the 
cultures were maintained in a humidified incubator at 37°C with 5 % CO2. When the 
cells reached 80-90% confluence (5×104 cells/cm2), the cultures were trypsinized and 
subcultured at 1:3 ratios. 
 
The paclitaxel loaded nanofibers on 15mm glass cover slip were sterilized by UV for 
30mins. The cells were seeded onto the nanofibers at a seeding density of 1.8×104 
cells/cm2 and cultured until the desired duration to evaluate cell viability. The 
medium was refreshed every 2-4 days according to cell density. After culturing for 2, 
5, 10, 18, 30 and 40 days, unattached cells were washed out and the attached cells 
were quantified by the MTS assay. Cells viability on the nanofibrous scaffolds was 
determined by the colorimetric MTS assay (CellTiter 96® AQueous One Solution 
Cell Proliferation Assay, Promega, USA) (W. He et al., 2005b). PCASMC cultured on 
non-drug-loaded nanofibers were served as negative control and HeLa cells (seeded 
confluently at 6×104 cells/cm2) cultured with DMEM with 10% FBS, which are 
known to be killed by paclitaxel, were served as a second control. 
 
6.2 Results 
6.2.1 NCS fabrication 
The NCS fabricated by direct electrospinning (Figure 6.1a), double-disk (Figure 6.1b) 
and single-disk method (Figure 6.1c) were imaged (Figure 6.3a) and the nanofibrous 
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morphologies were confirmed by SEM as expected (Figure 6.3b-d). Both double-disk 
and single-disk methods successfully created longitudinally aligned nanofibers on the 
stent. 
 
Figure 6.3 (a) A typical NCS fabricated by direct electrospinning, double-disk or single-disk 
method. The SEM images reveals the random nanofibrous structure of NCS fabricated by direct 
electrospinning (b) and aligned structures of NCS fabricated by double-disk (c) or single-disk (d). 
 
6.2.2 Mechanical strength of the nanofiber cover 
Figure 6.4 reveals the mechanical properties of nanofibrous membrane on NCS 
fabricated by the three different methods. The resistance of nanofibrous cover during 
NCS deployment will be reflected by the tensile test in circumferential direction. 
Clearly, the aligned nanofibers (“single” and “double” in Figure 6.4) were more 
stretchable than random nanofibers (“single-circum” and “double-circum” versus 






nanofibers were stronger than random nanofibers (“single-long” and “double-long” 
versus “direct-long”). Clinically, NCS needs to be deployed from 1mm in diameter to 
2.5-5 mm in diameter, which means 150-400% of expansion over circumferential 
direction. Apparently, only NCS fabricated by single-disk method met the criteria ---- 
it could be stretched over 1000% of original length (“Single-circum” in Figure 6.4). 
Additionally, the resistance (tensile strength) of nanofibrous cover by single-disk 
method was also lowest among three. And low resistance of nanofibrous cover could 
effectively reduce the balloon pressure to deploy NCS. It is suspected that higher 
pressure  to deploy commercial covered stents (18atm for covered stents versus 
~12atm for bare metal stents) may induce deeper injury to the vessel wall, leading to 
higher rate of restenosis (M. A. Turco et al., 2006). Therefore single-disk could be the 


























Figure 6.4 Tensile test result of nanofibrous covers of NCS fabricated by direct electrospinning 
(direct), double-disk (double) and single-disk (single) methods. The nanofibrous cover were 
stretched over longitudinally (long) or circumferential (circum) direction.  
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6.2.3 In vitro Deployment of NCS 
Nine NCS fabricated by three different methods (3 pieces of NCS for each method) 
were deployed following BMS supplier’s instruction (Figure 6.5). The nanofibrous 
covers on all three NCS by direct electrospinning were torn during the stent 
deployment (Figure 6.5a-c), while all three covers of aligned NCS by single-disk 
remained intact (Figure 6.5g-i). Only one out of three NCSs by double-disk was 
deployed without tearing the cover (Figure 6.5d-f). The results of stent deployment 
were consistent with the results of tensile test on the nanofibrous cover (Figure 6.4). 
The random nanofibrous cover by direct electrospinning was easiest to break. 
Although the expansion of NCS was from 1 mm in diameter to only 2.5 mm in 
diameter (150% of expansion), two covers out of three NCSs by double-disk method 
were torn because of the rapid expansion (deployed within 2 seconds). Nanofibrous 
covers from NCS by double-disk method were able to expand over 300% only 
because the stroke rate is 25%/min. In contrast, all three NCSs by single-disk were 
deployed with the cover intact. The NCS by single-disk were also able to be further 
expanded to 5mm in diameter using bigger size balloon (images not shown). In 
addition, the aligned fibers by single-disk method seemed to form a knitted structure, 
which tended to form porous net-like structure after expansion (Figure 6.6f&g). This 
net-like structure was not observed on the NCS by double-disk method. 
 
Figure 6.6 shows the morphology of nanofibrous cover of NCS by double-disk (a-d) 
and by single-disk (e-g) after deployment. It is found that nanofibers in some regions 
of NCS by double-disk remained aligned (Figure 6.6c) while some in other regions 
became randomly oriented (Figure 6.6d). The nanofiber morphology on NCS by 








Figure 6.5 Representative snapshots of deployment of NCS by direct electrospinning (Figure a-c), 
double-disk (Figure d-f) and single-disk method (g-i). 
 
(c)(a) (b)
(d) (e) (f) 
(g) (h) (i) 
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Figure 6.6 SEM images of deployed NCS 










The pressure-volume curve of NCS by single-disk method was plotted to evaluate the 
resistance of nanofiber during stent deployment, as compared to those of BMS and 
Balloon only. As indicated in Figure 6.7, the resistance of nanofibrous cover was 
reflected by the small shadow area during stent expansion, which indicated the extra 
work required when deploying NCS as compare to BMS. After the stents were 
partially expanded (i.e. after 160μl of liquid was injected), the pressures of NCS, 
BMS and Balloon were the same, indicating little resistance was induced by the 
nanofibrous cover. 
  
The NCS by single-disk method was deployed in a dissected rabbit aorta in vitro. 
Figure 6.8 indicated that the NCS could be successfully implanted and fit well into the 
aorta without any destruction on the NCS or aorta. 
 
 
Figure 6.7 Pressure-volume curve of deployment of NCS by single-disk method (orange), 
































Figure 6.8 NCS by single-disk method was deployed in a dissected rabbit aorta (a-e). The unfolded 
aorta was only shown by SEM (f). The while scale bars indicate 2msm. 
 
6.2.4 In vitro degradation of nanofibers on NCS. 
Figure 6.9 shows the SEM images of nanofibers on deployed and non-deployed NCS 
by double-disk method after 5 months and 7 months of in vitro degradation in PBS. It 
is found there was no obvious change in fiber morphology of deployed NCS after 5 
months. In contrast, broken fibers were seen on the non-deployed NCS after 5 months. 
The broken fibers on the surface on non-deployed NCS could be attributed to its 
exposure to the turbulent fluids, caused by the shaker. The morphologies of deployed 
NCS were less affected as they were protected by the silicone tubing. After 7 months, 
the broken fibers can be observed on both exterior and interior surfaces of deployed 
NCS. More broken fibers could be seen on the non-deployed NCS. The 
morphological changes are consistent with the degradation study in chapter 5. No 
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Figure 6.9 SEM images of nanofibers on deployed and non-deployed NCS after 5 months and 7 
months of in vitro degradation in PBS. 
 
6.2.5 Drug release study of Paclitaxel loaded P(LLA-CL) 
z Morphology of paclitaxel loaded P(LLA-CL) nanofiber 
10wt % paclitaxel loaded P(LLA-CL) was electrospun into nanofiber as shown in 
Figure 6.10a. The mean diameter of paclitaxel-loaded P(LLA-CL) nanofibers was 
482nm, with a standard deviation of 183nm, with no significant difference with the 
non-loaded one (484±172nm). The drug loaded was 9.1%±0.4%. The encapsulation 
efficiency was round 90%. The morphologies of fibers were similar before and after 




   
 
Figure 6.10 Typical morphologies of paclitaxel-loaded P(LLA-CL) nanofibers before and 60 days 
for drug release study. 
 
z In Vitro Drug Release Profiles 
Figure 6.11 showed the preliminary release profile of paclitaxel-loaded P(LLA-CL) 
nanofibers. Diffusion of a small amount of paclitaxel on the surface of nanofibers 
could most likely contribute to the initial burst release. Around 7% of the total amount 
of drugs was released in 24 h. Also, the sustained release of paclitaxel lasted for more 
than 2 months and demonstrated a nearly linear release kinetic (zero order) as shown 
in Figure 6.11. It was observed that the amount of paclitaxel released from P(LLA-CL) 
nanofibers in 60 days was ONLY 11% of the total amount of drug in the fibers. The 
amount of paclitaxel remained in nanofiber after 60 days’ release was confirmed by 
HPLC.  
 
z In Vitro Cytotoxicity Test  
In this study paclitaxel-loaded P(LLA-CL) nanofibers were tested for the cytotoxicity 
on HeLa and PCASMC cells. MTS assay was then used to quantify the cell viability 
on the nanofibers. Figure 6.12 showed the quantitatively cytotoxicity study of 




confluently on drug-loaded or non-loaded P(LLA-CL) nanofibers. It is found that 
HeLa cells maintained high level of cell activity on non-loaded nanofibers while the 
cell activity on paclitaxel-loaded nanofibers reduced to zero after 5 days of cell 
culture. PCASMC were also seeded on the drug-loaded nanofiber at 30% confluency. 
The PCASMC viability on non-loaded nanofiber was increased with culture time, but 
that on drug-loaded nanofiber remained unchanged till the end of study period. The 
results indicated that paclitaxel-loaded nanofiber could kill HeLa cells while 
inhibiting PCASMC proliferation when they were cultured on it, which was 
confirmed by SEM (Figure 6.13). SEM images revealed that HeLa cells on 
drug-loaded nanofiber could have undergone induced apoptosis while the morphology 
of PCASMC remained unchanged. The result suggested that paclitaxel-loaded 
























Figure 6.11 In vitro release profiles of representative samples. Each data point represents the 























Figure 6.12 Cell viability of HeLa (seeded at 6×104 cells/cm2) and PCASMC (seeded at 1.6×104 
cells/cm2) culture on non-loaded [P(LLA-CL)] or paclitaxel-loaded [P(LLA-CL) pax] nanofiber for 




Figure 6.13 SEM images of HeLa (a&b) and PCASMC (c&d) after 5 days of culture on 










z Paclitaxel-loaded NCS. 
Paclitaxel was also loaded onto NCS by blended electrospinning. The drug loading 
amount was 48.5±9.9μg per stent (n=8), with loading concentration of 9% (w/w) in 
P(LLA-CL). Therefore the paclitaxel loading density is 0.475±0.097 μg/mm2 for 
2.5mm by 13mm stent. The mechanical property of Paclitaxel-loaded NCS was tested 
and the Paclitaxel-loaded NCS by single-disk method were successfully deployed 
(images not shown). The tensile tests of nanofibrous covers revealed that paclitaxel 
did not seriously affect the stretchability of the nanofibrous cover over circumferential 



















Figure 6.14 Tensile test of nanofibrous cover of paclitaxel-loaded (blue) and non-loaded (pink) 
NCS in circumferential direction. 
 
6.3 Discussions 
In the study, three methods of NCS fabrication were developed and compared. 
Coronary stent deployment usually completes within 10 second, although the pressure 
could hold for up to 1 minute after it is fully inflated (T. Olbrich et al., 2006). The 
nanofibrous membrane on the NCS would have to survive the rapid stretch to 





Given the fact that random nanofiber membrane could only be stretched to 300% of 
the original length under a much slower stroke rate, longitudinally aligned fibers, 
which could be stretched to more than 1000% of the original length, seems to be a 
good choice. There are some limitations for the tensile test shown in Figure 6.4. The 
sample dimension does not meet the requirements of the standards of mechanical tests 
for fabric materials (ASTM D4595). This was limited by the size of the stent (1mm in 
diameter and 13 mm in length). Also, in order to compare with previous study in 
chapter 5 (Y. X. Dong et al., 2008), the stroke rate was set at 25%/min, which can not 
represent the stretching rate during stent deployment. Therefore, performance tests 
were made to evaluate the in vitro deployment of NCS fabricated by the direct 
electrospinning, double-disk and single-disk methods. Only NCS fabricated by 
single-disk method did not tear the nanofibrous membrane during stent deployment. 
In comparison, only 1 out of 3 NCSs by double-disk and none of the NCS by direct 
electrospinning passed the deployment test. This result is consistent with tensile 
property of nanofibrous memrance on NCS, in which nanofibrous cover by 
single-disk method was much more compliant than that by double-disk method 
(figure 6.4). It has also been tested that NCS by single-disk method could at least be 
deployed from 1mm to 5mm in diameter. However, the reason of the big difference 
between NCSs by single-disk and by double-disk methods is not clear. In fact fibers 
generated by double-disk method were more aligned than those by single-disk method, 
because in principle every single fiber from double-disk method should be 
perpendicular to the disks. Therefore the difference could result from the way of 
depositing fibers onto the stents. It is possible that the constant rotation of BMS 
during double-disk fabrication induced twisting and tension over the deposited 
nanofibers. The tension made them easier to break. In comparison, in the single-disk 
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method the stent was manually rotated after the fibers were cut off at the edge. 
Therefore there should not have been more twists and tension over the fibers by 
double-disk method. However, it was difficult to confirm this hypothesis by SEM, 
where only surface fibers could be observed. 
 
Another concern of NCS deployment is whether the pore size of nanofiber after stent 
deployment would still be small enough to prevent SMCs infiltration. Figure 6.6e-g 
indicates that the pore size of nanofibrous membrane after stent deployment was 
below 1 micron, which should be sufficiently small, subjected to confirmation by 
animal study. Other than changing fiber diameter, we could also adjust the effective 
pore size by increasing or reducing the thickness of nanofibrous membrane (S. Kaur 
et al., 2008). However, the ideal pore size should be in the range that the SMC 
infiltration is significantly delayed rather than completely stopped. Proper pore size of 
nanofibrous membrane would effectively reduce restenosis while allowing limited 
extent of SMC infiltration, which may accelerate the SMC-nanofiber integration and 
thus endothelialization. Therefore, more in-depth in vitro cell migration studies and 
animal studies would be desired to test this hypothesis and optimize the parameters 
(i.e. thickness, fiber diameters) of nanofibrous membrane on NCS. 
 
Due to time and materials restriction, the degradation study was only made on NCS 
by double-disk method. But similar morphological change would be expected on NCS 
by single-disk method. It is critical that the nanofibrous membrane should not break 
into big pieces during degradation, which could induce disastrous embolism. 
Although we did not obeserve fragmentations of nanofibrous membrane in this study, 
it is important to verify this issue in animal study. Nevertheless, fallen pieces would 
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be less likely to happen with tissue surrounded, as compared to the degradation in 
PBS only. It is believed that surrounding tissue would penetrate into degrading 
nanofibrous membrane and hold it from breaking into pieces. Endothelialisation is 
expected on both infiltrated smooth muscle cells and nanofibrous membrane. Given 
the fact that EC may not be able to completely cover the P(LLA-CL) nanofibers 
(figure 4.6e), double anti-platelet treatment is recommended until complete 
degradation of nanofibers. Another issue of degradable polymeric stent is stent recoil 
(S. S. Venkatraman et al., 2006). During the degradation study, no recoil was 
observed at the end of the study. This could be explained by the longitudinal 
alignment of the fiber, where the force of radial contraction was minimized. But an 
average 10% of reduction in nanofibrous membrane was observed along the 
longitudinal direction. The shrinkage of nanofiber was consistent with the degradation 
study presented in chapter 5. The adverse effects of the longitudinal shrinkage need to 
be addressed by animal study. 
 
Furthermore, preliminary studies have been made to explore the possibility of loading 
anti-proliferation drug onto NCS. Paclitaxel, an anti-proliferation drug which is used 
in TaxusTM drug eluting stents, was successfully loaded onto P(LLA-CL) nanofibers 
by blended electrospinning. The bioactivity of the drug-loaded nanofibers was proved 
by cytotoxicity study and its in vitro drug releasing profile of the first two months was 
established. Only 11% of paclitaxel was released in 2 months. Similar study was 
reported that around 80% of paclitaxel was released from paclitaxel-blend PLGA 
(LA:GA=50:50) nanofibers in 2 months under similar conditions (J. W. Xie and 
Wang,C.H., 2006). The author also reported a fast degradation of the PLGA nanofiber, 
with “melting fibrous structure” after 60 days. The slow release rate of P(LLA-CL) 
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nanofiber could result from the slow degradation of P(LLA-CL) nanofiber. The slow 
release of paxlitaxel could delay the re-endothelializaion after implant (A. V. Finn et 
al., 2007;M. Joner et al., 2006). The ways to increase the drug release rate include 
reducing fiber diameter (J. W. Xie and Wang,C.H., 2006) or reducing membrane 
thickness. The drug release study on paxlitaxel-loaded NCS was not conducted due to 
time and materials restriction. However, pilot studies indicated that the drug release 
was significantly increased when the nanofibers are stretched or in fluidic condition 
(data not shown). Therefore, faster release would be expected from drug-loaded NCS. 
Drug loaded NCS was fabricated with loading density of 0.475μg/mm2. A standard 
paclitaxel loading platform for TAXUS stent was reported to be 0.25μg/mm2 (R. 
Wessely et al., 2007). Therefore loading capacity of P(LLA-CL) nanofiber is enough 
for clinical need. This study has also demonstrated that drug loading does not 
significantly affect the mechanical property of nanofibrous membrane. It implied that 
small molecules (paclitaxel in this case) may not affect the structure integrity of 
polymer matrix within nanofibers even the drug was loaded at a concentration as high 
as 10% (dry weight). 
 
6.4 Summary 
Three different electrospinning methods were developed to fabricate P(LLA-CL) 
nanofiber covered stents and single-disk method showed best performance in terms of 
mechanical property. NCS by single-disk can be deployed in vitro without creating 
any defects on the nanofibrous cover. Paclitaxel was successfully loaded onto 
P(LLA-CL) nanofiber without losing its bioactivity. The in vitro release profile of 
P(LLA-CL) nanofiber was measured, with only 11% of paclitaxel released in the first 
2 months. Paclitaxel loaded onto NCS did not affect its mechanical property. 
Chapter 6 
 154
Paclitaxel loaded NCS could minimize the in-stent restenosis by providing both 







Chapter 7  
Conclusions and Perspectives 
7.1 Conclusions 
I have in this project identified an unmet medical need namely the failed SVG for 
CAD which currently does not have a satisfactory medical treatment. Nanofiber 
covered stent (NCS) was proposed as an improved stenting device for SVG 
intervention. Designing medical device for specific medical condition often relies on 
existing technical data. This project is unique in the sense that at the start of the 
project there were no technical data to guide our design to meet the desired 
specification. Through series of systematic research, data were generated giving us 
new insights into physical, chemical and biological properties of the studied materials. 
 
Current stenting of SVG intervention is associated with severe restenosis and high 
risks of embolism. Covered stent has been proposed to overcome these problems by 
creating a physical barrier. However, traditional PTFE covered stent failed to show 
clinical benefits possibly due to bulky design, improper coating and high deployment 
pressure. Therefore, there is a need of a new design of covered stent with new type of 
coating materials. An ideal coating material should have improved biocompatibility, 
proper biodegradability, high stretchability and potentials for drug loading. In this 
project, electrospun nanofibrous membrane was proposed as such a candidate. 
 
PGA, PLGA and P(LLA-CL) were chosen as polymer candidates given their reported 
cardiovascular applications. The first aspect of the study was to optimize the 
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electrospinning condition of the three polymers. It was found that HFIP is a good 
solvent for electrospinning, with suitable properties of conductivity and evaporation 
rate. Electrospun PLGA nanofibers using three different reported solvents were 
compared in the study. The electrospun fibers from HFIP solution showed smaller 
fiber size and better mechanical strength than those from DMF and 
chloroform/methanol solutions.  
 
After optimization of electrospinning condition for the three polymers, research was 
made to determine a suitable polymer candidate for nanofiber covered stent (NCS). In 
the study, three degradable polymers, PGA, PLGA and P(LLA-CL) were compared 
for PCASMC biocompatibility and degradability. The results indicated that PGA 
nanofiber supported initial PCASMC attachment and proliferation. However due to its 
rapid degradation (fully degraded within 20 days), it is not a suitable scaffold for long 
term tissue engineering. For NCS application, PGA nanofibers could not provide 
sustainable physical barrier to reduce restenosis. PLGA nanofiber facilitated cell 
growth during the first 30 days after seeding but the cell growth was slow thereafter. 
P(LLA-CL) facilitated long term (1-3 months) cell proliferation with multilayers of 
PCASMC attachment, although the initial cell growth was slow. As the low initial 
adhesion can help to reduce restenosis and long-term PCASMC proliferation on 
P(LLA-CL) nanofiber can accelerate the healing process, P(LLA-CL) is a satisfactory 
candidate for nanofiber covered stent application. We further measured the ECM 
secretion by PCASMC on P(LLA-CL) nanofiber and results suggested a high ECM 
secretion after 2 months. P(LLA-CL) nanofibers were also shown to support 
endothelial cells proliferation. Both results suggested that P(LLA-CL) nanofibers 




Degradation behaviors of the three polymeric nanofibers with and without cell culture 
were determined in the study. It was found that cell culture on the surface nanofibrous 
mesh did not significantly increase the bulk degradation rate of the nanofibers, except 
that a slight increase of surface erosion was observed. For the first time, the 
degradation behavior of polymeric nanofiber with cell culture has been studied for up 
to 100 days. The results provide a good reference for tissue engineering study using 
nanofiber scaffold where prolonged culture time is needed. Both PLGA and 
P(LLA-CL) exhibited a linear decrease of molecular weight during degradation with 
and without cell culture. This could be explained by unzipping mechanism in polymer 
chain hydrolysis and absence of autocatalysis due to high surface to volume ratio. The 
linear degradation profile of polymeric nanofiber has not been reported before and 
this is a useful assumption/model in predicting degradation rate of polymeric 
nanofiber, which is of great importance in determining the suitable type of polymer in 
various tissue engineering applications. 
 
Given that the degradation time of P(LLA-CL) nanofiber is around 7 months in vitro, 
there is a need to adjust its degradation rate to meet different clinical requirements. 
UV irradiation was used to accelerate the degradation and its degradation effect was 
characterized. The study demonstrated that normal dosage UV sterilization induced 
significant damage on PLGA and P(LLA-CL) nanofiber, reducing the molecular 
weights and mechanical strengths, but with no obvious effects on cell proliferation. 
The study is the first to report the degradation effect of UV sterilization on nanofibers. 
Therefore degradation effect has to be taken into consideration when sterilizing 
polymeric nanofibers by UV irradiation, which is a common approach in tissue 
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engineering studies. In addition, the nature of UV-induced degradation could be 
utilized for tissue engineering application. Degradation time of nanofibrous scaffolds 
can be tailored by pre-treating them with UV irradiation. One of the biggest 
limitations of electrospun nanofiber scaffolds is that their pore size is usually too 
small for cell penetration, which has long been a barrier for 3D nanofibrous scaffold 
application in tissue engineering. In this study, a UV-photolithography technique was 
developed to produce micro-porous nanofibrous scaffold. The micropores on the 
nanofibrous mesh allowed cell penetration, which could pave the way for construction 
of 3D nanofibrous scaffolds.  
 
P(LLA-CL) was chosen as the candidate for NCS fabrication, and three patent 
pending electrospinning methods has been developed and compared. The methods 
could uniformly deposit either random or longitudinally aligned nanofibers onto a 
bare metal stent. We successfully demonstrated the superior elastic property of the 
aligned nanofibrous structure produced by single-disk method, which could be easily 
stretched to 10 times of its original length without being torn. Using this set-up, NCS 
has been successfully fabricated with reliable qualities and its deployment pressure as 
low as that of bare metal stent. The low deployment pressure could reduce trauma on 
vessel during implantation and thus help to reduce risks of restenosis. There were no 
fragmentations of nanofibrous membrane observed during in vitro degradation study 
of NCS, indicating low risk embolism caused by the nanofiber degradation.  
 
Paclitaxel has been loaded into the P(LLA-CL) nanofibrous membrane and the 
bioactivity of drug-loaded nanofiber has been proved by cytotoxicity study. Drug 
release study revealed a zero order drug release over the 2-month study period. 
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Paclitaxel-loaded NCS were also fabricated by single-disk and tensile test results 
indicated that paclitaxel incorporation did not affect the nanofiber mechanical 
property. The drug loaded NCS could greatly reduce in-stent restenosis by providing 
both anti-proliferative agent and physical barrier. Incomplete re-endothelialization is 
less likely to happen because the paxlitaxel will be fully released upon complete 
degradation of nanofibrous membrane, if not earlier. 
 
The above results strongly indicated that P(LLA-CL) nanofiber covered stent could be 
a potential treatment for SVG intervention. 
 
7.2 Limitations and future studies 
In this study, P(LLA-CL) nanofiber has been found to be a good material for 
cardiovascular tissue engineering. The pre-clinical results indicate a promising future 
for P(LLA-CL) nanofiber covered stent, with high potential in treating failed 
saphenous vein grafts. However, there are several limitations in this study which need 
to be addressed in the future. 
 
First, although the study of cell-scaffold interaction lasted up to 100 days, there is a 
need to study the interaction until the nanofibrous scaffolds are completely degraded. 
The shrinkage of the scaffold in the late stage of the in vitro cell culture has prevented 
further characterization. Therefore the only way is to monitor the degradation in an 
animal model. Second, P(LLA-CL) nanofiber was proved to be superior in this study, 
as compared to PLGA and PGA nanofiber in vascular tissue engineering. But no 
additional modification was made to the studied nanofibers. Additional chemical 
modification/functionalization or alternative polymer should be explored to determine 
if they can further improve the biocompatibility and mechanical property. Third, we 
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have proposed a way to accelerate the polymer degradation by using UV irradiation.  
UV irradiation could be utilized if shorter degradation time is desired. But due to time 
and budget restriction, the ideal degradation time for NCS is uncertain. An animal 
study is desired to optimize the degradation rate of NCS by the UV treatment. Fourth, 
the drug release study was only made on paclitaxel-loaded random nanofibrous 
membrane, and drug release study did not carry on from 62 days onward. It would be 
more meaningful to investigate the drug release profile of drug-loaded NCS fabricated 
by single-disk method. Also, we would expect that deployed drug-loaded NCS in a 
fluidic environment would have a much faster drug release rate. The drug release 
profile in the animal model would also be desired.  
 
The research works have indicated a technical solution for NCS. Animal study in a 
rabbit iliac model is currently undergoing to confirm its benefits. Rabbit iliac model is 
widely used animal model to test safety and feasibility of vascular stenting. Histology 
can examine the infiltration of SMC into the stenting area, a phenomenon called 
hyperplasia, similar to restenosis. Study on larger animals (e.g porcine & goat) will be 
carried out if rabbit study is satisfactory, before carrying on to clinical trial. In the 
rabbit study, NCS stent will be implanted in the middle segment of an iliac artery, 
while a BMS will be implanted in the contralateral artery for control, for a period of 1, 
3 and 6 months. The balloon expanded stent to artery ratio should be 1.1:1 in all stents, 
achieved by adjusting the inflation pressure. Post-dilatation could be needed and 
verified by post-operation angiography. Angiogram will be performed to measure and 




At the end of each time point (30, 90, 180 days), QCA (quantitative coronary 
angiography) will be performed and recorded. Euthanasia (with an intravenous 
overdose of thiopentone) will be performed right after. Iliac arteries with stents will 
be explanted and perfused at physiological pressure with heparinized saline and then 
4% neutral buffered paraformaldehyde (or 10% buffered formalin). The stented 
segments (>25mm, with stent centered) will be collected for histology and 




Other than SVG intervention, another potential application of NCS is to treat brain 
aneurysm, another type of cardiovascular diseases without satisfactory treatment (K. 
Kuraishi et al., 2009). The flexibility of NCS could allow it to be navigated to areas of 
tortuous small intrancranial vessels that previously cannot be reached by existing 
covered stent design. Our fabrication technique also enables precise control of the 
covering area over the stent to avoid blocking the side branches of brain vessels, 
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